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Introduction
Over the past decades, the axillary management of breast cancer has evolved 
substantially, and there has been a shift from radical to more conservative approaches, 
aiming to reduce morbidity and improve quality of life without compromising oncologic 
outcomes and staging. With the introduction of the Halsted radical mastectomy in the 
late 19th century, the axilla was viewed as the major pathway for distant metastatic 
spread. Consequently, the removal of all axillary lymph nodes (i.e., axillary lymph node 
dissection (ALND)) was considered necessary, even in the absence of clinical axillary 
disease (i.e., clinically node-negative patients).1 With time and a better understanding of 
breast cancer, the removal of axillary lymph nodes was not considered as an important 
procedure for the prevention of distant metastatic spread anymore, but an essential 
component of staging and for determining prognosis in breast cancer patients.2 
However, ALND is associated with a signi!cant risk of morbidity, including lymphedema, 
seroma, and paresthesias.3,4
In 1985, a landmark trial by the National Surgical Adjuvant Breast and Bowel Project 
(NSABP) B04 study group was published with 10-year results of clinically node-negative 
patients. This study showed no di$erence in survival outcomes between patients 
randomized to ALND, regional radiation therapy, or no upfront axillary treatment. In 
this last group, ALND was only performed if the axillary lymph nodes were subsequently 
positive.5 These survival results remained consistent even after 25-year of follow-up.6 
The NSABP B04 study showed that only 40% of the ALND patients had axillary lymph 
node metastases at !nal pathology, and the remaining patients had undergone ALND 
without any treatment bene!t or prognostic implications. Furthermore, positive axillary 
lymph nodes that had not been surgically removed did not negatively impact distant 
recurrence rate or breast cancer-related mortality.6 In the meantime, for management 
of the primary breast tumor, multiple randomized controlled trials were initiated and 
demonstrated that breast-conserving therapy (i.e., lumpectomy followed by breast 
radiation therapy) was equivalent to mastectomy regarding survival outcomes.7-9
In the early 1990s, the sentinel lymph node biopsy (SLNB) was introduced for the axillary 
lymph node staging, which results in less morbidity, to replace the ALND in clinically 
node-negative patients, while for patients with positive sentinel lymph node(s), ALND 
remained standard of care.10,11 In the late 1990s, the American College of Surgeons 
Oncology Group (ACOSOG) developed the Z0011 trial supported by the earlier results of 
the NSABP B04 study.2,12 This multicenter trial demonstrated that in clinical T1-T2 node-
negative breast cancer patients with one or two positive sentinel lymph node(s) who had 
undergone breast-conserving therapy and adjuvant systemic therapy, the locoregional 
control and survival outcomes were not compromised by omitting ALND.13 In addition 
to the ACOSOG Z0011 results, the International Breast Cancer Study Group (IBCSG) 23-
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01, the AATRM 048/13/2000, and After Mapping of the Axilla: Radiotherapy or Surgery? 
(AMAROS) trial also showed that patients with limited sentinel lymph node involvement 
do not bene!t from ALND.14-16 These trials changed the axillary management of breast 
cancer patients with up to two positive sentinel lymph node(s) and decreased the rate 
of completion ALND over time.17-19
In parallel to the surgical advancements, imaging techniques play an important role in the 
axillary lymph node staging to provide extensive preoperative information. Currently, in 
the case of breast cancer diagnosis, the diagnostic workup consists of the assessment of 
regional lymph nodes by physical examination of the axilla and a preoperative axillary 
ultrasound combined with tissue sampling if suspicious axillary lymph node(s) are 
detected to identify clinically node-positive patients.20 In these clinically node-positive 
patients, the di$erentiation between limited (de!ned as pN1) and advanced (de!ned as 
pN2-3) axillary lymph node disease can guide adjuvant locoregional radiation therapy. 
With axillary ultrasound, only 50% of the patients with axillary lymph node metastases 
are correctly identi!ed.21 At the same time, in the case of positive !ndings on axillary 
ultrasound, the di$erentiation between limited and advanced axillary lymph node 
disease is inaccurate.22
For the diagnostic workup in the preoperative setting, breast MRI can be considered, 
which usually includes the axilla in the same !eld of view.20,23 The advantage of MRI 
compared to ultrasound for the assessment of axillary lymph nodes is the ability 
to evaluate the axilla bilaterally, visualizing deeper-lying lymph nodes, being less 
operator-dependent, and the use of di$erent imaging sequences such as T1-weighted, 
T2-weighted, and di$usion-weighted imaging.24 Previous studies reported clinical 
potential, but the diagnostic performance of standard breast MRI for the assessment of 
axillary lymph node metastases varies with sensitivity between 48-88% and speci!city 
between 78-90%.24-29 Given the limited !eld of view of the axillary region on breast 
MRI, dedicated axillary MRI has been investigated to improve axillary lymph node 
imaging.30-33 However, no previous study has compared the diagnostic performance of 
both standard breast MRI and dedicated axillary MRI in the same group of patients.
To date, there are no accurate imaging modalities in the diagnostic workup to 
replace the surgical staging procedure of the axilla. In the era of arti!cial intelligence, 
current developments in radiology focus on maximizing the potential role of imaging 
modalities. In 2012, radiomics was introduced by Lambin et al. and refers to extracting 
and analyzing large numbers of quantitative features from medical images, possibly 
combined with clinical data, to develop diagnostic, predictive, and prognostic models 
to improve clinical decision-making.34,35 Radiomics is based on the concept that medical 
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images contain complementary information of underlying pathophysiology that is 
imperceptible with traditional visual assessment of the images. This discipline has 
rapidly evolved in the !eld of breast cancer, and several previous studies focused on the 
prediction of axillary lymph node metastases with radiomics based on mammography, 
breast ultrasound, and breast MRI.36-40 Though in previous research, the radiomics 
features were only extracted and analyzed from the primary breast tumor, and the 
radiomics features of the axillary lymph nodes were not explored.
Neoadjuvant systemic therapy
In breast cancer, chemotherapy has historically been administered after breast and 
axillary surgery (i.e., adjuvant treatment). In 1988, the NSABP B-18 trial was initiated 
in operable breast cancer patients to compare the administration of chemotherapy in 
the preoperative setting (i.e., neoadjuvant treatment) and in the adjuvant setting.41 The 
5-year and 9-year follow-up results showed no statistically signi!cant di$erence between 
the locoregional recurrence rate, disease-free survival, and overall survival for both 
groups.41,42 However, the NSABP B-18 trial and other following studies demonstrated 
that chemotherapy in the neoadjuvant setting has several advantages.43,44  Neoadjuvant 
chemotherapy can downsize the primary breast tumor increasing the rate of breast-
conserving surgery, allows the monitoring of response to therapy, and can result in 
pathologic complete response (pCR) of the breast tumor and/or axillary lymph node 
metastases.43-45
Initially, neoadjuvant chemotherapy therapy was mainly administered in locally 
advanced breast cancer; at present, it has also become an integral part of early-stage 
breast cancer treatment.46,47 With the advances of systemic therapy and our growing 
understanding of tumor biology, less invasive treatment has been proposed, and even 
the omission of breast surgery in patients with an excellent response to neoadjuvant 
systemic therapy (chemotherapy with or without HER2-targeted therapy). Ongoing 
trials are currently investigating the accuracy and safety of image-guided biopsy after 
neoadjuvant systemic therapy to select patients suitable for the omission of breast 
surgery.48,49 Furthermore, axillary management in the neoadjuvant setting has been 
an area of active research and discussion. Until recently, ALND was a routine axillary 
procedure after neoadjuvant systemic therapy in clinically node-positive patients, 
irrespective of the treatment response. Previous studies reported axillary pCR rates up 
to 74%, depending on the breast cancer subtype.50,51 Therefore, less invasive surgical 
staging procedures of the axilla have been investigated to replace ALND in patients 
who respond well to neoadjuvant systemic therapy.52-55 However, these less invasive 
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staging procedures are associated with false-negative rates. Restaging the axilla after 
neoadjuvant systemic therapy with noninvasive imaging modalities might minimize 
the false-negative rate and select suitable patients for less invasive axillary staging.
In the management of breast cancer, both immediate breast reconstruction and 
postmastectomy radiation therapy (i.e., radiation therapy of the chest wall with or 
without the regional lymph nodes) are important aspects of multimodal treatment. 
Immediate breast reconstruction can improve the quality of life, psychosocial well-
being, and enhance the aesthetic outcome compared to delayed reconstruction.56-59 
Integrating radiation therapy in the setting of immediate breast reconstruction has 
become challenging with the goal to minimize radiation therapy complications and 
the adverse e$ects on the aesthetic outcome. With the increasing use of neoadjuvant 
systemic therapy, it has become clear that tumor response is an important prognostic 
factor.60 Patients with residual axillary lymph node disease after neoadjuvant systemic 
therapy have an increased risk of locoregional recurrence, and therefore these patients 
have an indication for postmastectomy radiation therapy.61,62 However, the pathologic 
axillary lymph node outcome after neoadjuvant systemic therapy remains unknown 
prior to mastectomy, and the decision to perform immediate breast reconstruction is 
made without the knowledge of whether there is an indication for postmastectomy 
radiation therapy.
THESIS OUTLINE
This thesis aims to provide insights into di$erent aspects of the axillary management 
of breast cancer patients: optimizing the axillary lymph node staging with noninvasive 
imaging modalities, prediction of axillary pCR based on the breast tumor response, 
overview of axillary pCR rates for di$erent breast cancer subtypes for de-escalation and 
escalation of treatment, and the implications of axillary response for the indication of 
postmastectomy radiation therapy and the timing of breast reconstruction.
Part I of this thesis focuses on optimizing the axillary lymph node staging by noninvasive 
imaging modalities in the preoperative setting and following neoadjuvant systemic 
therapy.
Chapter 2 investigates whether breast MRI has comparable diagnostic performance 
as dedicated axillary MRI for the assessment of node-negative and node-positive 
disease. Chapter 3 investigates the diagnostic performance of axillary ultrasound and 
breast MRI in the preoperative setting to di$erentiate between limited and advanced 
axillary lymph node disease in clinically node-positive patients. In Chapter 4, MRI-
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based radiomics analysis was used for the prediction of axillary lymph node metastasis. 
Chapter 5 provides an overview of the diagnostic performance of currently available 
imaging modalities for assessment of axillary lymph node response after neoadjuvant 
systemic therapy in clinically node-positive patients in a systematic review and meta-
analysis.
Part II of this thesis focuses on the prediction of axillary pCR following neoadjuvant 
systemic therapy for di$erent breast cancer subtypes.
Chapter 6 describes the correlation between breast pCR and axillary pCR in clinically 
node-negative and clinically node-positive patients. Chapter 7 provides pooled data of 
axillary pCR rates for each breast cancer subtype in clinically node-positive patients in a 
systematic review and meta-analysis.
Part III of this thesis focuses on the implications of residual axillary lymph node disease 
following neoadjuvant systemic therapy for postmastectomy radiation therapy and 
immediate breast reconstruction.
The axillary lymph node outcome after neoadjuvant systemic therapy in clinically node-
negative patients is provided in Chapter 8 and expanded with clinically node-positive 
patients in Chapter 9 to determine the likelihood of postmastectomy radiation therapy 
prior to the decision-making of breast reconstruction. Chapter 8 also includes a brief 
commentary regarding the signi!cance and relevance of this topic.
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breast MRI compared to dedicated axillary 
MRI for assessment of node-negative 
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Objectives: To investigate whether breast MRI has comparable diagnostic performance 
as dedicated axillary MRI regarding assessment of node-negative and node-positive 
breast cancer.
Methods: Forty-seven patients were included. All had undergone both breast MRI and 
dedicated axillary MRI, followed by surgery. All included breast MRI exams had complete 
!eld of view (FOV) of the axillary region. First, unenhanced T2-weighted (T2W) and 
subsequent di$usion-weighted (DW) images of both MRI exams were independently 
analyzed by two breast radiologists using a con!dence scale and compared to 
histopathology. ADC values were measured by two researchers independently. 
Diagnostic performance parameters were calculated on a patient-by-patient basis.
Results: T2W breast MRI had the following diagnostic performance: sensitivity of 50.0% 
and 62.5%, speci!city of 92.3%, PPV of 57.1% and 62.5%, NPV of 90.0% and 92.3%, 
and AUC of 0.72 for reader 1 and 0.78 for reader 2. T2W dedicated axillary MRI had the 
following diagnostic performance: sensitivity of 37.5% and 62.5%, speci!city of 82.1% 
and 92.3%, PPV of 44.6% and 50.0%, NPV of 87.8% and 91.4%, and AUC of 0.65 for 
reader 1 and 0.73 for reader 2. In both evaluations, addition of DW images resulted in 
comparable diagnostic performance. For both breast MRI and dedicated axillary MRI, 
there was no signi!cant di$erence between mean ADC values of benign and malignant 
lymph nodes.
Conclusions: T2W breast MRI with complete FOV of the axillary region has comparable 
diagnostic performance as T2W dedicated axillary MRI regarding assessment of node-
negative and node-positive breast cancer. Optimization of T2W breast MRI protocol 
by including a complete FOV of the axillary region can, therefore, be recommended in 
clinical practice.
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INTRODUCTION
In breast cancer, the presence and extent of axillary lymph node metastases is an 
important prognostic indicator and helps in determining the optimal treatment plan.1-4 
Accurate assessment of axillary lymph node involvement, therefore, plays a pivotal role 
in breast cancer treatment. Over the past years, the surgical staging procedures of the 
axilla have evolved from routine axillary lymph node dissection (ALND) toward less 
extensive procedures, such as the sentinel lymph node biopsy (SLNB).
Parallel to surgical advances, the imaging techniques for axillary lymph node staging 
have improved and become increasingly useful as a non-invasive diagnostic imaging 
modality to assess the axillary lymph node status. This is important since accurate 
preoperative axillary imaging can contribute to a more patient-tailored treatment 
strategy regarding axillary surgery. In clinical practice, breast magnetic resonance 
imaging (MRI) is predominantly used in the preoperative setting to evaluate (initial) 
tumor extent.5-7 Previous studies suggested promising results of breast MRI for assessing 
the axillary lymph node status.8,9 Breast MRI enables radiologists to simultaneously assess 
the breast tumor and axillary lymph nodes in the same !eld of view (FOV) if the axillary 
region is completely visualized with an acceptable signal-to-noise ratio (SNR). However, 
in 40% of the standard breast MRI exams, no complete FOV of the axillary region is 
planned, limiting the assessment of extensive axillary lymph node involvement in the 
upper part of the axilla.10 Consequently, dedicated axillary MRI has been investigated 
to improve axillary lymph node imaging by representing the complete axillary region. 
Several studies have suggested that using a dedicated axillary surface coil increases 
the diagnostic performance of MRI for assessing the axillary lymph node status.11-15 
However, these results were based on studies, including patients that underwent only 
one of the two imaging protocols, not both.
To our knowledge, no previous study has compared standard breast MRI with dedicated 
axillary MRI within a single cohort of breast cancer patients who had undergone both MRI 
exams. Similar performance of axillary lymph node assessment on standard breast MRI, 
as opposed to dedicated axillary MRI, can make broad implementation possible given 
the existing breast MRI protocols. This study aimed to investigate whether standard 
breast MRI has a comparable diagnostic performance with that of dedicated axillary 
MRI regarding the assessment of node-negative and node-positive breast cancer using 
unenhanced T2-weighted (T2W) and di$usion weighted (DW) images.





All patients with histopathologically con!rmed invasive breast cancer between August 
2012 and December 2014, who had undergone both standard breast MRI and dedicated 
axillary MRI followed by either SLNB or ALND, were considered for inclusion. Exclusion 
criteria were neoadjuvant systemic therapy (NST) before axillary surgery and breast MRI 
exams with incomplete FOV or poor SNR of the axillary region. The local medical ethics 
committee waived the necessity to acquire informed consent due to the retrospective 
study design.
MRI acquisition
The breast MRI exams were performed with three di$erent 1.5-T and 3.0-T scanners 
(Intera, Ingenia, and Achieva, Philips Healthcare), using a dedicated bilateral 16-channel 
breast coil with the patient in the prone position. The imaging protocol of 1.5-T breast 
MRI consisted of the following: (1) unenhanced three-dimensional (3D) T2W turbo spin-
echo sequence without fat suppression (pixel size, 0.87 x 0.87 mm; repetition time (TR), 
2000 ms; echo time (TE), 222 ms; echo train length, 92; %ip angle, 90°; slice thickness, 
2.0 mm); (2) contrast-enhanced T1W sequence; and (3) DW imaging sequence with fat 
suppression (b-values of 0, 150, and 800 s/mm2; pixel size, 1.28 x 1.28 mm; TR, 9670 ms; 
TE, 89 ms; echo train length, 68; %ip angle, 90°; slice thickness, 3.0 mm). The imaging 
protocol of 3.0-T breast MRI consisted of the following: (1) unenhanced two-dimensional 
(2D) T2W turbo spin-echo sequence without fat suppression (pixel size, 0.59 x 0.59 mm; 
TR, 5294 ms; TE, 100 ms; echo train length, 27; %ip angle, 90°; slice thickness, 2.0 mm); (2) 
contrast-enhanced T1W sequence; and (3) DW imaging sequence with fat suppression 
(b-values of 0, 150, and 800 s/mm2; pixel size, 1.25 x 1.25 mm; TR, 8683 ms; TE, 51 ms; 
echo train length, 43; %ip angle, 90°; slice thickness, 3.0 mm). For standard breast MRI, 
the anatomic con!nes for an adequate FOV were between the humeral head and 
xiphoid process of the sternum. The dedicated axillary MRI exams were performed with 
a 3.0-T scanner (Achieva, Philips Healthcare), using a 32-channel cardiac coil with the 
patient in the supine position and ipsilateral arm elevated. The imaging protocol of 
dedicated axillary MRI consisted of the following: (1) unenhanced 3D T2W turbo spin-
echo sequence without fat suppression (pixel size, 1.25 x 1.25 mm; TR, 2000 ms; TE, 155 
ms; echo train length, 51; %ip angle, 90°; slice thickness, 2.5 mm); (2) contrast-enhanced 
T1W; and (3) DW imaging sequence with fat suppression (b-values of 0, 500, and 800 s/
mm2; pixel size, 1.38 x 1.38 mm; TR, 2110 ms; TE, 52 ms; echo train length, 71; %ip angle, 
90°; slice thickness, 3.0 mm). For dedicated axillary MRI, the anatomic con!nes for an 
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adequate FOV were between the humeral head and inferior border of the scapula. The 
apparent di$usion coe&cient (ADC) maps were automatically constructed for all DW 
images using the built-in MR software.
Image analysis
The breast and dedicated axillary MRI exams were analyzed by two dedicated breast 
radiologists independently with signi!cant experience in breast imaging (M.B.I.L. [reader 
1] and S.V. [reader 2] with 11 and 8 years of experience, respectively). Comparable with 
clinical practice, the radiologists were aware of the laterality of the breast tumor and 
the clinical tumor size assessed by MRI. However, the histopathological outcome was 
not provided. For qualitative assessment, !rst, the ipsilateral axillary lymph nodes were 
assessed on the unenhanced T2W images and subsequently on the DW images of the 
standard breast MRI and dedicated axillary MRI exams separately. Both readers scored 
the axillary lymph nodes on the MRI exams using a 5-point con!dence scale, ranging 
from 0 (no lymph nodes) to 4 (de!nitely malignant).16 The additional information from 
the DW images was used to adjust the score of the axillary lymph nodes based on 
the T2W images. If the DW image was unavailable or of poor image quality, the score 
remained unchanged. Characteristics of a malignant lymph node were based on size 
and morphologic features including irregular margins, inhomogeneous cortex, perifocal 
edema, asymmetry, loss of fatty hilum, and/or the absence of chemical shift artifact.16,17 
For quantitative assessment, the DW images were analyzed by two researchers (S.S. 
[reader 3] and T.J.A.v.N. [reader 4]) dedicated to axillary lymph node imaging. Both 
readers were blinded to the histopathological outcome. High signal intensity area in the 
ipsilateral axilla on the DW images was detected and compared with the T2W images 
to evaluate whether or not it was an axillary lymph node. If multiple lymph nodes were 
detected, the lymph node with the longest axis was identi!ed.18,19 A region of interest 
(ROI) was manually drawn on the DW images at b = 800 s/mm2 on one representative 
slice and then copied to the corresponding ADC map.20,21 The whole lymph node region 
with evidently high signal intensity was delineated in the case of subcentimeter lymph 
nodes, and in larger lymph nodes only the cortex was delineated avoiding the (fatty) 
hilum and surrounding tissue.22 After the delineations, a consensus meeting was held 
to con!rm the lymph node’s delineation between the two readers. Subsequently, 
both readers independently measured the mean ADC of the largest lymph node. The 
quantitative assessment was performed in OsiriX (version 10.0, Pixmeo SARL).
Histopathological analysis
The lymph nodes obtained by axillary surgery were recorded as benign, isolated tumor 
cells (' 0.2 mm and/or < 200 cells in a single histological cross section), micrometastasis 
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(0.2 ' 2.0 mm), or macrometastasis (> 2.0 mm).23 The isolated tumor cells and the 
micrometastases were considered negative, and macrometastases were considered 
positive axillary lymph nodes.24
Statistical analysis
Median and interquartile range (IQR) were given if patient characteristics were not 
normally distributed. On the con!dence scale, the lymph nodes with the scores 0–2 
were categorized as benign and lymph nodes with the scores 3–4 were categorized 
as malignant. Histopathology of the axillary surgery, SLNB or ALND, served as the 
gold standard. Diagnostic performance parameters of T2W images and T2W with 
DW images were calculated for both standard breast MRI and dedicated axillary MRI 
(sensitivity, speci!city, positive predictive value (PPV), negative predictive value (NPV), 
and area under the receiver operating characteristic (ROC) curve (AUC)). The diagnostic 
performance parameters were presented with 95% con!dence intervals (CIs). The 
nonparametric DeLong test was used to calculate the comparison between two AUCs.25 
Two-sided p values of < 0.05 were considered statistically signi!cant. The mean ADC 
was compared between benign and malignant lymph nodes using the Wilcoxon 
signed-rank test. For the quantitative analysis, the intraclass correlation coe&cient was 
calculated between readers 3 and 4. The di$erence between readers 3 and 4 in the ADC 
measurement and 95% limits of agreement were computed for standard breast MRI and 
dedicated axillary MRI. Statistical analyses were performed by using R project software 
(version 3.5.1, R Foundation for Statistical Computing) and Statistical Package for the 
Social Sciences software (version 25, IBM).
RESULTS
A total of 70 patients had undergone both standard breast MRI and dedicated axillary 
MRI. Twelve patients were excluded who had been treated with NST before axillary 
surgery. Eleven patients were excluded because of breast MRI exams with incomplete 
FOV of the axillary region. For !nal analyses, 47 patients (median age, 59 years; IQR, 51–
66 years) were included. Thirty-nine (83.0%) patients had benign axillary lymph nodes at 
!nal pathology and 8 (17.0%) patients had malignant axillary lymph nodes. The median 
size of macrometastases was 11.5 mm (IQR, 8.0–25.5 mm). Patient characteristics are 
summarized in Table 1.
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TABLE 1. Patient characteristics
Variable Patients (n=47)
Age (years) (median; IQR) 59 (51 – 66)
Clinical tumor size (mm) (median; IQR) 19 (13 – 28.5)







 Tumor type (%)
Ductal
Lobular
































Abbreviations: ALND, axillary lymph node dissection; ER, estrogen receptor; HER2, human epidermal growth factor 
receptor 2; IQR, interquartile range; PR, progesterone receptor; SLNB, sentinel lymph node biopsy
*Other tumor types: adenoid cystic carcinoma, mucinous carcinoma, encapsulated papillary carcinoma
The T2W breast MRI had the following diagnostic performance: sensitivity of 50.0% 
and 62.5%, speci!city of 92.3%, PPV of 57.1% and 62.5%, NPV of 90.0% and 92.3%, and 
AUC of 0.72 for reader 1 and 0.78 for reader 2. The addition of DW images resulted in 
comparable sensitivity (50.0%), speci!city (92.3% and 94.9%), PPV (57.1% and 66.7%), 
NPV (90.0% and 90.2%), and AUC for reader 1 (0.73) and reader 2 (0.72). The comparison 
between the AUC values of T2W breast MRI and with the addition of DW images for 
reader 1 and reader 2 separately had a p value of 0.67 and 0.33, respectively. Two of the 
standard breast MRI exams had no DW images, and nine DW images had poor image 
quality assessed by the radiologists.
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The T2W dedicated axillary MRI had the following diagnostic performance: sensitivity 
of 37.5% and 62.5%, speci!city of 82.1% and 92.3%, PPV of 44.6% and 50.0%, NPV of 
87.8% and 91.4%, and AUC of 0.65 for reader 1 and 0.73 for reader 2. The addition of 
DW images resulted in comparable sensitivity (25.0% and 62.5%), speci!city (87.2% and 
92.3%), PPV (28.6% and 62.5%), NPV (85.0% and 92.3%), and AUC for reader 1 (0.57) and 
reader 2 (0.78). The comparison between the AUC values of T2W dedicated axillary MRI 
and with the addition of DW images for reader 1 and reader 2 separately had a p value of 
0.21 and 0.068, respectively. One of the dedicated axillary MRI exams had no DW image. 
The results of the diagnostic performance parameters of T2W and T2W with DW images 
can be found in Table 2 and the ROC curves are presented in Figure 1.
For standard breast MRI, the mean ADC values of benign lymph nodes were 0.608 x 10(3 
mm2/s and 0.611 x 10(3 mm2/s for readers 3 and 4, respectively. The mean ADC values 
for malignant lymph nodes were 0.627 x 10(3 mm2/s and 0.556 x 10(3 mm2/s for readers 
3 and 4, respectively. For both readers, there was no signi!cant di$erence between the 
mean ADC value of benign and malignant lymph nodes (reader 3, p = 0.40; reader 4, p = 
0.61) (Figure 2a). The intraclass correlation coe&cient was excellent (0.94). Since two of 
the standard breast MRI exams had no DW images, the corresponding ADC maps were 
also unavailable for those MRI exams. Three other ADC maps had poor image quality 
assessed by the readers. The mean di$erence in ADC measurement pairs was 0.0092 x 
10(3 mm2/s with 95% limits of agreement of (0.033 x 10(3 and 0.051 x 10(3 mm2/s.
For dedicated axillary MRI, the mean ADC values of benign lymph nodes were 0.879 x 
10(3 mm2/s and 0.866 x 10(3 mm2/s for readers 3 and 4, respectively. The mean ADC values 
for malignant lymph nodes were 0.727 x 10(3 mm2/s and 0.838 x 10(3 mm2/s for readers 
3 and 4, respectively. For both readers, there was no signi!cant di$erence between the 
mean ADC values of benign and malignant lymph nodes (reader 3, p = 0.74; reader 4, 
p = 0.87) (Figure 2b). The intraclass correlation coe&cient was good (0.75). Since one of 
the dedicated axillary MRI exams had no DW image, the corresponding ADC map was 
also unavailable. The mean di$erence in ADC measurement pairs was (0.0056 x 10(3 
mm2/s with 95% limits of agreement of (0.053 x 10(3 and 0.042 x 10(3 mm2/s. Examples 
of an axillary lymph node on T2W image, DW image, and ADC map for standard breast 
MRI and dedicated axillary MRI are shown in Figures 3 and 4.
















Reader 2 T2W + DWI    AUC 0.72
Reader 2 T2W               AUC 0.78
Reader 1 T2W + DWI    AUC 0.73















Reader 2 T2W + DWI    AUC 0.78
Reader 2 T2W               AUC 0.73
Reader 1 T2W + DWI    AUC 0.57
Reader 1 T2W               AUC 0.65 
Page 1
FIGURE 1. (a) Receiver operating characteristic curves show a qualitative assessment of T2-weighted (T2W) 
and T2W with di$usion-weighted (DW) standard breast MR images for readers 1 and 2. (b) Receiver operating 
characteristic curves show a qualitative assessment of T2W and T2W with DW dedicated axillary MR images 
for readers 1 and 2.
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FIGURE 2. Boxplots show the comparison of the mean ADC value (x 10-3 mm2/s) for benign and malignant 
lymph nodes. (a) Standard breast MRI: readers 3 and 4. (b) Dedicated axillary MRI: readers 3 and 4
A
B
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FIGURE 3. Images of a 64-year-old female patient with a 27 mm large invasive ductal carcinoma in her 
right breast, which was treated with mastectomy and ALND (pT2N1). The white arrow points to an axillary 
lymph node. The green delineation shows an axillary lymph node. (1a) Axial T2W breast MR image shows 
the axillary lymph node with the longest axis. (1b) Axial DW breast MR image (b-value = 800 s/mm2) shows 
the same axillary lymph node with relatively high signal intensity. (1c) Axial ADC map of breast MRI shows 
corresponding lymph node with relatively low signal intensity with an ADC value of 0.646 x 10-3 mm2/s. (2a) 
Coronal T2W dedicated axillary MR image shows the axillary lymph node with the longest axis. (2b) Coronal 
DW dedicated axillary MR image (b-value = 800 s/mm2) shows the same lymph node with relatively high 
signal intensity. (2c) Coronal ADC map of dedicated axillary MRI shows corresponding lymph node with 
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FIGURE 4. Images of a 76-year-old female patient with a 24 mm large invasive ductal carcinoma in her left 
breast, which was treated with breast-conserving surgery and SLNB (pT2N0). The white arrow points to an 
axillary lymph node. The green delineation shows an axillary lymph node. (1a) Axial T2W breast MR image 
shows the axillary lymph node with the longest axis. (1b) Axial DW breast MR image (b-value = 800 s/mm2) 
shows the same axillary lymph node with relatively high signal intensity. (1c) Axial ADC map of breast MRI 
shows corresponding lymph node with relatively high signal intensity with an ADC value of 0.526 x 10-3 mm2/s. 
(2a) Coronal T2W dedicated axillary MR image shows the axillary lymph node with the longest axis. (2b) 
Coronal DW dedicated axillary MR image (b-value = 800 s/mm2) shows the same lymph node with relatively 
high signal intensity. (2c) Coronal ADC map of dedicated axillary MRI shows corresponding lymph node with 








This study showed that the diagnostic performance of unenhanced T2W standard breast 
MRI with complete FOV of the axillary region is comparable with unenhanced T2W 
dedicated axillary MRI regarding the assessment of node-negative and node-positive 
breast cancer. Concerning the diagnostic performance of both MRI exams, especially 
the relatively high NPV can be used for clinical decision making. For both standard 
breast MRI and dedicated axillary MRI, DW images and ADC measurements were of no 
added value. To our knowledge, this is the !rst study that has compared standard breast 
MRI and dedicated axillary MRI within a single cohort of breast cancer patients.
In this present study, all breast cancer patients underwent a standard breast MRI for 
the evaluation of disease extent, to identify multicentric or multifocal disease, or to 
identify the presence of additional breast lesions. The evaluation of all axillary lymph 
nodes can be limited if only breast coils are used especially the lymph nodes located 
in the upper part of the axilla. In this study, only breast MRI exams with complete FOV 
and su&cient SNR of the axillary region were included to make the comparison with 
dedicated axillary MRI exams as equal as possible. Dedicated axillary MRI exams may 
improve the visualization of lymph nodes in axillary levels )) and ))) which may not be 
identi!ed easily due to the location. However, previous research showed that up to 94% 
of the SLNs are located in axillary levels ) and )).26-29 This implies that visualizing axillary 
level ))), especially in the case of clinically node-negative !ndings, can be redundant in 
most cases.
In this study, the unenhanced MR sequence was used since it has been previously 
described that this sequence has the best anatomical presentation of the lymph nodes 
based on size and morphology.10,12,22 In addition to the unenhanced T2W sequence, DW 
imaging has been investigated as an adjunct to help di$erentiate between benign and 
malignant lymph nodes. Previously published data about lymph node assessment on 
unenhanced breast MR imaging showed a sensitivity of 88%, a speci!city of 82%, and 
an accuracy of 85%, and the addition of DW imaging resulted in a sensitivity of 84%, a 
speci!city of 77%, and an accuracy of 80%.22 The addition of DW imaging was insu&cient 
to improve the diagnostic performance of axillary lymph node assessment, which is in 
line with our results for both standard breast and dedicated axillary MRI. Further studies 
evaluating DW imaging showed varying results of sensitivity and speci!city of 51.3–
94.7% and 90.0–91.8%, respectively.20,30
For the quantitative analysis, the ADC values were calculated from the DW imaging. 
Discordant results have been reported about the ADC values of lymph nodes. Previous 
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research reported similar ADC values for benign and malignant lymph nodes31, higher 
values in malignant nodes32, and lower values in malignant nodes.30,33,34 Our analyses 
for both standard breast and dedicated axillary MRI showed that the ADC values for 
benign and malignant lymph nodes are similar. These varying results can be possibly 
explained by the following: signal intensity on DW imaging can be in%uenced by lymph 
node changes like necrotic areas and in%ammatory processes. These changes can cause 
artifacts on the ADC map and therefore not re%ect the cellularity of the lymph node. 
Also, the variety of b-value combinations in di$erent studies can signi!cantly a$ect the 
ADC value of lymph nodes.35
In addition to standard breast MRI, a dedicated axillary MRI was performed in a di$erent 
session by using a surface coil on the patients’ axilla. With the surface coil, the complete 
axillary region is visualized in a coronal plane. An additional dedicated axillary MR 
image requires scanning time per axilla and bilateral evaluation to check for asymmetry 
is not possible. A few studies have evaluated the diagnostic performance of MR imaging 
with a dedicated axillary surface coil in the preoperative detection of axillary lymph 
node metastases.11,12,15,36 These studies reported sensitivity and speci!city between 79.0 
and 94.6% and 90.0 and 98.5%, respectively.11,15,36 However, these results of dedicated 
axillary MR imaging are not comparable with those of the present study since contrast-
enhanced T1W and T2*W sequence were used for analyses of axillary lymph node 
metastases.
Recent advances in the medical image analysis !eld have been made by introducing 
arti!cial intelligence for image recognition tasks.37 Arti!cial intelligence with methods 
ranging from radiomics to convolutional neural networks can provide quantitative rather 
than qualitative imaging data in an automated fashion.37 With arti!cial intelligence as 
a tool to assist radiology image work%ow, the imaging assessment can be made more 
accurate and reproducible.37 The assessment of axillary lymph nodes by combining 
the MR images and arti!cial intelligence can increase the diagnostic outcome. Future 
research should provide insights into this topic.
Our study has certain limitations. The number of included patients in this study was 
relatively small, so that potential minor di$erences between diagnostic performances 
could have gone undetected. Given the small sample size, further research on this 
topic is necessary. Also, the statistical analyses were not based on a node-by-node 
comparison between the visualized lymph nodes and their pathological !ndings. We 
assumed that the overall T2W and DWI score of the axilla (benign or malignant) was 
correlated with the pathology outcome. This was also the case for the identi!ed lymph 
node with the longest axis on DWI and the corresponding ADC map. Further, two types 
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of MRI systems (1.5 and 3.0 T) were used. However, the varying MR protocols could not 
be compared due to the small sample size. Finally, nine DW images of breast MRI were 
inevitably excluded because of movement or susceptibility artifacts, which could have 
in%uenced our DW imaging !ndings for standard breast MRI. A previous study has also 
su$ered from the same issue.22
In conclusion, the diagnostic performance of T2W standard breast MRI with complete 
FOV of the axillary region is comparable with that of the T2W dedicated axillary 
MRI regarding the assessment of node-negative and node-positive breast cancer. 
Optimization of T2W standard breast MRI protocol by including a complete FOV of the 
axillary region can, therefore, be recommended in clinical practice.
149873-samiei-layout.indd   42 11/03/2021   20:41
43
Standard breast MRI compared to dedicated axillary MRI
REFERENCES
1. Oliveira M, Cortes J, Bellet M, et al. Management of the axilla in early breast cancer patients 
in the genomic era. Ann Oncol. 2013;24(5):1163-1170.
2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 
24,740 breast cancer cases. Cancer. 1989;63(1):181-187.
3. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the 
prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52(9):1551-
1557.
4. Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer 
prognostication. J Clin Oncol. 2004;22(13):2567-2575.
5. Plana MN, Carreira C, Muriel A, et al. Magnetic resonance imaging in the preoperative 
assessment of patients with primary breast cancer: systematic review of diagnostic accuracy 
and meta-analysis. Eur Radiol. 2012;22(1):26-38.
6. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical 
examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 
2004;233(3):830-849.
7. Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: 
recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296-1316.
8. Kuijs VJ, Moossdor$ M, Schipper RJ, et al. The role of MRI in axillary lymph node imaging in 
breast cancer patients: a systematic review. Insights Imaging. 2015;6(2):203-215.
9. Mortellaro VE, Marshall J, Singer L, et al. Magnetic resonance imaging for axillary staging in 
patients with breast cancer. J Magn Reson Imaging. 2009;30(2):309-312.
10. van Nijnatten TJA, Ploumen EH, Schipper RJ, et al. Routine use of standard breast MRI 
compared to axillary ultrasound for di$erentiating between no, limited and advanced axillary 
nodal disease in newly diagnosed breast cancer patients. Eur J Radiol. 2016;85(12):2288-
2294.
11. Kvistad KA, Rydland J, Smethurst HB, Lundgren S, Fjosne HE, Haraldseth O. Axillary lymph 
node metastases in breast cancer: preoperative detection with dynamic contrast-enhanced 
MRI. European Radiology. 2000;10(9):1464-1471.
12. Schipper RJ, Paiman ML, Beets-Tan RG, et al. Diagnostic Performance of Dedicated Axillary 
T2- and Di$usion-weighted MR Imaging for Nodal Staging in Breast Cancer. Radiology. 
2015;275(2):345-355.
13. van Nijnatten TJA, Schipper RJ, Lobbes MBI, et al. Diagnostic performance of gadofosveset-
enhanced axillary MRI for nodal (re)staging in breast cancer patients: results of a validation 
study. Clin Radiol. 2018;73(2):168-175.
14. Murray AD, Sta$ RT, Redpath TW, et al. Dynamic contrast enhanced MRI of the axilla in 
women with breast cancer: comparison with pathology of excised nodes. Br J Radiol. 
2002;75(891):220-228.
15. Yoshimura G, Sakurai T, Oura S, et al. Evaluation of Axillary Lymph Node Status in Breast 
Cancer with MRI. Breast Cancer. 1999;6(3):249-258.
149873-samiei-layout.indd   43 11/03/2021   20:41
44
Chapter 2
16. Baltzer PA, Dietzel M, Burmeister HP, et al. Application of MR mammography beyond local 
staging: is there a potential to accurately assess axillary lymph nodes? evaluation of an 
extended protocol in an initial prospective study. AJR Am J Roentgenol. 2011;196(5):W641-
647.
17. Farshchian N, Tamari S, Farshchian N, Madani H, Rezaie M, Mohammadi-Motlagh HR. 
Diagnostic value of chemical shift artifact in distinguishing benign lymphadenopathy. Eur J 
Radiol. 2011;80(2):594-597.
18. Belli P, Costantini M, Bu! E, et al. Di$usion magnetic resonance imaging in breast cancer 
characterisation: correlations between the apparent di$usion coe&cient and major 
prognostic factors. Radiol Med. 2015;120(3):268-276.
19. Chung J, Youk JH, Kim JA, et al. Role of di$usion-weighted MRI: predicting axillary lymph 
node metastases in breast cancer. Acta Radiol. 2014;55(8):909-916.
20. Kim SH, Shin HJ, Shin KC, et al. Diagnostic Performance of Fused Di$usion-Weighted Imaging 
Using T1-Weighted Imaging for Axillary Nodal Staging in Patients With Early Breast Cancer. 
Clinical Breast Cancer. 2017;17(2):154-163.
21. Rahbar H, Conlin JL, Parsian S, et al. Suspicious axillary lymph nodes identi!ed on clinical 
breast MRI in patients newly diagnosed with breast cancer: can quantitative features 
improve discrimination of malignant from benign? Acad Radiol. 2015;22(4):430-438.
22. Scaranelo AM, Eiada R, Jacks LM, Kulkarni SR, Crystal P. Accuracy of unenhanced MR imaging 
in the detection of axillary lymph node metastasis: study of reproducibility and reliability. 
Radiology. 2012;262(2):425-434.
23. Lester SC, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients 
with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009;133(10):1515-1538.
24. Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi7-23.
25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more 
correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 
1988;44(3):837-845.
26. Chung MA, DiPetrillo T, Hernandez S, Masko G, Wazer D, Cady B. Treatment of the axilla 
by tangential breast radiotherapy in women with invasive breast cancer. Am J Surg. 
2002;184(5):401-402.
27. Rabinovitch R, Ballono$ A, Newman F, Finlayson C. Evaluation of breast sentinel lymph node 
coverage by standard radiation therapy !elds. Int J Radiat Oncol Biol Phys. 2008;70(5):1468-
1471.
28. Schlembach PJ, Buchholz TA, Ross MI, et al. Relationship of sentinel and axillary level I-II 
lymph nodes to tangential !elds used in breast irradiation. Int J Radiat Oncol Biol Phys. 
2001;51(3):671-678.
29. van Roozendaal LM, Schipper RJ, Smit LH, et al. Three-Dimensional Breast Radiotherapy 
and the Elective Radiation Dose at the Sentinel Lymph Node Site in Breast Cancer. Ann Surg 
Oncol. 2015;22(12):3824-3830.
149873-samiei-layout.indd   44 11/03/2021   20:41
45
Standard breast MRI compared to dedicated axillary MRI
30. Fornasa F, Nesoti MV, Bovo C, Bonavina MG. Di$usion-weighted magnetic resonance imaging 
in the characterization of axillary lymph nodes in patients with breast cancer. J Magn Reson 
Imaging. 2012;36(4):858-864.
31. Nakai G, Matsuki M, Harada T, et al. Evaluation of Axillary Lymph Nodes by Di$usion-Weighted 
MRI Using Ultrasmall Superparamagnetic Iron Oxide in Patients With Breast Cancer: Initial 
Clinical Experience. Journal of Magnetic Resonance Imaging. 2011;34(3):557-562.
32. Kamitani T, Hatakenaka M, Yabuuchi H, et al. Detection of axillary node metastasis using 
di$usion-weighted MRI in breast cancer. Clin Imag. 2013;37(1):56-61.
33. Luo NB, Su DK, Jin GQ, et al. Apparent Di$usion Coe&cient Ratio Between Axillary Lymph 
Node With Primary Tumor to Detect Nodal Metastasis in Breast Cancer Patients. Journal of 
Magnetic Resonance Imaging. 2013;38(4):824-828.
34. Kim EJ, Kim SH, Kang BJ, Choi BG, Song BJ, Choi JJ. Diagnostic value of breast MRI for 
predicting metastatic axillary lymph nodes in breast cancer patients: di$usion-weighted 
MRI and conventional MRI. Magn Reson Imaging. 2014;32(10):1230-1236.
35. Dorrius MD, Dijkstra H, Oudkerk M, Sijens PE. E$ect of b value and pre-admission of contrast 
on diagnostic accuracy of 1.5-T breast DWI: a systematic review and meta-analysis. Eur 
Radiol. 2014;24(11):2835-2847.
36. Li CM, Meng S, Yang XH, Wang J, Hu JN. The Value of T2*in Di$erentiating Metastatic from 
Benign Axillary Lymph Nodes in Patients with Breast Cancer - A Preliminary In Vivo Study. 
Plos One. 2014;9(1).
37. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436-444.
149873-samiei-layout.indd   45 11/03/2021   20:41
149873-samiei-layout.indd   46 11/03/2021   20:41
CHAPTER 3
Diagnostic performance of axillary 
ultrasound and standard breast MRI 
for di!erentiation between limited and 
advanced axillary nodal disease in clinically 
node-positive breast cancer patients
Sanaz Samiei, Thiemo J.A. van Nijnatten, Hermen C. van Beek, Martin P.J. Polak, Adriana 
J.G. Maaskant-Braat, Esther M. Heuts, Sander M.J. van Kuijk, Robert-Jan Schipper, Marc B.I. 
Lobbes, Marjolein L. Smidt
Sci Rep. 2019 Nov 25;9(1):17476




Preoperative di$erentiation between limited (pN1; 1–3 axillary metastases) and 
advanced (pN2–3; *4 axillary metastases) nodal disease can provide relevant information 
regarding surgical planning and guiding adjuvant radiation therapy. The aim was to 
evaluate the diagnostic performance of preoperative axillary ultrasound (US) and breast 
MRI for di$erentiation between pN1 and pN2–3 in clinically node-positive breast cancer. 
A total of 49 patients were included with axillary metastasis con!rmed by US-guided 
tissue sampling. All had undergone breast MRI between 2008–2014 and subsequent 
axillary lymph node dissection. Unenhanced T2-weighted MRI exams were reviewed by 
two radiologists independently. Each lymph node on the MRI exams was scored using 
a con!dence scale (0–4) and compared with histopathology. Diagnostic performance 
parameters were calculated for di$erentiation between pN1 and pN2–3. Interobserver 
agreement was determined using Cohen’s kappa coe&cient. At !nal histopathology, 
67.3% (33/49) and 32.7% (16/49) of patients were pN1 and pN2–3, respectively. Breast 
MRI was comparable to US in terms of accuracy (MRI reader 1 vs US, 71.4% vs 69.4%, p = 
0.99; MRI reader 2 vs US, 73.5% vs 69.4%, p = 0.77). In the case of 1–3 suspicious lymph 
nodes, pN2–3 was observed in 30.4% on US (positive predictive value (PPV) 69.6%) and 
in 22.2–24.3% on MRI (PPV 75.7–77.8%). In the case of *4 suspicious lymph nodes, pN1 
was observed in 33.3% on US (negative predictive value (NPV) 66.7%) and in 38.5–41.7% 
on MRI (NPV 58.3–61.5%). Interobserver agreement was considered good (k = 0.73). In 
clinically node-positive patients, the diagnostic performance of axillary US and breast 
MRI is comparable and limited for accurate di$erentiation between pN1 and pN2–3. 
Therefore, there seems no added clinical value of preoperative breast MRI regarding 
nodal staging in patients with positive axillary US.
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INTRODUCTION
The axillary lymph node status in breast cancer patients provides relevant information 
regarding treatment planning and prognosis.1,2 In our current breast cancer workup, 
a preoperative axillary ultrasound (US) is routinely performed for evaluation of the 
axillary lymph nodes.3–5 If suspicious axillary lymph nodes are detected with US, !ne 
needle aspiration cytology (FNAC) or core needle biopsy is performed to identify 
clinically node-positive patients. Formerly, an axillary lymph node dissection (ALND) 
was performed in these clinically node-positive patients as standard practice. With 
increasing use of neoadjuvant systemic therapy (NST) and therefore the advantage 
of possible downstaging of the axilla, alternative approaches are proposed for the 
axillary lymph node staging, such as sentinel lymph node biopsy (SLNB), marking 
axillary lymph nodes with radioactive iodine seed (MARI), targeted axillary dissection 
(TAD), and combining radioactive iodine seed localisation in the axilla with the sentinel 
node procedure (RISAS), all to avoid ALND associated comorbidities.6–9 By using such 
alternative approaches, the true pathological axillary lymph node status is unknown 
since these techniques have false-negative !ndings of up to 15%.6,7,10 Combining an 
imaging technique before NST with these less invasive surgical staging methods, such 
as SLNB, MARI, TAD, or RISAS, can contribute to the selection of patients for whom 
further axillary treatment is (un)necessary.
In clinically node-negative patients treated with primary surgery, the role of a 
complementary ALND in sentinel node-positive breast cancer patients has been 
addressed in previous trials, such as the ACOSOG Z0011 and AMAROS.11,12 These trials 
showed that omitting ALND or in the case of treatment with axillary radiotherapy in 
sentinel node-positive patients did not result in worse locoregional recurrence or 
survival rate.11–13 When omitting (complementary) ALND or in the case of treatment with 
axillary radiotherapy, some patients with advanced axillary nodal disease (pN2–3; i.e., 
*4 axillary lymph node metastases) might not be identi!ed. Patients with advanced 
axillary nodal disease are recommended to undergo radiation therapy of the chest wall 
or (reconstructed) breast with the addition of infraclavicular/supraclavicular lymph 
nodes, an imaging technique to identify pN2–3 disease before surgery is necessary.
Consequently, preoperative di$erentiation between limited (pN1; i.e., 1–3 axillary 
lymph node metastases) and advanced axillary nodal disease in breast cancer patients 
can provide relevant information regarding the surgical planning and guiding adjuvant 
radiation therapy. The role of breast MRI for evaluating axillary lymph node metastases 
has been described in earlier studies with reported sensitivity and speci!city between 
33.3–97.0% and 14.0–98.5%, respectively.14–16 Hyun et al. showed that a negative breast 
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MRI can exclude pN2–3 with negative predictive value (NPV) of 99.6%. However, the 
di$erentiation between pN1 and pN2–3 has not been addressed earlier in clinically 
node-positive patients and appears to be of clinical relevance.
Therefore, this study aimed to evaluate the diagnostic performance of preoperative 
axillary US and standard breast MRI for di$erentiation between pN1 and pN2–3 in 
clinically node-positive breast cancer patients. Furthermore, the second aim of this 
study was to evaluate whether an additional preoperative standard breast MRI is of 
added clinical value in patients with 1–3 suspicious axillary lymph nodes on US for 
di$erentiation between pN1 and pN2–3.
MATERIAL AND METHODS
Study population
All patients diagnosed with invasive breast cancer between January 2008 and December 
2014, who had undergone preoperative axillary US and standard breast MRI, were 
retrospectively identi!ed from two medical centres (Maxima Medical Centre (MMC) 
and Maastricht University Medical Centre+ (MUMC+)). Patients with preoperative 
axillary lymph node metastasis, con!rmed by US-guided FNAC or core needle 
biopsy (i.e., clinically node-positive patients), were included for analyses. All patients 
had undergone primary breast surgery and ALND. Data on the patient, tumour, and 
treatment characteristics were retrospectively collected. The medical ethics committee 
of MMC and MUMC+ approved this study and waived the necessity to acquire informed 
consent due to the retrospective study design.
Ultrasound evaluation
The preoperative axillary lymph node status was determined by the axillary US 
performed by dedicated breast radiologists. Di$erent US systems were used for the 
axillary US examinations: Aplio XG (Toshiba Medical Systems Europe, Zoetermeer, the 
Netherlands) with a linear 12 MHz array transducer, ATL-HDI5000 (Philips Healthcare, 
Best, the Netherlands) with a linear 5–12 MHz array transducer, and iU22-xMATRIX 
(Philips Healthcare, Best, the Netherlands) with a linear 2–17 MHz array transducer. 
During the axillary US examination, the patient was positioned with the ipsilateral hand 
placed behind the head if possible. The axillary region was examined in a standardised 
approach, starting at the low axilla (level I: inferior and lateral to the pectoralis minor 
muscle) and continuing upwards toward mid-axilla (level II: medial and lateral to the 
pectoralis minor muscle and interpectoral). The apical axilla (level III: superior and 
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medial to the pectoralis minor muscle with apical lymph nodes) was only evaluated 
when suspicious axillary lymph nodes were found in level I and/or level II. In the case 
of suspicious axillary lymph node(s), FNAC or a 16–18 gauge core needle biopsy was 
performed of the most suspicious lymph node. The total number of suspicious lymph 
nodes was estimated and reported. Characteristics of suspicious axillary lymph nodes 
on US included round or irregular shape, cortical thickness greater than 2.3 mm, di$use 
cortical thickening, e$acement or replacement of fatty hilum, and increased peripheral 
blood %ow.17–21
Breast MRI acquisition and analysis
All included patients had undergone a standard breast MRI in the prone position using 
a 1.5 Tesla MRI scanner (Philips Healthcare, Best, the Netherlands). In MMC, they started 
using the Philips Gyroscan NT scanner in 2008 with a body coil which was later replaced 
with an 8-channel breast coil. In 2013, the MRI scanner was replaced by Philips Ingenia 
R4.2 scanner with a 16-channel breast coil. In MUMC+, two types of MRI scanners, Philips 
Ingenia and Intera, were used with a body coil that was replaced with a 16-channel 
breast coil in 2011. Overview of MR protocols can be found as Supplementary Material 
A.
The breast MRI exams were pre-screened by a radiology resident (T.J.A.v.N.) with 
three years of breast imaging experience. Screening of the MRI exams for eligibility 
was based on the complete !eld of view (FOV) of the axillary region, the absence of 
movement artifacts, and adequate signal-to-noise ratio. Two breast radiologists with 
7 years (H.C.v.B. [reader 1]) and 14 years (M.P.J.P. [reader 2]) of experience with breast 
MRI retrospectively evaluated all axillary lymph nodes (i.e., axillary level 1–3) on the 
unenhanced T2-weighted MR sequence. Each lymph node on the MRI exams was 
scored using a con!dence scale (0, no axillary lymph nodes; 1, de!nitely benign; 2, 
probably benign; 3, probably malignant; 4, de!nitely malignant) (Figures 1 and 2).22 
Characteristics of suspicious axillary lymph nodes on MRI included irregular margins, 
inhomogeneous cortex, perifocal oedema, asymmetry, and absence of fatty hilum or 
chemical shift artifact.22,23 These criteria were used to classify an axillary lymph node as 
either negative or positive. Similar to clinical practice, the radiologists were aware of the 
tumour side, clinical tumour size as assessed on MRI, and the clinical axillary lymph node 
status. However, they were blinded from each other’s results and had no information 
about the !nal pathological axillary lymph node status.



















FIGURE 1. Images of the axilla of a 52-year-old female patient with a 34 mm large invasive ductal carcinoma 
in her left breast, which was treated with mastectomy and ALND. For both US and MRI (reader 1 and 2) N1 
axillary lymph node disease was reported. The white arrow indicates the suspicious lymph node on US and 
MRI. Histopathology of the ALND reported pN2-3 (largest diameter, 14 mm). (a) Axillary US (b) Transversal 















FIGURE 2. Images of the axilla of a 55-year-old female patient with a 31 mm large invasive lobular carcinoma in her right breast, which was treated with mastectomy and ALND. For both US and MRI (reader 1 and 2) N2-3 
axillary lymph node disease was reported. Histopathology of the ALND reported pN2-3 (largest diameter, 50 
mm). (a) Axillary US (b) Transversal unenhanced T2-weighted breast MRI
Clinical and pathological axillary lymph node status
The clinical nodal status was based on the total number of suspicious axillary lymph 
nodes (N1: 1–3 suspicious lymph nodes; N2–3: *4 suspicious lymph nodes). The 
A B
A B
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ALND lymph nodes (i.e., pathological axillary lymph nodes) were para&n-embedded 
after formalin !xation for histological assessment. All harvested lymph nodes with a 
diameter larger than 5 mm were sliced with a maximum thickness of 3 mm. All slides 
were stained with hematoxylin and eosin. Isolated tumour cells ('0.2 mm and/or <200 
cells in a single histological cross-section) and micrometastases (0.2 ' 2.0 mm) were 
considered as negative, and macrometastases (>2.0 mm) as positive axillary lymph 
nodes. The number of axillary lymph node metastases on !nal histopathology de!ned 
the pathological axillary lymph node status. Pathological N1 disease was de!ned by 
1–3 axillary lymph node metastases and pathological N2–3 disease was de!ned by *4 
axillary lymph node metastases.24
Statistical analysis
The con!dence scale was dichotomised into benign (lymph nodes scores 0–2) and 
malignant (lymph nodes scores 3–4). Histopathology served as the gold standard. 
Diagnostic performance parameters (sensitivity, speci!city, positive predictive value 
(PPV), NPV, accuracy) were calculated for axillary US and breast MRI for di$erentiation 
between pN1 and pN2–3. Sensitivity and speci!city were de!ned as probabilities that in 
the case of pN1 or pN2–3, imaging showed 1–3 or *4 suspicious axillary lymph nodes, 
respectively. PPV and NPV were de!ned as probabilities that in the case of 1–3 and 
*4 suspicious axillary lymph nodes on imaging, the patient truly had pN1 and pN2–3, 
respectively. Comparison of sensitivity, speci!city, and accuracy of US and MRI were 
performed with the McNemar test for paired proportions. The PPV and NPV of US and 
MRI were compared by using the generalised score test statistics.25 In the subgroup 
analysis, the diagnostic performance parameters of breast MRI for di$erentiation 
between pN1 and pN2–3 were calculated for patients who had 1–3 suspicious axillary 
lymph nodes on US. The diagnostic performance parameters were presented with 95% 
con!dence intervals (CIs). The reported CIs and p-values were two-sided and 0.05 was 
used as a cuto$ for signi!cance. Interobserver agreement between the two radiologists 
for evaluating the breast MRI exams was calculated by using Cohen’s kappa coe&cient 
(k < 0.2 = poor, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = good, 0.81–1.0 = very 
good).26 Statistical analyses were performed by using R project software (version 3.5.1, R 
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
A total of 49 patients [mean age, 57 years; range, 34–79 years] were included for analyses; 
17 patients from MMC and 32 patients from MUMC+ . Mastectomy was performed in 41 
(83.7%) patients and breast-conserving surgery was performed in 8 (16.3%) patients. 
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The most common tumour histology and receptor subtype were of ductal origin 
(81.6%) and ER+HER2- subtype (67.3%), respectively. At !nal histopathology, 67.3% 
(33/49) and 32.7% (16/49) of the patients had pN1 and pN2–3 axillary lymph node 
disease, respectively. The mean size of the macrometastases was 15 mm (range, 6–50 
mm). Patient, tumour, and treatment characteristics are summarised in Table 1.
TABLE 1. Patient, tumour, and treatment characteristics
All patients (n=49)
Age (years) (mean; range) 57 [34 – 79]
Clinical tumour size (mm) (mean; range) 35 [4 – 100]















































Abbreviations: ER, Estrogen Receptor; HER2, Human Epidermal growth factor Receptor 2; Triple negative, negative 
for ER, PR, and HER2
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Diagnostic performance of axillary ultrasound
Of the 49 patients classi!ed as clinically node-positive on US, 46 (93.9%) were classi!ed 
as having N1 axillary lymph node disease and 3 (6.1%) were classi!ed as having N2–3 
axillary lymph node disease. In the case of 1–3 suspicious axillary lymph nodes evaluated 
on US, pN2–3 was found in 30.4% of the patients with a PPV of 69.6%. In the case of 
*4 suspicious axillary lymph nodes evaluated on US, pN1 was found in 33.3% of the 
patients with an NPV of 66.7% (Table 2).
Diagnostic performance of standard breast MRI
Of the 49 patients that were clinically node-positive on US, reader 1 classi!ed 37 (75.5%) 
patients as having N1 axillary lymph node disease and 12 (24.5%) patients as having 
N2–3 axillary lymph node disease on breast MRI. Reader 2 classi!ed 36 (73.5%) patients 
as having N1 axillary lymph node disease and 13 (26.5%) patients as having N2–3 axillary 
lymph node disease on breast MRI. In the case of 1–3 suspicious axillary lymph nodes 
evaluated on breast MRI, pN2–3 was found in 22.2–24.3% of the patients with a PPV 
of 75.7–77.8%. In the case of *4 suspicious axillary lymph nodes evaluated on breast 
MRI, pN1 was found in 38.5–41.7% of the patients with an NPV of 58.3–61.5% (Table 
2). Interobserver agreement between the two radiologists for reviewing the breast MRI 
exams was considered good (k = 0.73).
Breast MRI of reader 1 was comparable to US in terms of both sensitivity (84.8% vs 97.0%, 
p = 0.10), PPV (75.7% vs 69.6%, p = 0.13), NPV (58.3% vs 66.7%, p = 0.77), and accuracy 
(71.4% vs 69.4%, p = 0.99). Breast MRI of reader 1 showed better speci!city (43.8% vs 
12.5%, p = 0.03) compared to US. Breast MRI of reader 2 was comparable to US in terms 
of both sensitivity (84.8% vs 97.0%, p = 0.10), PPV (77.8% vs 69.6%, p = 0.06), NPV (61.5% 
vs 66.7%, p = 0.85), and accuracy (73.5% vs 69.4%, p = 0.77). Breast MRI of reader 2 also 
showed better speci!city (50.0% vs 12.5%, p = 0.01) compared to US.
The subgroup analysis showed that 46 patients had N1 axillary lymph node disease on 
US. Reader 1 correctly classi!ed 75.0% (27/36) of the patients as having pN1 axillary 
lymph node disease and 50.0% (5/10) of the patients as having pN2–3 axillary lymph 
node disease on breast MRI. Reader 2 correctly classi!ed 77.1% (27/35) of the patients 
as having pN1 axillary lymph node disease and 54.5% (6/11) of the patients as having 
pN2–3 axillary lymph node disease on breast MRI (Table 3). Interobserver agreement 
between the two radiologists for reviewing the subgroup breast MRI exams was 
considered good (k = 0.69).
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Abbreviations: MRI1, MRI reader 1; MRI2, MRI reader; NPV, negative predictive value; PPV, positive predictive value
a McNemar and generalised score test for comparison of diagnostic performance parameters between US and 
breast MRI of reader 1
b McNemar and generalised score test for comparison of diagnostic performance parameters between US and 
breast MRI of reader 2
Data in parenthesis are absolute numbers. Data in brackets are 95% con#dence intervals.
TABLE 3. Diagnostic performance of standard breast MRI for di$erentiation between pN1 and pN2-3 if 
ultrasound showed 1-3 suspicious axillary lymph nodes
MRI reader 1 (n=46) MRI reader 2 (n=46)
Sensitivity 84.4% (27/32) [67.2 – 94.7] 84.4% (27/32) [67.2 – 94.7]
Speci!city 35.7% (5/14) [12.8 – 64.9] 42.9% (6/14) [17.7 – 71.1]
PPV 75.0% (27/36) [57.8 – 87.9] 77.1 % (27/35) [59.9 – 89.6] 
NPV 50.0% (5/10) [18.7 – 81.3] 54.5% (6/11) [23.4 – 83.3]
Accuracy 69.6% (32/46) [54.2 – 82.3] 71.7% (33/46) [56.5 – 84.0]
Abbreviations: NPV, negative predictive value; PPV, positive predictive value
Data in parenthesis are absolute numbers. Data in brackets are 95% con#dence intervals.
DISCUSSION
Non-invasive preoperative di$erentiation between pN1 and pN2–3 has become 
increasingly important since this can provide relevant information regarding surgical 
planning and guiding adjuvant radiation therapy. In this study, we showed that 
the diagnostic performance of preoperative axillary US and standard breast MRI is 
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comparable and inaccurate for di$erentiation between pN1 and pN2–3 in clinically 
node-positive breast cancer patients. Furthermore, when US showed 1–3 suspicious 
axillary lymph nodes, an additional preoperative standard breast MRI correctly 
diagnosed pN2–3 in only 50.0–54.5% of these patients.
ALND and radiation therapy to the chest wall or (reconstructed) breast and infraclavicular/
supraclavicular lymph nodes are recommended in breast cancer patients with *4 axillary 
lymph node metastases who are at signi!cant risk of locoregional recurrence in the chest 
wall or conserved breast and nodal basins, regardless of the response to NST.27–29 The 
number of positive nodes is not only important for guiding adjuvant radiation therapy, 
but also the timing of breast reconstruction in patients treated with primary surgery. 
Previous research has demonstrated that radiation therapy on the reconstructed breast 
can increase complication rates and may compromise the aesthetic outcomes, especially 
in implant-based reconstructions.30–33 Therefore, preoperative identi!cation of pN2–3 
disease is preferable in patients with a desire for immediate breast reconstruction to 
avoid potential radiation therapy complications.
In the diagnostic workup of breast cancer patients, the US and US-guided FNAC or 
core needle biopsy are widely accepted for the assessment of axillary lymph node 
metastases given the low morbidity, cost-e$ectiveness, and high accuracy.17,34 Previous 
studies have addressed the ability of axillary US for di$erentiation between pN0-N1 
and pN2-N3.17,35 They reported that a negative axillary US can exclude pN2–3 with an 
NPV of 96.0–97.7%.17,35 In the case of a positive axillary US, the ability to exclude pN2–3 
was considered insu&cient with a reported NPV of 58.5–71%.35,36 This is in line with our 
results. We demonstrated that the ability to exclude pN2–3 was 69.6% in the case of 1–3 
suspicious axillary lymph nodes on US.
A standard breast MRI is frequently added to the diagnostic workup of breast cancer 
patients for a more accurate display of tumour size or extent. Since breast MRI includes 
the complete FOV of the axillary region in 1 out of 3 patients, it may provide the radiologist 
with the opportunity to evaluate axillary lymph node metastases.36 Compared to the US, 
MRI has the advantage to visualise deeper-lying lymph nodes, the ability to assess the 
contralateral axilla at the same time, and lack of operator dependence.37 An additional 
breast MRI in clinically node-positive patients has not been studied before. Hyun et al. 
reported that by adding breast MRI to negative cases of US and US-guided biopsy, pN2–
3 was excluded in 98.0% of the patients.38 In our study, we added a breast MRI to positive 
cases of US-guided biopsy. We showed that an additional breast MRI in clinically node-
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positive patients excluded pN2–3 in 75.7–77.8% of the patients. However, 38.5–41.7% 
of the patients were incorrectly classi!ed as N2–3 axillary lymph node disease on breast 
MRI.
Since US and breast MRI are of limited value in clinically node-positive patients for 
di$erentiation between pN1 and pN2–3, the focus should perhaps shift to other imaging 
modalities. Other promising non-invasive imaging modalities are being investigated 
for the assessment of axillary lymph node metastases, such as PET/CT and PET/MRI. In 
the meta-analysis of Liang et al., the diagnostic performance of MRI and PET/CT was 
compared for the assessment of axillary lymph node metastases.39 They showed that 
MRI (94.0%) has a higher pooled area under the ROC curve compared to PET/CT (88.0%) 
for diagnosing axillary lymph node metastases.39 With the introduction of hybrid PET/
MRI systems, the diagnostic advantages of MRI and PET are combined. Melsaether et 
al. showed that PET/MRI improves the diagnostic performance of axillary lymph node 
metastases detection from 88.0% to 100% compared to PET/CT.40 In the Nijnatten et al. 
study, dedicated axillary PET/MRI was compared to other imaging modalities (i.e., US, 
MRI, and PET/CT).41 PET/MRI resulted in a nodal status change of 40.0–75.0% compared 
to US and MRI, respectively, and a nodal status change of 22.0% compared to PET/CT.41 
However, not all studies on PET/CT and PET/MRI take into account the number of lymph 
node metastases.
In the present study, size and morphology were used for the assessment of axillary lymph 
node metastases on the unenhanced T2-weighted MR sequence. The unenhanced MR 
imaging seems to be one of the most promising sequences for axillary lymph node 
metastases assessment due to the anatomical characterisation of the axillary lymph 
nodes.42,43 It has been previously shown that the use of a dedicated axilla coil improves 
the accuracy of axillary lymph node staging.44–47 However, it was chosen to use the size 
and morphology on the unenhanced T2-weighted breast MR sequence to facilitate 
possible implementation in other hospitals.
This study has certain limitations. The analyses were based on a small group of patients. 
This might have caused clinically meaningful di$erences in diagnostic performance 
to go undetected. However, the di$erentiation between pN1 and pN2–3 has not 
been studied before in clinically node-positive patients. Sample size expansion is not 
possible given that nowadays almost every clinically node-positive patient receives 
NST. In addition, the diagnostic performance parameters were based on a patient-
by-patient level instead of a node-by-node level. All patients were treated with ALND, 
but the precise correlation between the visualised suspicious lymph nodes on US and 
breast MRI and the pathological results were not available, resulting in no node-by-
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node analysis. Further, di$erent MRI scanners with varying protocols were used in the 
two medical centres. Given the small sample size in this study, a comparison between 
MR protocols was not possible. However, all MRI systems and protocols conform to the 
guidelines of the European Society of Breast Imaging. Finally, in this study, a dedicated 
axillary MR protocol was not available. A dedicated axilla coil could have improved the 
diagnostic performance parameters of MRI. Although, all MRI exams were pre-screened 
for a complete FOV of the axillary region.
CONCLUSION
In clinically node-positive breast cancer patients, the diagnostic performance of 
preoperative axillary US and standard breast MRI is comparable and both imaging 
modalities are unable to accurately di$erentiate between pN1 and pN2–3. An additional 
preoperative standard breast MRI can correctly diagnose pN2–3 in only 50.0–54.5% of 
the patients when US showed 1–3 suspicious axillary lymph nodes. Based on this study, 
there is no added clinical value of preoperative standard breast MRI for di$erentiation 
between pN1 and pN2–3 in patients with positive axillary US.
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SUPPLEMENTARY MATERIAL A. OVERVIEW OF 
MR PROTOCOLS FOR STANDARD BREAST MRI
Maxima Medical Centre, Eindhoven, The Netherlands
MRI 1: Philips Gyroscan NT 1.5 Tesla
Coil






















Pixel size (mm) 0.7 x 0.7 0.7 x 0.7 0.7 x 0.7 0.7 x 0.7 0.7 x 0.7 0.7 x 0.7
Repetition time (ms) 2500 2500 2500 2500 2500 2500
Echo time (ms) 100 100 100 100 100 100
Echo train length 24 24 24 24 24 24
Flip angle (°) 90 90 90 90 90 90
Slice thickness (mm) 2.5 2.5 2.5 2.5 2.5 2.5
MRI 2: Philips Ingenia R4.2
Coil
2013 2014
Sense breast 16-channel Sense breast 16-channel
Pixel size (mm) 0.8 x 0.8 0.8 x 0.8
Repetition time (ms) 3957 3957
Echo time (ms) 110 110
Echo train length 23 23
Flip angle (°) 90 90
Slice thickness (mm) 2.5 2.5
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Maastricht University Medical Centre+, Maastricht, The Netherlands
MRI 1: Philips Intera 1.5 Tesla
Coil



















Pixel size (mm) 0.7 x 0.7 0.6 x 0.6 1.0 x 1.0 1.0 x 1.0 1.0 x 1.0 1.0 x 1.0
Repetition time (ms) 5922 3012 2000 2000 2000 2000
Echo time (ms) 110 110 204 205 205 258
Echo train length 33 33 80 80 80 96
Flip angle (°) 90 90 90 90 90 90
Slice thickness (mm) 3.0 3.0 2.0 2.0 2.0 2.0
MRI 2: Philips Ingenia 1.5 Tesla
Coil



















Pixel size (mm) 0.7 x 0.7 0.6 x 0.6 0.9 x 0.9 0.9 x 0.9 0.9 x 0.9 0.9 x 0.9
Repetition time (ms) 8213 6845 2000 2000 2000 2000
Echo time (ms) 110 110 215 218 218 218
Echo train length 29 29 95 95 95 95
Flip angle (°) 90 90 90 90 90 90
Slice thickness (mm) 3.0 3.0 2.0 2.0 2.0 2.0
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Radiomics features may contribute to increased diagnostic performance of MRI in 
prediction of axillary lymph node metastasis. The objective of the study was to predict 
preoperative axillary lymph node metastasis in breast cancer using clinical models 
and radiomics models based on T2-weighted (T2W) dedicated axillary MRI features 
with node-by-node analysis. From August 2012 until October 2014, all women who 
had undergone dedicated axillary 3.0T T2W MRI, followed by axillary surgery, were 
retrospectively identi!ed, and available clinical data were collected. All axillary lymph 
nodes were manually delineated on the T2W MR images, and quantitative radiomics 
features were extracted from the delineated regions. Data was partitioned patient-
wise to train 100 models using di$erent splits for the training and validation cohorts 
to account for multiple lymph nodes per patient and class imbalance. Features were 
selected in the training cohorts using recursive feature elimination with repeated 5-fold 
cross-validation, followed by development of random forest models. Performance of 
the models was assessed using the area under the curve (AUC). A total of 75 women 
(median age, 61 years; interquartile range, 51-68 years) with 511 axillary lymph nodes 
were included. On !nal pathology, 36 (7%) of the lymph nodes had metastasis. A 
total of 105 original radiomics features were extracted from the T2W MR images. Each 
cohort split resulted in di$erent number of lymph nodes in the training cohorts and 
di$erent set of selected features. Performance of the 100 clinical and radiomics models 
showed a wide range of AUC values between 0.41-0.74 and 0.48-0.89 in the training 
cohorts, respectively, and between 0.30-0.98 and 0.37-0.99 in the validation cohorts, 
respectively. With these results, it was not possible to obtain a !nal prediction model. 
Clinical characteristics and dedicated axillary MRI-based radiomics with node-by-node 
analysis did not contribute to prediction of axillary lymph node metastasis in breast 
cancer based on data where variations in acquisition and reconstruction parameters 
were not addressed.
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INTRODUCTION
In breast cancer patients, the axillary lymph node status provides essential prognostic 
information about the locoregional recurrence and overall survival rate.1-4 The !ve-year 
survival rate decreases from 99% to 85% with the presence of lymph node metastasis 
in the axilla.5 The presence of axillary lymph node metastasis determines the extent of 
the surgical treatment plan, the potential need for (neo)adjuvant systemic therapy, and 
the possible indication for postmastectomy radiation therapy with regard to immediate 
breast reconstruction.6,7
In the preoperative setting, imaging for axillary lymph node assessment is recommended 
in the clinical workup of invasive breast cancer patients.6 For the evaluation of tumor 
extent in the breast or following neoadjuvant treatment, breast magnetic resonance 
imaging (MRI) is often performed, which includes the axilla in the !eld of view.8 However, 
when using dedicated breast coils, the !eld of view of the axillary region can be limited.9 
Therefore, dedicated MR coils for visualization and assessment of the axillary region 
have been investigated.10-12 Dedicated unenhanced T2-weighted (T2W) axillary MRI 
showed good diagnostic performance based on node-by-node analysis but remained 
insu&cient to accurately exclude axillary lymph node metastasis.12
Although preoperative imaging may be performed to guide the axillary management 
of patients, no current imaging modality with optimal diagnostic performance can 
replace the surgical axillary staging procedure. In the era of arti!cial intelligence, 
current developments in radiology focus on the improvement of decision support 
systems to maximize the potential role of noninvasive imaging modalities. Radiomics, 
the application of machine learning to medical imaging, is a rapidly evolving !eld that 
enables high-throughput quantitative data extraction from standard medical images 
in an automated fashion and subsequent data analysis, possibly combined with 
patient and tumor characteristics, improving the accuracy of diagnostic, predictive, 
and prognostic models.13,14 The evaluation of the usefulness of radiomics based on 
mammography, ultrasound, and breast MRI has been explored, showing potential in 
axillary lymph node metastasis prediction.15-19 However, this research focused on the 
prediction of axillary lymph node metastasis from the delineated breast tumor as the 
region of interest (ROI), and not from the lymph nodes themselves.
Accurate preoperative prediction of axillary lymph node metastasis in breast cancer 
patients can assist in clinical decision-making regarding the type of treatment. 
Radiomics features extracted from axillary lymph nodes may contribute to increased 
diagnostic performance of MRI in the prediction of metastasis. To our knowledge, no 
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previous study has reported on node-by-node matching of axillary lymph nodes with 
pathological !ndings in breast cancer patients in the !eld of radiomics. The purpose 
of this study was to predict preoperative axillary lymph node metastasis in breast 
cancer patients using clinical models and radiomics models based on unenhanced T2W 
dedicated axillary MRI features with node-by-node analysis.
MATERIAL AND METHODS
Patient population
Consecutive women with histopathologically proven breast cancer, who had undergone 
dedicated axillary MRI between August 2012 and October 2014, followed by sentinel 
lymph node biopsy (SNLB) or axillary lymph node dissection (ALND), were considered 
for inclusion. Patients were excluded if they had undergone neoadjuvant systemic 
therapy before axillary surgery and in the case of ductal carcinoma in situ only. This 
study was approved by the local medical ethics committee, and the requirement of 
written informed consent was waived due to the retrospective study design. Fifty of 
the dedicated axillary T2W and di$usion-weighted MR images were earlier described 
by Schipper et al. for axillary lymph node staging, and 90 of the dedicated axillary T2W 
and gadofosveset-enhanced MR images were earlier described by Van Nijnatten et al. 
for axillary lymph node staging.12,20
Clinical and pathological characteristics
Clinical and pathological data were derived from the patients’ medical records: age, 
clinical TNM stage, pathological TNM stage, tumor histology, tumor grade, breast cancer 
subtype, and type of axillary surgery. Lymph nodes with isolated tumor cells ('0.2 mm) 
and micrometastases (>0.2-'2.0 mm) were considered negative, while those with 
macrometastases (>2.0 mm) were considered positive.
MRI acquisition
The dedicated axillary MR images were performed using a 32-channel cardiac coil on 
a 3.0 Tesla scanner (Achieva, Philips Healthcare, Best, the Netherlands). During the MRI 
examination, the patient was positioned in a supine position with the ipsilateral arm 
elevated. The anatomical con!nes of the dedicated axillary MR images were between 
the humeral head and the inferior border of the scapula. The MRI protocol included an 
unenhanced three-dimensional T2W turbo spin-echo sequence without fat suppression 
(pixel size, 1.25 x 1.25 mm; repetition time, 2000 ms; echo time between 150-202 ms; echo 
149873-samiei-layout.indd   70 11/03/2021   20:41
71
Dedicated axillary MRI-based radiomics 
train length, 52 or 66; %ip angle, 90°; acquisition slice thickness, 2.5 mm; reconstruction 
slice thickness, 1.25 mm), a contrast-enhanced T1-weighted sequence, and a di$usion-
weighted imaging sequence with fat suppression.
MRI lymph node delineation
All axillary lymph nodes of each dedicated axillary T2W MR image were manually 
delineated in three dimensions using MIM software (version 6.9.4, MIM Software 
Inc., Cleveland, Ohio, Unites States) by a medical researcher (S.S.) with three years of 
experience in axillary lymph node imaging validated by a dedicated breast radiologist 
(M.B.I.L.) with eleven years of experience (Figure 1). No clinical information and 
pathology results were available during delineation and validation. The delineated 
lymph nodes were subsequently matched with their histopathological !ndings (node-
by-node matching). Reliable node-by-node matching was obtained using single-
photon emission computed tomography-X-ray computed tomography (SPECT-CT) in 
patients undergoing SLNB, and an anatomical map was used for patients undergoing 
ALND. The exact procedure of the node-by-node matching was previously described by 
Schipper et al.21
MRI preprocessing and feature extraction
Image preprocessing of the T2W images was performed after delineation. Bias !eld 
correction was applied to every T2W MR image using MIM software to correct for 
non-uniform grayscale intensities caused by !eld inhomogeneities. To ensure better 
comparability of voxel intensities, additional image normalization and discretization 
was performed by the open-source Pyradiomics software (version 2.2.0) prior to feature 
extraction.22 For discretization, grayscale values were aggregated with a !xed bin width 
of 10, which ensured the recommended amount of bins between 30-130.22 Resampling 
was not required, as all images consisted of isotropic voxels of equal size 1.25 mm3. 
Quantitative radiomics features were extracted from the delineated regions using the 
Pyradiomics software. The extracted features can be subdivided into the following 
classes: !rst-order statistics, three-dimensional shape-based, gray level co-occurrence 
matrix, gray level run length matrix, gray level size zone matrix, neighboring gray tone 
di$erence matrix, and gray level dependence matrix.
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FIGURE 1. Coronal T2-weighted dedicated axillary MR image of a 55-year old woman with invasive breast 
cancer, who was treated with mastectomy and axillary lymph node dissection (pT1N2). The MR image 
demonstrates an example of delineations of lymph nodes in the right axilla on the MIM software.
Radiomics feature selection and model development
Taking into account the small skewed dataset and the unavailability of an external 
validation dataset, the data were randomly divided into training and validation cohort 
100 times using two di$erent strategies to create a more balanced training cohort. In the 
!rst strategy, 85% (12 out of 14) of the node-positive (i.e., patients with axillary lymph 
node metastasis at !nal pathology) breast cancer patients were selected in the training 
cohort, and all remaining node-positive and node-negative (i.e., patients without axillary 
lymph node metastasis at !nal pathology) patients in the validation cohort, considering 
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each axillary lymph node as an individual data point when training the model. In the 
second strategy, only the lymph nodes of patients with node-positive breast cancer 
were considered as individual data points when training and validating the model. To 
maintain the original class imbalance of the node-positive patients, 10 patients were 
selected in the training cohort. For both strategies, additional models were developed 
using a random undersampled balanced training cohort. All lymph nodes of one 
patient were always included in either the training cohort or the validation cohort, and 
therefore each split caused a varying number of positive lymph nodes in each cohort. 
Feature selection started with the removal of near-zero variance features followed by 
the removal of highly correlated features using the Pearson pairwise correlation greater 
than 0.95. Subsequently, recursive feature elimination with bagged trees was applied 
with repeated 5-fold cross-validation to select a maximum number of features in the 
training cohort. The number of features was chosen at the point when the addition of 
more features did not increase the diagnostic performance of the models. Random forest 
binary classi!cation models were trained, using optimized random forest parameters 
(number of trees and features per node) for the training cohort, selecting the optimal 
number of features for each generated model. In addition, a separate set of models was 
generated using the same pipeline but by adding an additional feature selection step at 
the very beginning. In this step, features robust to the variability of manual delineations 
of breast tumors on MRI by four observers were selected according to three di$erent 
cut-o$ values (intraclass correlation coe&cient of >0.75, >0.80, and >0.90).23 Figure 2 
provides an overview of strategies 1 and 2 with the di$erent developed models.
FIGURE 2. Model strategies




A separate set of models was generated using the !rst and second strategy as described 
earlier on a dataset where ROIs with less than 50 voxels were excluded.22 On these 
models, only the additional feature selection step with di$erent intraclass correlation 
coe&cient cut-o$ values was not performed.
Clinical model development
Clinical models were trained based on clinical characteristics available before the 
axillary surgery. Random forest models with bagged tree function for the prediction of 
axillary lymph node metastasis were trained and validated using the same strategies 
as described above, except for the feature selection step, which was only the removal 
of highly correlated clinical characteristics. These clinical models were used to indicate 
the e$ect of known and unknown patient’s biological covariates compared to a pure 
imaging-based model as well as to rank the importance of the clinical characteristics in 
this dataset using the Gini impurity method.
Statistical analyses and study evaluation
The statistical analyses, including dataset splitting and balancing, feature selection, 
model development and performance evaluation, were performed in R (version 3.6.3; 
http//www.r-project.org) using R studio (version 1.2.1335, Vienna, Austria).24 The 
performance of all models was assessed using the area under the receiver operating 
characteristics curve (AUC), sensitivity, speci!city, positive predictive value (PPV), and 
negative predictive value (NPV). The Spearman correlation was used to calculate the 
correlation between the number of voxels per ROI and the corresponding pathological 
outcome. The radiomics work%ow was evaluated using the radiomics quality score 
(RQS).25 This study followed the Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines.26
RESULTS
Patients characteristics
A total of ninety women were considered for inclusion, of whom twelve were excluded 
due to treatment with neoadjuvant systemic therapy before axillary surgery and 
three with ductal carcinoma in situ only. Seventy-!ve patients (median age, 61 years; 
interquartile range, 51-68 years) with 511 axillary lymph nodes were included. Patient, 
tumor, and treatment characteristics are summarized in Table 1. The median number of 
axillary lymph nodes per patient was six, with a range of 1-18. Fourteen of the included 
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patients were node-positive at !nal pathology, with a total of 36 axillary lymph nodes 
with macrometastases and 58 axillary lymph nodes without metastasis. The remaining 
61 patients had 417 axillary lymph nodes without metastasis. The median number of 
voxels per ROI for all delineated axillary lymph nodes was 100 (interquartile range, 44-
236) and 310 (interquartile range, 130-1676) for all delineated axillary lymph nodes with 
metastasis. The Spearman correlation between the number of voxels per ROI and the 
corresponding pathological outcome was 0.22.
TABLE 1. Patient, tumor, and treatment characteristics
Characteristic Value
No. of patients 75
Age (years) (median; IQR) 61 (51-68)
Clinical tumor size (mm) (median, IQR) 19 (13-28)












































Abbreviations: ALND, Axillary lymph node dissection; ER, Estrogen receptor; HER2, Human epidermal growth factor 
receptor 2; IQR, interquartile range; SLNB, Sentinel lymph node biopsy
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Radiomics feature extraction and model development
A total of 105 original radiomics features were extracted from the dedicated axillary 
T2W MR images. No near-zero variance features were detected. Pearson pairwise 
correlation removed 53 highly correlated features. The optimal subset of features was 
selected in the training cohort using recursive feature elimination with repeated 5-fold 
cross-validation with a maximum of 20 features. Figure 3 shows the distribution of the 
number of selected features from the 100 iterations for the two di$erent strategies 
(lymph nodes from all patients versus only lymph nodes from node-positive patients as 
data points) for each model. Supplementary Material A includes a list of how often each 
feature was chosen in the 100 iterations for each model.
FIGURE 3. First (A) and second (B) strategy: distribution of the number of features in each developed model. 
The two di$erent models in both strategies were all developed 100 times.
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As each iteration resulted in a di$erent set of selected features for each model in both 
strategies, it was not possible to obtain a !nal prediction model. The minimum and 
maximum area under the curve (AUC) values in the training cohorts were 0.59-0.80, 
0.60-0.85, 0.48-0.84, 0.55-0.89 for models 1a, 1b, 2a, 2b, respectively. The median AUC 
values for all models in the training cohorts were between 0.72-0.73. All models showed 
a wider range of AUC values in the validation cohorts. The AUC value distribution for all 
models in the training and validation cohorts are presented in the violin plots in Figure 
4. The minimum and maximum sensitivity in the training cohorts were 30-66%, 53-83%, 
7-74%, 48-82% for models 1a, 1b, 2a, 2b, respectively. The median sensitivity for all 
models in the training cohorts was between 47-66%. All models showed lower median 
sensitivity in the validation cohorts. The minimum and maximum PPV in the training 
cohorts were 46-78%, 55-83%, 25-80%, 52-90% for models 1a, 1b, 2a, 2b, respectively. 
The median PPV for all models in the training cohorts were between 61-67%. All models 
showed a lower median PPV in the validation cohorts. The diagnostic performance 
parameters of the radiomics models (100 iterations) are shown in Table 2.
The additional feature selection step with the cut-o$ values >0.75, >0.80, and >0.90 
resulted in 44, 35, and 8 original features, respectively, available for recursive feature 
elimination with repeated 5-fold cross-validation. These results showed no di$erences 
compared to the results found without this additional feature selection step. The violin 
plots of the models developed after adding the additional feature selection step can be 
found in Figures S1-S3.
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FIGURE 4. Violin plots for the radiomics models developed using the !rst (A) and second (B) strategy: AUC 
value distributions (100 iterations) for the four models (1a, 1b, 2a and 2b) in both the training and validation 
cohort.
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FIGURE S1. Violin plots for the radiomics models developed using the !rst (A) and second (B) strategy with 
additional feature selection step (ICC > 0.75): AUC value distributions (100 iterations) for the four models (1a, 
1b, 2a and 2b) in both the training and validation cohort.
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FIGURE S2. Violin plots for the radiomics models developed using the !rst (A) and second (B) strategy with 
additional feature selection step (ICC > 0.80): AUC value distributions (100 iterations) for the four models (1a, 
1b, 2a and 2b) in both the training and validation cohort.
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FIGURE S3. Violin plots for the radiomics models developed using the !rst (A) and second (B) strategy with 
additional feature selection step (ICC > 0.90): AUC value distributions (100 iterations) for the four models (1a, 
1b, 2a and 2b) in both the training and validation cohort.
Radiomics subanalysis
After the exclusion of ROIs with less than 50 voxels, a total of 71 patients were included 
for analyses, with 371 axillary lymph nodes. Thirteen of these patients were node-
positive, with a total of 31 axillary lymph nodes with metastasis and 34 axillary lymph 
nodes without metastases. The remaining 58 patients had 340 axillary lymph nodes 
without metastasis. Excluding small lymph nodes resulted in balanced training cohorts 
in models 1a and 2a, eliminating the need to perform random undersampling (models 
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1b and 2b). The minimum and maximum AUC values of the balanced models 1a and 
2a in the training and validation cohorts of this subanalysis were 0.53-0.82 and 0.41-
0.83, respectively. Violin plots with the distribution of the AUC values and the diagnostic 
performance parameters of the subanalysis are provided in Table S1 and Figure S4.
FIGURE S4. Violin plots for the radiomics models with the exclusion of ROIs<50 voxels developed using the 
!rst strategy and second strategy: AUC value distribution (100 iterations) for the two models (1a and 2a) in 
both the training and validation cohort. 
Abbreviations: ROI, region of interest
Clinical model development
The following clinical characteristics were available and selected for the development 
of the clinical models: patient age, clinical tumor size, clinical tumor stage, tumor 
histology, tumor grade, and receptor subtype (ER, PR, and HER2+). No highly correlated 
clinical characteristics were present. The minimum and maximum AUC values in the 
training cohorts were 0.52-0.66, 0.43-0.71, 0.41-0.67, 0.43-0.74 for models 1a, 1b, 2a, 
2b, respectively. The median AUC values for all models in the training cohorts were 
between 0.59-0.60. All models showed a wider range of AUC values in the validation 
cohorts. The AUC value distribution for all models in the training and validation cohorts 
are presented in the violin plots in Figure 5. The minimum and maximum sensitivity in 
the training cohorts were 18-64%, 31-71%, 0-65%, 33-73% for models 1a, 1b, 2a, 2b, 
respectively. The median sensitivity for all models in the training cohorts was between 
42-58%. All models showed lower median sensitivity in the validation cohorts, except 
for model 2b. The minimum and maximum positive predictive value (PPV) in the training 
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cohorts were 42-71%, 41-85%, 48-73%, 43-86% for models 1a, 1b, 2a, 2b, respectively. 
The median PPV for all models in the training cohorts was between 68-70%. All models 
showed a lower median PPV in the validation cohorts, except for model 2a. In all four 
models, the clinical tumor size was ranked as the most important clinical characteristic 
followed by age. The diagnostic performance parameters of the clinical models (100 
iterations) are shown in Table 3.
FIGURE 5. Violin plots for the clinical models developed using the !rst (A) and second (B) strategy: AUC value 
distributions (100 iterations) for the four models (1a, 1b, 2a and 2b) in both the training and validation cohort.











































































































































































































































































































































































































































149873-samiei-layout.indd   86 11/03/2021   20:41
87
Dedicated axillary MRI-based radiomics 
RQS and TRIPOD
This study scored an radiomics quality score (RQS) of 58% (21 out of 36 points) (Table 
S2). The score of the transparent reporting of a multivariable prediction model for 
individual prognosis or diagnosis (TRIPOD) checklist was 67% (18 out of 27 applicable 
items) (Table S3).
TABLE S2. Radiomics Quality Score
Criteria Points
Image protocol quality + 1
Multiple segmentations + 1
Phantom study on all scanners + 0
Imaging at multiple time points + 0
Feature reduction or adjustment for multiple testing + 3
Multivariate analysis with non radiomics features + 0
Detect and discuss biological correlates + 0
Cut-o$ analyses + 0
Discrimination statistics + 2
Calibration statistics + 1
Prospective study registered in a trial database + 7
Validation + 2
Comparison to 'gold standard' + 2
Potential clinical utility + 2
Cost-e$ectiveness analysis + 0
Open science and data + 0
Total 21 
A total of 36 points can be achieved, with higher scores indicating higher research quality. !
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TABLE S3. TRIPOD Checklist.
Y=yes; N=no; R=referenced; NA=not applicable
Title and abstract
1 Identify the study as developing and/or validating a multivariable 
prediction model, the target population, and the outcome to be predicted.
0
i The words developing/development, validation/validating, 
incremental/added value (or synonyms) are reported in the title
N
ii The words prediction, risk prediction, prediction model, risk models, prognostic 
models, prognostic indices, risk scores (or synonyms) are reported in the title
Y
iii The target population is reported in the title Y
iv The outcome to be predicted is reported in the title Y
2 Provide a summary of objectives, study design, 
setting, participants, sample size, predictors, outcome, 
statistical analysis, results, and conclusions.
0
i The objectives are reported in the abstract Y
ii Sources of data are reported in the abstract
E.g. Prospective cohort, registry data, RCT data.
Y
iii The setting is reported in the abstract
E.g. Primary care, secondary care, general population, adult  care, 
or paediatric care. The setting should be reported for  both the 
development and validation datasets, if applicable.
Y
iv A general de!nition of the study participants is reported in the abstract
E.g. patients with suspicion of certain disease, patients with 
a speci#c disease, or general eligibility criteria. 
Y
v The overall sample size is reported in the abstract Y
vi The number of events (or % outcome together with 
overall sample size) is reported in the abstract
If a continuous outcome was studied, score Not applicable (NA).
Y
vii Predictors included in the !nal model are reported in the 
abstract. For validation studies of well-known models, at least 
the name/acronym of the validated model is reported
Broad descriptions are su$cient, e.g. ‘all information from 
patient history and physical examination’.
Check in the main text whether all predictors of the #nal 
model are indeed reported in the abstract.
N
viii The outcome is reported in the abstract Y
ix Statistical methods are described in the abstract
For model development, at least the type of statistical model should be reported. 
For validation studies a quote like “model’s discrimination and calibration was 
assessed” is considered adequate. If done, methods of updating should be reported.
Y
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TABLE S3. Continued
x Results for model discrimination are reported in the abstract
This should be reported separately for development and validation 
if a study includes both development and validation.
N
xi Results for model calibration are reported in the abstract
This should be reported separately for development and validation 
if a study includes both development and validation.
N
xii Conclusions are reported in the abstract
In publications addressing both model development and validation, there 
is no need for separate conclusions for both; one conclusion is su$cient.
Y
3a Explain the medical context (including whether diagnostic or 
prognostic) and rationale for developing or validating the multivariable 
prediction model, including references to existing models.
1
i The background and rationale are presented Y
ii Reference to existing models is included (or stated 
that there are no existing models)
Y
3b Specify the objectives, including whether the study describes 
the development or validation of the model or both.
1
i It is stated whether the study describes development and/
or validation and/or incremental (added) value
Y
Methods !
4a Describe the study design or source of data (e.g., 
randomized trial, cohort, or registry data), separately for the 
development and validation data sets, if applicable.
1
i The study design/source of data is described
E.g. Prospectively designed, existing cohort, existing RCT, 
registry/medical records, case control, case series.
This needs to be explicitly reported; reference to this 
information in another article alone is insu$cient.
Y
4b Specify the key study dates, including start of accrual; 
end of accrual; and, if applicable, end of follow-up.  
1
i The starting date of accrual is reported Y
ii The end date of accrual is reported Y
iii The length of follow-up and prediction horizon/
time frame are reported, if applicable
E.g. “Patients were followed from baseline for 10 years“ and “10-year 
prediction of…”; notably for prognostic studies with long term follow-up.
If this is not applicable for an article (i.e. diagnostic study 
or no follow-up), then score Not applicable (NA).
NA
5a Specify key elements of the study setting (e.g., primary care, secondary 
care, general population) including number and location of centres.
1




i The study setting is reported (e.g. primary care, 
secondary care, general population)
E.g.: ‘surgery for endometrial cancer patients’ is considered 
to be enough information about the study setting.
Y
ii The number of centres involved is reported
If the number is not reported explicitly, but can be concluded from the 
name of the centre/centres, or if clearly a single centre study, score Yes.
Y
iii The geographical location (at least country) of centres involved is reported
If no geographical location is speci#ed, but the location can be 
concluded from the name of the centre(s), score Yes.
Y
5b Describe eligibility criteria for participants. 1
i In-/exclusion criteria are stated
These should explicitly be stated. Reasons for exclusion 
only described in a patient %ow is not su$cient. 
Y
5c Give details of treatments received, if relevant.
(i.e. notably for prognostic studies with long term follow-up)
Not applicable
i Details of any treatments received are described
This item is notably for prognostic modelling studies and is about 
treatment at baseline or during follow-up. The ‘if relevant’ judgment 
of treatment requires clinical knowledge and interpretation.
If you are certain that treatment was not relevant, e.g. in some 
diagnostic model studies, score Not applicable.
NA
6a Clearly de"ne the outcome that is predicted by the 
prediction model, including how and when assessed. 
1
i The outcome de!nition is clearly presented
This should be reported separately for development and 
validation if a publication includes both. 
Y
ii It is described how outcome was assessed (including all elements 
of any composite, for example CVD [e.g. MI, HF, stroke]).
Y
iii It is described when the outcome was assessed (time point(s) since T0) Y
6b Report any actions to blind assessment of the outcome to be predicted. 1
i Actions to blind assessment of outcome to be predicted are reported
If it is clearly a non-issue (e.g. all-cause mortality or an outcome not requiring 
interpretation), score Yes. In all other instances, an explicit mention is expected.
Y
7a Clearly de"ne all predictors used in developing 
or validating the multivariable prediction model, 
including how and when they were measured.
1
i All predictors are reported
For development, “all predictors” refers to all predictors that 
potentially could have been included in the ‘#nal’ model 
(including those considered in any univariable analyses).
For validation, “all predictors” means the predictors in the model being evaluated.
Y
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TABLE S3. Continued
ii Predictor de!nitions are clearly presented Y
iii It is clearly described how the predictors were measured Y
iv It is clearly described when the predictors were measured Y
7b Report any actions to blind assessment of predictors 
for the outcome and other predictors. 
1
i It is clearly described whether predictor assessments were blinded for outcome
For predictors for which it is clearly a non-issue (e.g. automatic 
blood pressure measurement, age, sex) and for instances where the 
predictors were clearly assessed before outcome assessment, score 
Yes. For all other predictors an explicit mention is expected.
Y
ii It is clearly described whether predictor assessments 
were blinded for the other predictors
Y
8 Explain how the study size was arrived at. 1
i It is explained how the study size was arrived at
Is there any mention of sample size, e.g. whether this was done 
on statistical grounds or practical/logistical grounds (e.g. an 
existing study cohort or data set of a RCT was used)? 
Y
9 Describe how missing data were handled (e.g., complete-
case analysis, single imputation, multiple imputation) 
with details of any imputation method. 
0
i The method for handling missing data (predictors and outcome) is mentioned
E.g. Complete case (explicit mention that individuals with missing values have been 
excluded), single imputation, multiple imputation, mean/median imputation.
If there is no missing data, there should be an explicit mention that there 
is no missing data for all predictors and outcome. If so, score Yes.
If it is unclear whether there is missing data (from e.g. 
the reported methods or results), score No.
If it is clear there is missing data, but the method for 
handling missing data is unclear, score No.
N
ii If missing data were imputed, details of the software used are given
When under 9i explicit mentioning of no missing data, complete 
case analysis or no imputation applied, score Not applicable.
NA
iii If missing data were imputed, a description of which variables 
were included in the imputation procedure is given
When under 9i explicit mentioning of no missing data, complete 
case analysis or no imputation applied, score Not applicable.
NA
iv If multiple imputation was used, the number of imputations is reported
When under 9i explicit mentioning of no missing data, complete 
case analysis or no imputation applied, score Not applicable.
NA
10a Describe how predictors were handled in the analyses. 1




i For continuous predictors it is described whether they were modelled 
as linear, nonlinear (type of transformation speci!ed) or categorized
A general statement is su$cient, no need to describe 
this for each predictor separately.
If no continuous predictors were reported, score Not applicable.
Y
ii
For categorical or categorized predictors, the cut-points were reported
If no categorical or categorized predictors were reported, score Not applicable.
NA
iii For categorized predictors the method to choose 
the cut-points was clearly described
If no categorized predictors, score Not applicable.
NA
10b Specify type of model, all model-building procedures (including 
any predictor selection), and method for internal validation. 
1
i The type of statistical model is reported
E.g. Logistic, Cox, other regression model (e.g. Weibull, ordinal), 
other statistical modelling (e.g. neural network)
Y
ii The approach used for predictor selection before modelling is described
‘Before modelling’ means before any univariable or multivariable 
analysis of predictor-outcome associations.
If no predictor selection before modelling is done, score Not applicable.
If it is unclear whether predictor selection before modelling is done, score No.
If it is clear there was predictor selection before modelling 
but the method was not described, score No.
Y
iii The approach used for predictor selection during modelling is described
E.g. Univariable analysis, stepwise selection, bootstrap, Lasso.
‘During modelling’ includes both univariable or multivariable 
analysis of predictor-outcome associations.
If no predictor selection during modelling is done (so-
called full model approach), score Not applicable.
If it is unclear whether predictor selection during modelling is done, score No.
If it is clear there was predictor selection during modelling 
but the method was not described, score No.
Y
iv Testing of interaction terms is described
If it is explicitly mentioned that interaction terms were not 
addressed in the prediction model, score Yes.
If interaction terms were included in the prediction model, 
but the testing is not described, score No.
Y
v Testing of the proportionality of hazards in survival models is described
If no proportional hazard model is used, score Not applicable.
NA
vi Internal validation is reported
E.g. Bootstrapping, cross validation, split sample.
If the use of internal validation is clearly a non-issue (e.g. in case of very large 
data sets), score Yes. For all other situations an explicit mention is expected.
Y
10c For validation, describe how the predictions were calculated. Not applicable
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TABLE S3. Continued
10d Specify all measures used to assess model performance 
and, if relevant, to compare multiple models.
These should be described in methods section of the paper (item 16 
addresses the reporting of the results for model performance). 
0
i Measures for model discrimination are described
E.g. C-index / area under the ROC curve.
Y
ii Measures for model calibration are described
E.g. calibration plot, calibration slope or intercept, calibration 
table, Hosmer Lemeshow test, O/E ratio.
N
iii Other performance measures are described
E.g. R2, Brier score, predictive values, sensitivity, speci#city, 
AUC di"erence, decision curve analysis, net reclassi#cation 
improvement, integrated discrimination improvement, AIC.
Y
10e Describe any model updating (e.g., recalibration) 
arising from the validation, if done.
Not applicable
11 Provide details on how risk groups were created, if done.
If risk groups were not created, score this item as Yes.
Not applicable
i If risk groups were created, risk group boundaries (risk thresholds) are speci!ed
Score this item separately for development and validation if 
a study includes both development and validation.
If risk groups were not created, score this item as not applicable.
NA
12 For validation, identify any di#erences from the development 
data in setting, eligibility criteria, outcome and predictors. 
Not applicable
Results !
13a Describe the $ow of participants through the study, including the 
number of participants with and without the outcome and, if applicable, 
a summary of the follow-up time. A diagram may be helpful.
1
i The %ow of participants is reported Y
ii The number of participants with and without the outcome are reported
If outcomes are continuous, score Not applicable.
Y
iii A summary of follow-up time is presented
This notably applies to prognosis studies and diagnostic 
studies with follow-up as diagnostic outcome.
If this is not applicable for an article (i.e. diagnostic study 
or no follow-up), then score Not applicable.
NA
13b Describe the characteristics of the participants (basic demographics, 
clinical features, available predictors), including the number of 
participants with missing data for predictors and outcome. 
0
i Basic demographics are reported Y
ii Summary information is provided for all predictors 
included in the !nal developed/validated model
N




iii The number of participants with missing data for predictors is reported N
iv The number of participants with missing data for the outcome is reported N
13c For validation, show a comparison with the development 
data of the distribution of important variables 
(demographics, predictors and outcome).
Not applicable
14a Specify the number of participants and outcome events in each analysis. 0
i The number of participants in each analysis (e.g. in the analysis of 
each model if more than one model is developed) is speci!ed
N
ii The number of outcome events in each analysis is speci!ed (e.g. in 
the analysis of each model if more than one model is developed)
If outcomes are continuous, score Not applicable.
N
14b If done, report the unadjusted association between 
each candidate  predictor and outcome.
Not applicable
i The unadjusted associations between each predictor and outcome are reported
If any univariable analysis is mentioned in the 
methods but not in the results, score No.
If nothing on univariable analysis (in methods or results) 
is reported, score this item as Not applicable.
NA
15a Present the full prediction model to allow predictions for 
individuals (i.e., all regression coe%cients, and model 
intercept or baseline survival at a given time point).
0
i The regression coe&cient (or a derivative such as hazard ratio, odds 
ratio, risk ratio) for each predictor in the model is reported 
N
ii The intercept or the cumulative baseline hazard (or baseline 
survival) for at least one time point is reported
N
15b Explain how to use the prediction model. 0
i An explanation (e.g. a simpli!ed scoring rule, chart, nomogram of the 
model, reference to online calculator, or worked example) is provided 
to explain how to use the model for individualised predictions.
N
16 Report performance measures (with con"dence 
intervals) for the prediction model.
These should be described in results section of the paper (item 10 
addresses the reporting of the methods for model performance).
0
i A discrimination measure is presented
E.g. C-index / area under the ROC curve.
Y
ii The con!dence interval (or standard error) of the 
discrimination measure  is presented
Y
iii Measures for model calibration are described
E.g. calibration plot, calibration slope or intercept, calibration 
table, Hosmer Lemeshow test, O/E ratio.
N
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TABLE S3. Continued
iv Other model performance measures are presented
E.g. R2, Brier score, predictive values, sensitivity, speci#city, 
AUC di"erence, decision curve analysis, net reclassi#cation 
improvement, integrated discrimination improvement, AIC.
Y
17 If done, report the results from any model updating (i.e., 
model speci"cation, model performance, recalibration).
If updating was not done, score this TRIPOD item as ‘Not applicable’. 
Not applicable
Discussion !
18 Discuss any limitations of the study (such as nonrepresentative 
sample, few events per predictor, missing data). 
1
i Limitations of the study are discussed
Stating any limitation is su$cient.
Y
19a For validation, discuss the results with reference to performance 
in the development data, and any other validation data. 
Not applicable
19b Give an overall interpretation of the results considering objectives, 
limitations, results from similar studies and other relevant evidence.  
1
i An overall interpretation of the results is given Y
20 Discuss the potential clinical use of the model 
and implications for future research. 
1
i The potential clinical use is discussed
E.g. an explicit description of the context in which the prediction 
model is to be used (e.g. to identify high risk groups to help direct 
treatment, or to triage patients for referral to subsequent care).
Y
ii Implications for future research are discussed
E.g. a description of what the next stage of investigation of the prediction 
model should be, such as ”We suggest further external validation”.
Y
Other information !
21 Provide information about the availability of supplementary 
resources, such as study protocol, web calculator, and data sets. 
!
i Information about supplementary resources is provided Y
22 Give the source of funding and the role of the 
funders for the present study. 
1
i The source of funding is reported or there is explicit mention 
that there was no external funding involved
Y
ii The role of funders is reported or there is explicit 
mention that there was no external funding 
Y
Number of applicable TRIPOD items 27
Number of TRIPOD items adhered 18
OVERALL adherence to TRIPOD 67%




Accurate preoperative prediction of axillary lymph node metastasis can assist in clinical 
decision-making regarding the extent of axillary surgery and radiation therapy, and 
provide essential prognostic information. In this study, clinical models and radiomics 
models based on T2-weighted dedicated axillary MRI features with node-by-node 
analysis were investigated for the preoperative prediction of axillary lymph node 
metastasis. The di$erent sets of features selected at each split resulted in a wide range 
of AUC values and did not allow for the development of a !nal radiomics prediction 
model. The performance of the clinical models (AUC values between 0.41-0.74) was 
lower compared to the radiomics models (AUC values between 0.48-0.89) in the training 
cohorts. The validation results of both models showed a wider range of diagnostic 
performance parameters compared to the training results possibly explained by the 
small dataset, methodology used for selection and model building, and potential 
over!tting. The wide AUC range in the clinical models leads us to the hypothesis that 
the small dataset contains unseen biological covariates, and that therefore the wide 
AUC range in the radiomics models cannot be explained by variations in imaging alone.
To the best of our knowledge, this is the !rst study investigating the role of MRI-based 
radiomics for the prediction of axillary lymph node metastasis in breast cancer patients 
by extracting features from delineated axillary lymph nodes. Previously published 
articles investigated the same topic by extracting the features from the delineated 
breast tumor.15,27,28 These articles showed promising validation results with AUC values 
between 0.77-0.82. In this recent study, initially, the small ROI volumes were seen as a 
reason for the inconclusive results. If an ROI contains a low number of voxels, it may not 
be possible to calculate meaningful radiomics features.29 However, after the subanalysis 
excluding ROI volumes less than 50 voxels, the AUC values were between 0.53-0.82 and 
0.41-0.83 for the training cohorts for models 1a and 2a, respectively, which highlights the 
e$ects of di$erences in scan acquisition and reconstruction parameters. Furthermore, 
the skewed data in this recent study may have caused inconsistent results compared to 
the previous studies as models tend to favor the outcome that is more common.
To date, only two previously published articles extracted features from delineated 
lymph nodes for radiomics and deep learning analyses. The !rst article used a neural 
network to develop prediction models in head and neck cancer.30 The second article 
developed a radiomics model based on CT images of colorectal cancer patients.31 Both 
studies showed that there is potential by delineating lymph nodes for radiomics and 
deep learning analysis for the classi!cation of positive and negative lymph nodes. 
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The di$erences in results compared to this recent study may be due to the variety 
of implementation of the di$erent steps in the radiomics work%ow and the chosen 
imaging modality (CT vs. MRI).
The diagnostic performance of dedicated axillary T2W MRI for axillary lymph node 
staging has previously been investigated using node-by-node analysis.12 Schipper et al. 
showed AUC values  between 0.78-0.88, with a good interobserver agreement (kappa = 
0.70). The current analysis with MRI-based radiomics using dedicated axillary T2W MR 
images suggested that the quantitative analysis did not exceed the qualitative analysis 
by the radiologists. It was decided to only perform radiomics analyses using the T2W MR 
images, as previous research indicated that di$usion-weighted images and apparent 
di$usion coe&cient measurements have no added value for the axillary lymph node 
staging.12,32 Furthermore, a recently published article has shown that the evaluation of 
axillary lymph nodes with dedicated axillary MRI is comparable to standard breast MRI 
with a complete !eld of view of the axillary region.32 However, the majority of the breast 
MRI examinations are still performed with an incomplete !eld of view of the axillary 
region.9 In addition, the coronal view of the dedicated axillary MRI possibly provides 
more accurate delineations compared to the transversal view of the standard breast 
MRI, which could be of added value to the radiomics analysis.
Most radiomics studies su$er from small and heterogeneous datasets collected from 
di$erent imaging systems. In this current study, a great advantage for the radiomics 
analyses was the prospectively collected set of MR images on the same MRI scanner 
using an equal acquisition protocol with the patients in corresponding positions. 
Despite the prospectively collected dataset, a number of acquisition and reconstruction 
parameters varied depending on the patient. Furthermore, the di$erent sets of features 
selected in every training cohort resulted in a wide range of AUC values and did not 
allow the development of a !nal radiomics prediction model. This could be justi!ed by 
two theories: (i) The variations in acquisition and reconstruction parameters signi!cantly 
a$ected the value of radiomics features, resulting in non-comparable data points; or 
(ii) Radiomics features do not have an added value in the prediction of axillary lymph 
nodes metastasis. However, theory (ii) is less likely, as radiomics models performed well 
in some splits. Future MRI phantom and reproducibility studies should investigate the 
e$ect of MR image acquisition and reconstruction parameters on feature values to 
determine repeatable and reproducible features. We nevertheless believe that it is also 
important to publish inconclusive radiomics results since publication bias seems to play 
a role in this research !eld, with only 6% of the radiomics articles presenting negative 
results.33
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This study also has certain limitations. The large skewness of the data with only 7% 
positive axillary lymph nodes was a drawback for the analyses. The skewness of the 
data was addressed by splitting the dataset using two di$erent strategies and by using 
repeated cross-validation in the training cohort. However, it is important to note that 
the ratio of node-positive (19%) and node-negative (81%) breast cancer patients in 
this study is comparable to the clinics. Besides the skewness of the data, the included 
number of patients was relatively low for radiomics analysis, and selecting only node-
positive patients in strategy 2 decreased the number even further. However, since the 
dedicated axillary MRI is not included in the breast MRI protocol and no similar public 
dataset is available, it is not possible to expand this current dataset. Lastly, manual 
delineation of the axillary lymph nodes was performed by one researcher, which 
potentially could be a major limitation of the !ndings because of susceptibility of inter- 
and intra-observer variabilities.34 Although this issue has been addressed in this current 
study by developing models based on only robust features for varying breast tumor 
delineations.23 Based on the assumption that breast and lymph node delineations on 
MRI are comparable, varying delineations did not a$ect the radiomics results. However, 
this topic needs to be thoroughly investigated in future studies.
CONCLUSIONS
In conclusion, based on our results dedicated axillary MRI-based radiomics with node-
by-node analysis did not contribute to the prediction of axillary lymph node metastasis 
based on data where variations in acquisition and reconstruction parameters were 
not addressed. Larger datasets combined with MRI phantom data and reproducibility 
studies are necessary to determine if further radiomics research using dedicated axillary 
MR images for the prediction of axillary lymph node metastasis is of added value.
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Objective: The purpose of this study was to perform a systematic review and meta-
analysis to determine the diagnostic performance of current noninvasive imaging 
modalities for assessment of axillary response after neoadjuvant systemic therapy (NST) 
in clinically node-positive breast cancer patients.
Summary of Background Data: NST can lead to downstaging of axillary lymph node 
disease. Imaging can potentially provide information about the axillary response to NST 
and, consequently, tailor the surgical management.
Methods: PubMed and Embase were searched for studies that compared noninvasive 
imaging after NST with axillary surgery outcome to identify axillary response in patients 
with initial pathologically proven axillary lymph node metastasis. Two reviewers 
independently screened the studies and extracted the data. A meta-analysis was 
performed by computing the pooled sensitivity, speci!city, positive predictive value 
(PPV), and negative predictive value (NPV).
Results: Thirteen studies describing 2380 patients were included for !nal analysis. Of 
these patients, 1322 had undergone axillary ultrasound, 849 breast MRI, and 209 whole-
body 18F-FDG PET-CT. The overall axillary pathologic complete response rate was 39.5% 
(941/2380). For axillary ultrasound, the pooled sensitivity, speci!city, PPV, and NPV were 
65%, 69%, 77%, 50%, respectively. For breast MRI, the pooled sensitivity, speci!city, PPV, 
and NPV were 60%, 76%, 78%, 58%, respectively. For whole-body 18F-FDG PET-CT, the 
pooled sensitivity, speci!city, PPV, and NPV were 38%, 86%, 78%, 49%, respectively.
Conclusions: The diagnostic performance of current noninvasive imaging modalities is 
limited to accurately assess axillary response after NST in clinically node-positive breast 
cancer patients.
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INTRODUCTION
The increasing use of systemic therapy in the neoadjuvant setting has signi!cantly 
changed the axillary management of breast cancer patients. Neoadjuvant systemic 
therapy (NST) can downstage axillary lymph node disease, facilitating less invasive 
axillary staging techniques, and improving survival in patients that achieve pathologic 
complete response (pCR).1 Previous studies reported that up to 74% of the clinically 
node-positive patients can achieve axillary pCR after NST, dependent on the biological 
subtype of cancer.1,2
Until recently, axillary lymph node dissection (ALND) was a routine axillary procedure for 
clinically node-positive patients undergoing NST, regardless of the treatment response. 
Less invasive axillary procedures, such as sentinel lymph node biopsy (SLNB), targeted 
axillary dissection, marking axillary lymph nodes with radioactive iodine seeds, and 
combining radioactive iodine seed localization in the axilla with the sentinel node 
procedure, have been introduced for the axillary staging to avoid unnecessary ALND 
and the associated comorbidity.3–5 However, the overall false-negative rates (FNRs) of 
these less invasive procedures are still a concern. Consequently, there is a persisting lack 
of consensus about the optimal surgical method of the axilla after NST.3,4,6 Hence, ALND 
is still the standard in clinical practice and recommended in the current guidelines as 
appropriate surgical management for patients with clinically node-positive disease and 
these patients are still exposed to the unnecessary sequelae of this axillary surgery.7–9
With the evolving role of axillary management, imaging in the neoadjuvant setting has 
become of great interest. Imaging modalities can potentially provide information about 
the axillary response to NST and, consequently, tailor surgical management. Identifying 
the axillary lymph node status after NST with noninvasive imaging modalities may 
determine suitable patients for less invasive axillary procedures and even identify 
patients in which axillary surgery may be omitted. If the radiological response to NST 
could be accurately assessed in clinically node-positive patients, the de-escalation of 
axillary surgery could reduce surgical morbidity.
The purpose of this study was to perform a systematic review and meta-analysis 
to determine the diagnostic performance of noninvasive imaging modalities for 
assessment of axillary response after NST in clinically node-positive breast cancer 
patients.




This systematic review was conducted in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses.10
Literature search
For this systematic review, the electronic databases Embase and PubMed were searched 
until March 9, 2020, to identify studies that compared noninvasive imaging after NST 
with axillary surgery outcome in clinically node-positive patients. No search restrictions 
were applied for both search strategies. The search strategies are provided in full detail 
in Appendix 1.
Inclusion criteria and outcome measures
Studies were eligible if the diagnostic performance of clinically available imaging 
modalities after NST was evaluated in breast cancer patients with initial pathologically 
proven axillary lymph node metastasis. Patients had to be scheduled for a noninvasive 
imaging technique after NST, followed by any type of axillary surgery as part of their 
breast cancer management. Only articles in English, randomized controlled trials, case-
control studies, and cohort studies were selected for inclusion. Reviews, conference 
abstracts, case reports, technical reports, and editorials were excluded. If both clinically 
node-negative and clinically node-positive patients were described, only the clinically 
node-positive patients were included for further analysis. If only a part of the study 
population had pathologically proven axillary lymph node metastasis, only the patients 
with pathologically proven axillary lymph node metastasis were included for further 
analysis. Included studies had to report absolute numbers of true positive, false 
positive, false negative, and true negative test results to enable the construction of 
a 2 x 2 contingency table. The outcome was the diagnostic performance parameters 
[sensitivity, speci!city, positive predictive value (PPV), negative predictive value (NPV)] 
of imaging modalities for identifying residual axillary lymph node disease and axillary 
pCR after NST.
Study selection and data extraction
First, duplicate studies were excluded. Two reviewers (S.S. and C.M.d.M.) independently 
screened the titles and abstracts to assess eligibility. Subsequently, full-text articles of all 
potentially eligible studies were read to decide if the article met all prede!ned inclusion 
criteria. A consensus was reached by the 2 reviewers in the case of discrepancies. In 
addition, the references of all included studies were manually checked for relevant 
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studies. The Quality Assessment of Diagnostic Accuracy Studies 2 tool was used for 
quality assessment of the included studies.11 The quality assessment was also performed 
by the 2 readers independently.
From the included studies, the following parameters were extracted: !rst author, year 
of publication, study design, sample size, clinical tumor and nodal stage, breast cancer 
subtype and histology, neoadjuvant systemic therapy regimen, imaging technique, 
type of axillary surgery, and de!nition of axillary pCR. For each imaging technique, the 
axillary pCR rate and absolute numbers of true positive, false positive, false negative, 
and true negative were reported.
Statistical analysis
All statistical analyses were performed using STATA/SE, version 16.0 (StataCorp LLC, 
College Station, TX). The overall pooled estimate of sensitivity, speci!city, PPV, and 
NPV of imaging modalities with their corresponding 95% con!dence interval (95% CI) 
was calculated using the random-e$ects model by the metaprop command in STATA/
SE.12 Residual axillary lymph node disease was considered positive, and axillary pCR 
was considered negative. Sensitivity was de!ned as the proportion of patients with 
residual axillary lymph nodes that were correctly identi!ed by the noninvasive imaging 
technique. Speci!city was de!ned as the proportion of patients with axillary pCR that 
were correctly identi!ed by the imaging technique. PPV was de!ned as the proportion of 
patients with positive imaging outcomes who had residual axillary lymph node disease. 
NPV was de!ned as the proportion of patients with negative imaging outcomes who 
had axillary pCR. FNR was de!ned as the proportion of patients with negative imaging 
outcomes who had residual axillary lymph node disease. Variation of the diagnostic 
parameters e$ect size estimates with 95% CI and weights from the included studies 
was visualized in forest plots. Heterogeneity was quanti!ed by the total variability of 
the diagnostic parameters estimates among the studies using the I2 index.13 The I2 index 
can only be applied to data with a minimum of 4 studies due to the total number of 
degrees of freedom. Statistical heterogeneity was assessed by the Chi-squared test with 
statistical signi!cance being reached with a 2-sided P-value < 0.05. Publication bias 
analysis was not performed because it is not recommended in diagnostic reviews due 
to heterogeneity.14





The initial database literature search identi!ed a total of 3495 records, including 2466 
records from Embase and 1029 records from PubMed. Of these, 574 duplicate records 
were excluded. After screening the title and abstracts of 2921 records, 2810 records were 
excluded according to the inclusion and exclusion criteria. Subsequently, the full text of 
111 studies was retrieved and read for eligibility. Finally, 13 studies met the inclusion 
criteria and were included for qualitative and quantitative synthesis. No additional 
studies were found after manually screening the references of the included studies. The 
























































FIGURE 1. PRISMA %ow diagram of the study selection
Quality appraisal
The quality assessment results, according to the Quality Assessment of Diagnostic 
Accuracy Studies 2, are shown in Table 1. Regarding the risk of bias and concerns on the 
applicability of the studies, all domains were mainly scored as low. Some high risk of 
bias was present because not all patients received the same reference standard, and the 
de!nition of axillary pCR was not consistent across all studies.
149873-samiei-layout.indd   120 11/03/2021   20:41
121
Noninvasive imaging for assessment of axillary response after NST
TABLE 1. Quality assessment of all included studies based on QUADAS-2
















Arimappamagan LOW UNCLEAR LOW LOW HIGH LOW LOW
Beek HIGH LOW LOW LOW LOW LOW LOW
Boughey LOW LOW LOW LOW LOW LOW LOW
Ha LOW LOW UNCLEAR UNCLEAR LOW LOW LOW
Hieken LOW LOW UNCLEAR HIGH LOW LOW HIGH
Hyun LOW LOW LOW LOW LOW LOW LOW
Javid LOW LOW LOW LOW LOW LOW LOW
Moo LOW LOW HIGH LOW HIGH LOW HIGH
Morency LOW HIGH LOW LOW LOW LOW HIGH
Shin LOW UNCLEAR HIGH LOW LOW LOW HIGH
Vicente LOW LOW LOW HIGH LOW LOW LOW
Weber LOW LOW HIGH HIGH HIGH LOW LOW
You LOW LOW HIGH HIGH LOW LOW LOW
Study characteristics
Thirteen studies describing a total of 2380 patients (range, 32–611 patients) were 
included for !nal analysis. All patients were node-positive at initial diagnosis with proven 
metastasis by !ne-needle aspiration cytology or core biopsy. Of these clinically node-
positive patients, 1322 had undergone axillary ultrasound,15–20 849 breast MRI,17,18,21–25 
and 209 whole-body 18F-FDG PET-CT.18,24,26 The reference standard varied between SLNB, 
SLNB and excision of the pre-NST clipped metastatic axillary lymph node, or ALND. The 
overall axillary pCR rate was 39.5% (941 of 2380) and ranged between 21.9% and 55.1%. 
The study characteristics are described in Table 2.
Axillary ultrasound
The estimated pooled sensitivity, speci!city, PPV, and NPV were 65% (95% CI 48%–80%), 
69% (95% CI 58%–79%), 77% (95% CI 70%–83%), 50% (95% CI 42%–58%), respectively. 
An overview of the diagnostic performance is included in Table 3. In 3 studies (778 
patients), the reference standard was ALND, in 3 studies (359 patients) ALND or SLNB, 
and in 1 study (185 patients) SLNB and excision of the pre-NST clipped metastatic 
axillary lymph node. The overall axillary pCR rate was 37.3% (494/1322), ranging from 
21.9% to 42.2%. Axillary pCR was de!ned as ypN0 in 4 studies (1066 patients), as ypN0 



















































































































































































































































































































































































































































































































































































































































































149873-samiei-layout.indd   122 11/03/2021   20:41
123



























































































































































































































































































































































































































































































































































































































































149873-samiei-layout.indd   123 11/03/2021   20:41
124
Chapter 5
including isolated tumor cells in 2 studies (224 patients), and not reported in 1 study (32 
patients). Signi!cant heterogeneity was seen between the studies with an I2 of 95.18% 
for sensitivity, 78.38% for speci!city, 66.79% for PPV, and 70.38% for NPV (Figure 2).
A subanalysis was performed of 3 studies with the reference standard ALND involving 
778 patients. The estimated pooled sensitivity, speci!city, PPV, and NPV were 67% (95% 
CI 32%–94%), 80% (95% CI 75%–85%), 83% (95% CI 68%–94%), 54% (95% CI 36%–71%), 
respectively.
Breast MRI
The estimated pooled sensitivity, speci!city, PPV, and NPV were 60% (95% CI 49%–70%), 
76% (95% CI 64%–87%), 78% (95% CI 69%–86%), 58% (95% CI 50%–65%), respectively 
(Table 3). In 2 studies (145 patients), the reference standard was ALND, in 5 studies (522 
patients) ALND or SLNB, and in 1 study (182 patients) SLNB. The overall axillary pCR 
rate was 33.0% (280/849), ranging from 26.4% to 53.3%. Axillary pCR was de!ned as 
ypN0 in 2 studies (318 patients), as ypN0 including isolated tumor cells in 3 studies 
(321 patients), and not reported in 3 studies (210 patients). Signi!cant heterogeneity 
was seen between the studies with an I2 of 80.91% for sensitivity, 84.39% for speci!city, 
73.97% for PPV, and 60.07% for NPV (Figure 2).
A subanalysis was performed of 2 studies with the reference standard ALND involving 
145 patients. The estimated pooled sensitivity, speci!city, PPV, and NPV were 63% (95% 
CI 52%–74%), 83% (95% CI 72%–91%), 81% (95% CI 70%–90%), 66% (95% CI 56%–76%), 
respectively.
Whole-body 18F-FDG PET-CT
The estimated pooled sensitivity, speci!city, PPV, and NPV were 38% (95% CI 18%–61%), 
86% (95% CI 77%–93%), 78% (95% CI 65%–88%), 49% (95% CI 24%–75%), respectively 
(Table 3). In 1 study (78 patients), the reference standard was ALND, and in 2 studies 
(131 patients) ALND or SLNB. The overall axillary pCR rate was 39.2% (82/209), ranging 
from 26.3% to 55.1%. Axillary pCR was de!ned as ypN0 in 1 study (99 patients), as ypN0 
including isolated tumor cells in 1 study (32 patients), and not reported in 1 study (78 
patients). The I2 index could not be calculated due to the limited number of studies.
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TABLE 3. An overview of the absolute numbers and diagnostic performance for each imaging technique for 































Arimappamagan 32 21.9% (7) 25 1 0 6 100% 86% 96% 100%
Boughey 611 39.0% 
(238)
130 51 243 187 35% 79% 72% 43%
Ha 118 36.4% (43) 45 17 30 26 60% 60% 73% 46%
Hieken 106 40.6% (43) 44 18 19 25 70% 58% 71% 57%
Morency 135 34.1% (46) 47 10 42 36 53% 78% 82% 46%
Shin 185 42.2% (78) 80 38 27 40 75% 51% 68% 60%
You 135 28.9% (39) 48 9 48 30 50% 77% 84% 38%
Breast MRI
Beek 98 50.0% (49) 24 10 25 39 49% 80% 71% 61%
Ha 118 26.4% (43) 43 12 32 31 57% 72% 78% 49%
Hieken 88 33.0% (29) 36 12 23 17 61% 59% 75% 43%
Hyun 115 48.7% (56) 30 1 29 55 51% 98% 97% 65%
Javid 47 40.4% (19) 24 2 4 17 86% 89% 92% 81%
Moo 182 53.3% (97) 32 23 53 74 38% 76% 58% 58%
Weber 65 50.8% (33) 21 11 11 22 66% 67% 66% 67%
You 136 28.7% (39) 70 18 27 21 72% 54% 80% 44%
PET-CT
Hieken 32 40.6% (13) 12 2 7 11 63% 85% 86% 61%
Vicente 78 55.1% (43) 13 6 22 37 37% 86% 68% 63%
You 99 26.3% (26) 16 4 57 22 22% 85% 80% 28%
Abbreviations: AUS, axillary ultrasound; FN, false negative; FP, false positive; NPV, negative predictive value; NST, 
neoadjuvant systemic therapy; pCR, pathologic complete response; PPV, positive predictive value; TN, true negative; 
TP, false positive
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FIGURE 2. Forest plots of sensitivity, speci!city, PPV, and NPV for AUS, breast MRI, and whole-body PET-CT
Abbreviations: AUS, axillary ultrasound; ES, e$ect size; NPV, negative predictive value; PPV, positive predictive 
value
DISCUSSION
In this systematic review and meta-analysis, the diagnostic performance of axillary 
ultrasound, breast MRI, and whole-body 18F-FDG PET-CT after NST was evaluated for 
axillary response in clinically node-positive breast cancer patients. To our knowledge, 
this is the !rst meta-analysis to provide an overview of currently applied noninvasive 
imaging modalities after NST in pathologically proven node-positive patients. Our 
pooled-analysis, based on 13 studies, including 2380 patients, showed that the 
diagnostic performance of ultrasound, MRI, and PET-CT is limited to accurately assess 
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axillary response after NST. A subanalysis for both ultrasound and MRI with the reference 
standard ALND showed an expected higher overall diagnostic performance for axillary 
response after NST due to the omission of false-negative events as opposed to the total 
reference standard group.
Axillary response assessment after NST with ultrasound was not routinely performed in 
clinically node-positive patients because ALND was standard surgical practice in these 
patients. In this meta-analysis, axillary ultrasound after NST showed that 77% of the 
patients with positive axillary ultrasound had residual axillary lymph node disease, and 
50% of the patients with negative axillary ultrasound had axillary pCR with a relatively 
high FNR of 35%. It has been shown that rates of pCR are higher in triple-negative and 
HER2+ breast cancers.1,2 However, in the current studies, the diagnostic performance of 
ultrasound was not divided by breast cancer subtype. Further, Boughey et al reported 
that patients with suspicious axillary lymph node status after NST based on ultrasound 
were more likely to have an increased likelihood of residual nodal positivity and greater 
nodal disease burden.16 However, the assessment of lymph nodes with ultrasound is 
still limited by operator-dependence and inter-observer variability. In addition, the 
evaluation of deeply located lymph nodes with ultrasound may be insu&cient.17
In the neoadjuvant setting, breast MRI can be used before the initiation of NST to evaluate 
the breast cancer extent and preoperatively determine response to therapy.27 The 
axillary region is included in the breast MRI and allows the radiologist to simultaneously 
evaluate the breast tumor and axillary lymph nodes before and after NST. Compared to 
axillary ultrasound, breast MRI is less operator dependent. In this meta-analysis, breast 
MRI after NST showed that 78% of the patients with positive breast MRI had residual 
axillary lymph node disease, and 58% of the patients with negative breast MRI had 
axillary pCR with a relatively high FNR of 40%. The limited diagnostic performance of 
breast MRI can be due to the axillary region not being fully covered in all breast MRI 
exams and, therefore, a limited axillary lymph node assessment.28 With regard to the 
diagnostic performance per subtype, none of the current studies divided the MRI results 
by breast cancer subtype.
In contrast to the morphologic data of axillary ultrasound and breast MRI, PET-CT is 
based on metabolic activity. In this meta-analysis, whole-body 18F-FDG PET-CT after NST 
showed that 38% of the patients with positive PET-CT had residual axillary lymph node 
disease, and 86% of the patients with negative PET-CT had axillary pCR with a high FNR 
of 62%. The high FNR of PET-CT can be explained by its limited capacity to detect small 
residual axillary lymph nodes with FDG uptake.29 Koolen et al showed that the diagnostic 
performance can be increased by early response monitoring and the evaluation of 
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relative changes of maximum standardized uptake value.30 Previous studies described 
that also the breast cancer subtype can contribute to accurate response prediction 
with PET-CT.31–33 In the current studies, the diagnostic performance of PET-CT was 
not divided by subtype. Because ultrasound, MRI, and PET-CT are currently limited 
to accurately assess axillary response after NST, more attention should be focused 
on arti!cial intelligence and other emerging imaging modalities. Major advances in 
arti!cial intelligence and the implementation in the medical imaging !eld has made 
it possible to provide an automated quantitative assessment of radiographic images.34 
Studies within the imaging work%ow, varying from radiomics and convolutional neural 
networks, can increase e&ciency, achieve an outcome with minimal manual input, 
and increase the accuracy of the assessment of radiographic images.34 On the other 
hand, one of the emerging imaging modalities is the PET-MRI scanner that allows the 
simultaneous integration of morphologic MRI data with metabolic PET data. PET-MRI 
can potentially improve the evaluation of axillary response to NST and eventually also 
contribute to arti!cial intelligence.
An advantage of this meta-analysis is that only patients with pathologically proven 
axillary lymph node metastasis pre-NST were included. If the patients were clinically 
node-positive based on only imaging, but not proven with pathology, the eventual 
number of true negative patients was higher and, therefore, the NPV value seemed 
incorrectly higher for these patients. However, a limitation of this meta-analysis is the 
heterogeneity between the included studies. By using the random-e$ects model in 
the analysis of this heterogeneous study set, the amount of variance in e$ect size was 
estimated. Also, di$erent NST regimens, type of axillary surgery, and de!nition of axillary 
pCR di$ered among the included studies and contributed to the diagnostic performance 
parameters of the imaging modalities. The type of axillary surgery varied between SLNB, 
SLNB and excision of the pre-NST clipped metastatic axillary lymph node, or ALND. The 
FNR of SLNB is reported to be as high as 17% with an NPV of 86%.35 However, Boughey 
et al showed that the FNR of SLNB can be decreased to 9.8% if a combination of axillary 
ultrasound was used for patient selection and 2 or more SLNs were removed.16 The 
FNR of the combined procedure, SLNB and excision of the pre-NST clipped metastatic 
axillary lymph node, was reported to be ranging from 2% to 4% with an NPV from 92% 
to 97%.3,36 The FNR rate of these axillary surgery methods could have in%uenced the 
diagnostic performance parameters. In addition, the correct de!nition of axillary pCR is 
a point of discussion. If isolated tumor cells were considered as positive, the FNR of the 
imaging modality could have increased because isolated tumor cells are more di&cult 
to detect by imaging. A previous study compared the prognosis of ypN0 and residual 
isolated tumor cells or micrometastasis after NST (ypNitc/mi) with subsequent ALND 
in clinically node-positive patients and demonstrated similar disease-free and overall 
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survival.37 This outcome is in contrast to the studies of Wong et al and Fisher et al, which 
showed that ypNitc/mi carries an inferior prognosis compared to ypN0.38,39 For Wong 
et al, these con%icting results may be explained by the di$erent populations and the 
uncoupling of patients with ypN1 and ypN2-3 disease.38
In conclusion, this meta-analysis showed that the diagnostic performance of currently 
applied noninvasive imaging modalities is limited in providing accurate information 
about the axillary response in pathologically proven node-positive breast cancer 
patients treated with NST. Axillary ultrasound, breast MRI, and whole-body PET-CT 
can only correctly identify residual axillary lymph node disease after NST in 77%, 78%, 
and 78% of the node-positive patients, respectively. For determining axillary pCR, 
these numbers are even lower, reporting 50%, 58%, and 49% for axillary ultrasound, 
breast MRI, and whole-body PET-CT, respectively. Based on these !ndings, at this point, 
imaging cannot contribute to or replace axillary procedures after NST in clinically node-
positive breast cancer.





1 exp breast tumor/ (520120)
2 exp breast/ (115045)
3 breast*.ti,ab,kw. (609510)
4 mamma*.ti,ab,kw. (443760)
5 2 or 3 or 4 (1026720)









15 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 (4933480)
16 5 and 15 (574635)
17 1 or 16 (664674)
18 exp axillary lymph node/ (18121)
19 exp axilla/ (10124)
20 axilla*.ti,ab,kw. (55620)
21 19 or 20 (57542)
22 exp lymphatic system/ (1183374)
23 lymph.ti,ab,kw. (307517)
24 lymphatic.ti,ab,kw. (63333)





30 exp metastasis/ (612796)
31 metasta*.ti,ab,kw. (715100)
32 26 or 27 or 28 or 29 or 30 or 31 (5690693)
33 25 and 32 (321206)
34 22 or 33 (1339806)
35 18 or 21 or 34 (1370939)
36 exp neoadjuvant therapy/ (19656)
37 exp preoperative treatment/ (17235)
38 36 or 37 (36321)
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39 neoadjuvant*.ti,ab,kw. (59831)
40 neo adjuvant*.ti,ab,kw. (6953)
41 preoperative*.ti,ab,kw. (386901)
42 pre operative*.ti,ab,kw. (59857)
43 primary.ti,ab,kw. (2066634)
44 induction.ti,ab,kw. (634957)
45 39 or 40 or 41 or 42 or 43 or 44 (3045690)
46 exp chemotherapy/ (641574)
47 exp systemic therapy/ (32347)
48 exp immunotherapy/ (210060)
49 exp molecularly targeted therapy/ (33983)
50 exp antineoplastic agent/ (2174169)
51 chemotherap*.ti,ab,kw. (629737)
52 chemo therap*.ti,ab,kw. (1817)
53 systemic therap*.ti,ab,kw. (27635)
54 immunotherap*.ti,ab,kw. (136266)
55 targeted therap*.ti,ab,kw. (78003)
56 antineoplastic.ti,ab,kw. (23053)
57 anti neoplastic.ti,ab,kw. (4027)
58 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 (2710393)
59 45 and 58 (502844)
60 38 or 59 (517251)
61 exp diagnostic imaging/ (185872)
62 diagnostic imag*.ti,ab,kw. (24325)
63 exp ultrasound/ (178085)
64 ultrasound*.ti,ab,kw. (387036)
65 ultrasonograph*.ti,ab,kw. (157127)
66 exp echography/ (769675)
67 echograph*.ti,ab,kw. (12645)
68 sonograph*.ti,ab,kw. (76044)
69 exp nuclear magnetic resonance imaging/ (934144)
70 magnetic resonance imag*.ti,ab,kw. (314548)
71 MR.ti,ab,kw. (184113)
72 MRI*.ti,ab,kw. (428978)
73 exp positron emission tomography/ (160553)
74 positron emission tomograph*.ti,ab,kw. (80035)
75 PET.ti,ab,kw. (172485)
76 exp positron emission tomography-computed tomography/ (27227)
77 positron emission tomography computed tomograph*.ti,ab,kw. (9905)
78 PETCT*.ti,ab,kw. (862)
79 PET CT*.ti,ab,kw. (56748)
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80 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77
or 78 or 79 (2229838)
81 17 and 35 and 60 and 80 (2466)
Pubmed search
((((((((((("Breast Neoplasms"[Mesh]) OR (((((Breast[Mesh]) OR breast*[Title/Abstract]) OR 
mamma*[Title/Abstract])) AND ((((((((("Neoplasms"[Mesh]) OR neoplas*[Title/Abstract]) 
OR tumor[Title/Abstract]) OR tumors[Title/Abstract]) OR tumour[Title/Abstract]) OR 
tumours[Title/Abstract]) OR cancer*[Title/Abstract]) OR malign*[Title/Abstract]) OR 
carcinom*[Title/Abstract])))))))))) AND (((((("Axilla"[Mesh]) OR axilla*[Title/Abstract])) OR 
(("Lymphatic System"[Mesh]) OR ((((lymph[Title/Abstract]) OR lymphatic[Title/Abstract])) 
AND ((((((node*[Title/Abstract]) OR noda*[Title/Abstract]) OR vessel*[Title/Abstract]) 
OR system*[Title/Abstract]) OR metasta*[Title/Abstract])))))))) AND ((((("Neoadjuvant 
Therapy"[Mesh]) OR ((((((((neoadjuvant[Title/Abstract]) OR neo adjuvant[Title/Abstract]) 
OR induction[Title/Abstract]) OR preoperative*[Title/Abstract]) OR pre operative*[Title/
Abstract]) OR primary[Title/Abstract])) AND (((((((((("Drug Therapy"[Mesh]) OR 
"Immunotherapy"[Mesh]) OR "Antineoplastic Agents"[Mesh]) OR immunotherap*[Title/
Abstract]) OR antineoplastic*[Title/Abstract]) OR anti neoplastic*[Title/Abstract]) OR 
chemotherap*[Title/Abstract]) OR chemo therap*[Title/Abstract]) OR systemic[Title/
Abstract]) OR targeted[Title/Abstract]))))))) AND ((((((((((((((((((((((("Diagnostic 
Imaging"[Mesh]) OR "Diagnostic Imaging"[Subheading]) OR diagnostic imag*[Title/
Abstract]) OR "Ultrasonography"[Mesh]) OR ultrasonograph*[Title/Abstract]) OR 
ultrasound*[Title/Abstract]) OR sonograph*[Title/Abstract]) OR echograph*[Title/
Abstract]) OR US[Title/Abstract]) OR "Magnetic Resonance Imaging"[Mesh]) OR magnetic 
resonance imag*[Title/Abstract]) OR MR[Title/Abstract]) OR MRI*[Title/Abstract]) OR 
"Positron-Emission Tomography"[Mesh]) OR positron emission tomograph*[Title/
Abstract]) OR PET[Title/Abstract]) OR "Positron Emission Tomography Computed 
Tomography"[Mesh]) OR positron emission tomography computed tomograph*[Title/
Abstract]) OR positron emission tomography/computed tomograph*[Title/Abstract]) 
OR PETCT*[Title/Abstract]) OR PET CT*[Title/Abstract])))
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Correlation between Pathologic Complete 
Response in the Breast and absence 
of Axillary Lymph Node Metastases 
after Neoadjuvant Systemic Therapy
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M. Simons, Loes F.S. Kooreman, Sabine Siesling, Marc B.I. Lobbes, Marjolein L. Smidt
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Objective: The aim was to investigate whether pathologic complete response (pCR) 
in the breast is correlated with absence of axillary lymph node metastases at !nal 
pathology (ypN0) in patients treated with neoadjuvant systemic therapy (NST) for 
di$erent breast cancer subtypes.
Background: Pathologic complete response rates have improved on account of 
more e$ective systemic treatment regimens. Promising results in feasibility trials with 
percutaneous image-guided tissue sampling for the identi!cation of breast pCR after 
NST raise the question whether breast surgery is a redundant procedure. Thereby, the 
need for axillary surgery should be reconsidered as well.
Methods: Patients diagnosed with cT1-3N0-1 breast cancer and treated with NST, 
followed by surgery between 2010 and 2016, were selected from the Netherlands 
Cancer Registry. Patients were compared according to the pathologic response of the 
primary tumor with associated pathologic axillary outcome. Multivariable analysis was 
performed to determine clinicopathological variables correlated with ypN0.
Results: A total of 4084 patients were included for analyses, of whom 986 (24.1%) 
achieved breast pCR. In clinically node negative patients (cN0), 97.7% (432/442) with 
breast pCR had ypN0 compared with 71.6% (882/1232) without breast pCR (P < 0.001). 
In clinically node positive patients (cN1), 45.0% (245/544) with breast pCR had ypN0 
compared with 9.4% (176/1866) without breast pCR (P < 0.001). The odds of ypN0 was 
decreased in case of clinical T3 stage (OR 0.59, 95% CI 0.40–0.87), cN1 (OR 0.03, 95% CI 
0.02–0.04) and ER+HER2- subtype (OR 0.30, 95% CI 0.20–0.44), and increased in case of 
breast pCR (OR 4.53, 95% CI 3.27–6.28).
Conclusions: Breast pCR achieved after NST is strongly correlated with ypN0 in cN0 
patients, especially in ER+HER2+, ER-HER2+, and triple negative subtypes. These results 
provide data to proceed with future clinical trials to investigate if axillary surgery can be 
safely omitted in these selected patients when image-guided tissue sampling identi!es 
a breast pCR.
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INTRODUCTION
Over recent years, systemic therapy in the treatment of breast cancer has increasingly 
been administered in the neoadjuvant setting. The indication of neoadjuvant systemic 
therapy (NST) has evolved from inoperable and locally advanced breast cancer to early 
stage breast cancer patients with unfavorable tumor pro!les.1 NST allows treatment 
response to be clinically assessed and can lead to the treatment plan being modi!ed 
in cases of poor response.2 It also o$ers the advantages of downsizing the primary 
tumor, decreasing the incidence of positive lymph nodes, or even results in complete 
eradication of cancer, so-called pathologic complete response (pCR) of the breast tumor 
(hereinafter referred to as breast pCR) and/or the axillary lymph nodes (ypN0).3,4 As well 
as these NST advantages, previous studies have reported that pCR in the breast and 
axilla is associated with superior survival outcomes.5–7
Over the past decade, improvements in the e&cacy of chemotherapy and targeted 
therapies have increased pCR rates. A meta-analysis, performed by Cortazar et al, found 
that breast pCR was achieved in 22.0% of patients after NST with higher pCR rates in 
HER2+ and triple negative breast cancer subtypes.8 Concerning axillary lymph nodes, 
NST can eradicate metastases in clinically node positive patients with a reported axillary 
pCR rate of 37.0%.9 The axillary pCR rate for HER2+ patients increases with the use of 
HER2-targeted therapy to between 43% and 74%.6,7,10,11 Patients who achieved axillary 
pCR were more likely to have breast pCR.6,11,12
At present, surgery is the gold standard for determining whether pCR after NST is 
achieved in breast cancer patients. However, research is increasingly being conducted 
with the focus on reducing or eliminating breast and/or axillary surgery. Promising 
results in feasibility trials with percutaneous image-guided biopsy for identifying breast 
pCR after NST raise the question of whether breast surgery is becoming a redundant 
procedure in selected group of patients with breast pCR.13–15 Since correlation between 
breast pCR and axillary pCR has been suggested, the need for axillary surgery should 
be reconsidered in the case of breast pCR.13,14 Evidence for this correlation is limited, 
however, and not yet studied for di$erent breast cancer subtypes.
Therefore, we aimed to investigate whether breast pCR is correlated with ypN0 in 
patients treated with NST for di$erent breast cancer subtypes.




In this study, 4084 consecutive patients were included who had all been diagnosed with 
primary invasive breast cancer in the Netherlands and treated with NST (chemotherapy 
with or without trastuzumab) between January 2010 and September 2016. To be 
considered for !nal analyses, patients needed to be staged as cT1-3N0-1 breast cancer 
prior to NST administration. After the completion of NST, all patients underwent 
standard breast and axillary surgery. Patients were excluded if the sentinel lymph node 
biopsy (SLNB) had been performed before NST administration. Other exclusion criteria 
were unknown pathological tumor stage, distant metastases at primary breast cancer 
diagnosis or within 91 days after surgery, unknown breast cancer subtype, neoadjuvant 
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FIGURE 1. Flow diagram of patient inclusion
Abbreviations: ALND, axillary lymph node dissection; cN1, clinically node positive; ER, estrogen receptor; 
HER2, human epidermal growth factor receptor 2; NST, neoadjuvant systemic therapy; SLNB, sentinel lymph 
node biopsy; Triple negative, negative for ER, PR, and HER2
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The axillary nodal status was determined before NST administration by axillary 
ultrasound. If axillary ultrasound showed no suspicious lymph nodes, patients were 
de!ned as clinically node negative (cN0). If suspicious lymph nodes were con!rmed 
with additional !ne-needle aspiration cytology (FNAC) or core needle biopsy, patients 
were de!ned as clinically node positive (cN1).
If the patient was de!ned as cN0 before NST administration, the patient underwent 
SLNB after NST. If the patient was classi!ed as cN1 before NST administration, the patient 
underwent axillary lymph node dissection (ALND) after NST.
The 2008 and 2012 Dutch national guidelines were applied during the 2010 to 2016 study 
period.16,17 These guidelines recommended systemic therapy consisting of the following 
chemotherapeutic regimens: 6 cycles of TAC (Taxotere, Adriamycin, Cyclofosfamide), or 
3 cycles of FEC (Fluorouracil (5FU), Epirubicin, Cyclophosphamide), or 4 cycles of AC 
(Adriamycine, Cyclophosphamide) followed by 12 cycles of paclitaxel or 4 cycles of 
docetaxel. In the case of HER2+ breast cancer, trastuzumab was recommended as the 
targeted therapy in addition to chemotherapy and continued until 1 year after the start. 
In the time frame 2010 to 2016 no HER2-targeted therapy was advised in addition to 
trastuzumab.
HER2 status was evaluated with immunohistochemistry (IHC). The IHC score of 0 or 1+ 
was considered negative (<10% of the tumor cells are stained, or >10% of the tumor 
cells are stained, with no circumferential staining and weak color intensity). In case of 
a 2+ IHC score (>10% circumferential membrane staining with moderate intensity), 
%uorescence in situ hybridization (FISH) was mandatory in addition to IHC and the 
result of FISH overruled. The IHC score of 3+ was considered positive (>30% of cells with 
strong intensity circumferential membrane staining).
Data were obtained from the Netherlands Cancer Registry (NCR) after this study had 
been approved by the Privacy Review Board of NCR, managed by the Netherlands 
Comprehensive Cancer Organisation (IKNL). On site trained registrars from the NCR 
extract data from patients’ medical records after noti!cation. Data were collected on 
age, tumor histology, receptor status, surgical procedures, systemic therapy, radiation 
therapy, clinical TNM stage, and pathology results, including stage after NST (ypTNM), 
tumor grade and number of axillary lymph nodes with and without metastases. Breast 
pCR was de!ned as the absence of both invasive and in situ breast cancer, with ypN0 
being de!ned as the absence of both macro- and micrometastases in the axillary lymph 
nodes.18 Isolated tumor cells were considered as ypN0.18
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Statistical analyses were performed by using Statistical Package for the Social Sciences 
software (SPSS, version 24, IBM, Armonk, NY). Patients were subdivided into breast 
pCR or without breast pCR for the following breast cancer subtypes: ER positive(+)
HER2+, ER negative(-)HER2+, ER+HER2-, and triple negative. For each subtype, the 
number of axillary lymph nodes with and without metastases at !nal pathology was 
reported. The +2 test and Fisher exact test were used to compare patients with breast 
pCR and without breast pCR. Univariable logistic regression analysis was conducted to 
determine the association between relevant clinicopathological variables and ypN0. 
Multivariable analysis was performed to identify the independent clinicopathological 
variables correlated with ypN0. Odds ratios (ORs) with 95% con!dence intervals (CIs) 
were calculated. Two-sided P values of <0.05 were considered statistically signi!cant.
RESULTS
Of the 4084 patients (median age, 49 yrs; range, 18–83 yrs) included for analyses, 585 
patients had ER+HER2+, 361 ER-HER2+, 2336 ER+HER2- and 802 had triple negative 
breast cancer subtype. A total of 1674 (41.0%) patients were cN0 and 2410 (59.0%) 
were cN1. Breast conserving surgery was performed in 1835 (44.9%) patients and 2249 
(55.1%) underwent mastectomy. SLNB was performed in 1483 (36.3%) patients and 
2601 (63.7%) underwent ALND (Table 1).
Overall, 986 out of 4084 patients (24.1%) achieved breast pCR. Of the patients with 
breast pCR, 68.7% (677 of 986) had ypN0 compared with 34.2% (1058 of 3098) without 
breast pCR (P < 0.001). In the case of cN0, 97.7% (432/442) with breast pCR had ypN0 
compared with 71.6% (882/1232) without breast pCR (P < 0.001). In the case of cN1, 
45.0% (245/544) with breast pCR had ypN0 compared to 9.4% (176/1866) without 
breast pCR (P < 0.001) (Table 2).
In univariable analysis, clinicopathological variables associated with lower odds of ypN0 
were age 35 to 50 years (OR 0.70, 95% CI 0.54–0.90, P < 0.006), age 50 to 75 years (OR 
0.60, 95% CI 0.47–0.79, P < 0.001), clinical T3 stage (OR 0.51, 95% CI 0.41–0.62, P < 0.001), 
cN1 stage (OR 0.06, 95% CI 0.05–0.07, P < 0.001), ER+HER2- subtype (OR 0.32, 95% CI 
0.27–0.39, P < 0.001), and triple negative subtype (OR 0.31, 95% CI 0.26–0.37, P < 0.001). 
Tumor grade 3 (OR 1.67, 95% CI 1.28–2.19, P = 0.045) and breast pCR (OR 4.22, 95% CI 
3.62–4.93, P < 0.001) were associated with higher odds of ypN0. In multivariable analysis 
after correcting for confounders, the odds of ypN0was decreased in the case of clinical 
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T3 stage (OR 0.59, 95% CI 0.40–0.87, P < 0.007), cN1 (OR 0.03, 95% CI 0.02–0.04, P < 
0.001) and ER+HER2- subtype (OR 0.30, 95% CI 0.20–0.44, P < 0.001), and increased in 
the case of breast pCR (OR 4.53, 95% CI 3.27–6.28, P < 0.001) (Table 3).































































































































































Breast pCR (%) 986 (24.1) 236 (40.3) 247 (68.4) 208 (8.9) 295 (36.8)
aIncludes adenocarcinoma not further de#ned, mucinous adenocarcinoma, medullary carcinoma, metaplastic 
carcinoma among other things.
Abbreviations: ALND, axillary lymph node dissection; ER, estrogen receptor; HER2, human epidermal growth factor 
receptor 2; pCR, pathologic complete response; SLNB, sentinel lymph node biopsy; Triple negative, negative for ER, 
PR and HER2
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TABLE 2. Overview of number of lymph node metastases for each breast cancer subtype di$erentiated 
between breast pCR and without breast pCR after NST
Number of Lymph Node Metastases on Final Pathology (%)
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TABLE 2. Continued
Number of Lymph Node Metastases on Final Pathology (%)














































































Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NST, neoadjuvant systemic 
therapy; pCR, pathological complete response; Triple negative, negative for ER, PR, and HER2
ER+HER2+ subtype
Trastuzumab in neoadjuvant setting was administered in 531 out of 585 (90.8%) 
ER+HER2+ patients. In this subtype, 236 out of 585 (40.3%) patients achieved breast 
pCR. In all ER+HER2+ patients with breast pCR, 76.3% (180 of 236) had ypN0 compared 
to 48.4% (169 of 349) without breast pCR (P < 0.001). In the case of cN0 with breast pCR, 
only 2 out of 124 patients (1.6%) had 1 axillary lymph node metastasis at !nal pathology, 
compared to 15.0% (23 of 153) without breast pCR (P < 0.001). In the case of cN1 with 
breast pCR, 51.8% (58 of 112) of the patients had ypN0 compared to 19.9% (39 of 196) 
without breast pCR (P < 0.001) (Table 4).
ER-HER2+ subtype
In the ER-HER2+ subtype, trastuzumab in neoadjuvant setting was administered in 336 
out of 361 (93.1%) patients. In this subtype, 247 out of 361 (68.4%) patients achieved 
breast pCR. In patients with breast pCR, 67.6% (167 of 247) had ypN0 compared to 
46.5% (53 of 114) without breast pCR (P < 0.001). All cN0 patients with breast pCR (n = 
97) had ypN0 compared to 90.3% (28 of 31) without breast pCR (P = 0.013). In the case 
of cN1 with breast pCR, 46.7% (70 of 150) of the patients had ypN0 compared to 30.1% 
(25 of 83) without breast pCR (P = 0.014).
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TABLE 3. Univariable and multivariable analyses for clinicopathological variables and the outcome ypN0 after 
NST
Univariable analysis Multivariable analysis
OR 95% CI p-value OR 95% CI p-value
Age
< 35 years
35 – 50 years












































0.06 0.05 – 0.07 p<0.001
1 [reference]


































































4.22 3.62 – 4.93 p<0.001
1 [reference]
4.53 3.27 – 6.28 p<0.001
Abbreviations: CI, con#dence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NST, 
neoadjuvant systemic therapy; OR, odds ratio; pCR, pathologic complete response; Triple negative, negative for ER, 
PR, and HER2
ER+HER2- subtype
In the ER+HER2- subtype, 208 out of 2336 (8.9%) patients achieved breast pCR of whom 
58.2% (121 of 208) had ypN0 compared to 28.7% (610 of 2128) without breast pCR (P 
< 0.001). In cN0 patients with breast pCR, 6 out of 89 patients (6.7%) had 1 or 2 axillary 
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lymph node metastases at !nal pathology, compared to 35.3% (298 of 843) without 
breast pCR (P < 0.001). In cN1 patients with breast pCR, 31.9% (38 of 119) of the patients 
had ypN0 compared to 5.1% (65 of 1285) without breast pCR (P < 0.001).
Triple negative subtype
In the triple negative subtype, 295 out of 802 (36.8%) patients achieved breast pCR of 
whom 70.8% (209 of 295) had ypN0 compared to 44.6% (226 of 507) without breast pCR 
(P < 0.001). In the case of cN0 with breast pCR, only 2 out of 132 patients (1.5%) had 1 
or 2 axillary lymph node metastases at !nal pathology, compared to 12.7% (26 of 205) 
without breast pCR (P < 0.001). In cN1 patients with breast pCR, 48.5% (79 of 163) of the 
patients had ypN0 compared to 15.6% (47 of 302) without breast pCR (P < 0.001).
TABLE 4. Overview of ypN0 in the case of breast pCR and without breast pCR after NST for the di$erent breast 
cancer subtypes
Breast pCR and ypN0
No breast pCR 
and ypN0 p-valuea
cT1-3N0 ER+HER2+ (n=277) 98.4 (122/124) 85.0 (130/153) p<0.001
cT1-3N1 ER+HER2+ (n=308) 51.8 (58/112) 19.9 (39/196) p<0.001
cT1-3N0 ER-HER2+ (n=128) 100 (97/97) 90.3 (28/31) p=0.013
cT1-3N1 ER-HER2+ (n=233) 46.7 (70/150) 30.1 (25/83) p=0.014
cT1-3N0 ER+HER2- (n=932) 93.3 (83/89) 64.7 (545/843) p<0.001
cT1-3N1 ER+HER2- (n=1404) 31.9 (38/119) 5.1 (65/1285) p<0.001
cT1-3N0 triple negative (n=337) 98.5 (130/132) 87.3 (179/205) p<0.001
cT1-3N1 triple negative (n=465) 48.5 (79/163) 15.6 (47/302) p<0.001
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NST, neoadjuvant systemic 
therapy; pCR, pathologic complete response; Triple negative, negative for ER, PR, and HER2
a&2 test and Fisher’s exact test between patients with breast pCR and ypN0 versus patients without breast pCR and 
ypN0. Data are presented as percentages with the numbers in parentheses.
DISCUSSION
In this study, we have reported on a large cohort of cT1-3N0-1 breast cancer patients 
who were treated with NST and showed an overall breast pCR rate of 24.1%.We found 
that breast pCR achieved after NST is positively correlated with ypN0. Further, the 
!ndings showed that in the case of breast pCR, 97.7% of cN0 patients had ypN0 and 
in the case of cN1 45.0% converted to ypN0. Of all breast cancer subtypes, only the 
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patients with ER+HER2- subtype were less likely to have ypN0. Recently, Tadros et al 14 
have demonstrated that breast pCR is strongly correlated with axillary nodal status after 
NST. They showed a total breast pCR rate of 36.6% (193 of 527) with a slightly higher 
rate of breast pCR in the triple negative group (37.5%) compared to the HER2+ group 
(35.7%). In contrast to the Tadros et al study, patients with clinical T3 stage and ER+HER2- 
subtype were also included in the present study which can explain the lower total 
breast pCR rate here. We found that in the case of ER+HER2- breast cancer, pCR rates of 
the breast and axilla were lower compared to the other breast cancer subtypes. For this 
subtype, the most important systemic therapy (ie, hormonal therapy) generally follows 
in the adjuvant setting. Previous studies had reported breast and axillary pCR rates for 
the ER+HER2- subtype ranging from 7.5% to 16.5%.4,7,8 We have shown similar breast 
pCR rates, but higher ypN0 rates due to the included number of cN0 patients. In the 
Tadros et al study, all 527 cT1-2N0 patients with HER2+ and triple negative breast cancer 
who achieved breast pCR after NST were found to have ypN0.14 We have con!rmed this 
strong correlation here between breast pCR and ypN0 in cN0 patients for ER+HER2+, 
ER-HER2+, and triple negative breast cancer subtypes.
Due to the presence of more e$ective treatment regimens, pCR rates in the breast and 
axilla have improved dramatically over the past decade.19 Ongoing trials are currently 
evaluating the accuracy of image-guided minimally invasive techniques for predicting 
breast pCR in order to potentially omit surgery.20,21 In the MICRA trial, biopsies of the 
original tumor bed are obtained after NST and prior to surgery in all patients with 
complete or partial radiologic response evaluated by MRI.20 Preliminary results show 
that ultrasound-guided biopsies identify breast pCR successfully in 91.4% (43 out of 47) 
of the patients after NST. In a study by Kuerer et al,22 FNAC and image-guided vacuum-
assisted biopsy of the tumor bed accurately identi!ed breast pCR after chemotherapy 
in 98.0% (38 out of 40) of the patients with a false negative rate (FNR) of 5.0%. The 
Kuerer et al !ndings have resulted in a prospective clinical trial evaluating omission of 
breast surgery after NST in patients with breast pCR con!rmed by image-guided tissue 
sampling.21
Identifying breast pCR appears important for guiding axillary treatment given the 
previously shown correlation between breast and axillary pCR.13,14 If breast pCR after 
NST can be identi!ed prior to surgery, resulting in the complete omission of breast 
surgery, how should the axillary lymph nodes be handled in such patients? In recent 
years the focus has been on minimizing axillary surgery in an aim to reduce surgical 
morbidity. In this study, we observed that 97.7% of cN0 breast cancer patients who 
achieved breast pCR had ypN0. This implies that the risk of missing patients with axillary 
lymph node metastases in these selected patients is highly unlikely. Therefore, these 
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patients should proceed to clinical trials to evaluate the safety of omission of axillary 
surgery when breast pCR after NST is identi!ed by image-guided tissue sampling.21 The 
requirement to proceed in these clinical trials is the determination of the axillary nodal 
status before NST administration by axillary ultrasound with or without biopsy.
In our study, only 45.0% of all cN1 patients who achieved breast pCR also had ypN0. 
Consequently, these cN1 patients remain at risk of having axillary lymph node metastases 
at !nal pathology, irrespective of breast pCR, and omission of axillary surgery would 
therefore be inappropriate. The performance of imaging techniques for assessing 
residual disease in the axillary lymph nodes after NST remains inaccurate.23,24 As for these 
cN1 patients, minimally invasive surgical methods for accurately predicting the axillary 
status are currently under investigation. These minimally invasive techniques aim to 
identify ypN0 after NST resulting in less ALND and thereby preventing the associated 
morbidity. Caudle et al showed in a retrospective study of 85 clinically node positive 
patients that SLNB in combination with selective removal of metastatic marked nodes 
for predicting ypN0 after NST has a FNR of 2.0%.25 The Dutch RISAS trial is a currently 
ongoing prospective multicenter study to validate this combined procedure of SLNB 
and MARI (marking the axillary lymph nodes with radioactive seeds) for identifying 
ypN0 after NST in clinically node positive patients.26
Limitations
This study included patients from all institutions in the Netherlands and thereby an 
advantage is generalizability of the results. However, our study has certain limitations. 
Due to the retrospective nature of the data, there can be no guarantee that all patients 
completed NST and, therefore, were treated su&ciently, since this may have contributed 
to not obtaining breast and/or axillary pCR. Additionally, the number of excluded 
patients as a consequence of missing data could have a$ected our results, such as 
unknown pathological tumor stage and breast cancer subtype.
CONCLUSIONS
These results indicate that cN0 patients who achieve breast pCR after NST are highly 
likely to achieve ypN0, especially in ER+HER2+, ER-HER2+, and triple negative breast 
cancer subtypes. Besides guiding omission of breast surgery, identifying breast pCR 
may guide de-escalating axillary treatment with the potential to omit axillary surgery in 
selected patients. Future clinical trials should investigate if omission of axillary surgery 
in these selected patients is safe when image-guided tissue sampling identi!es breast 
pCR after NST.
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Background: Residual axillary lymph node involvement after neoadjuvant systemic 
therapy (NST) is the determining factor for postmastectomy radiation therapy (PMRT). 
Preoperative identi!cation of patients needing PMRT is essential to enable shared 
decision-making when choosing the optimal timing of breast reconstruction. We 
determined the risk of positive sentinel lymph node (SLN) after NST in clinically node-
negative (cN0) breast cancer.
Methods: All cT1-3N0 patients treated with NST followed by mastectomy and SLNB 
between 2010 and 2016 were identi!ed from the Netherlands Cancer Registry. Rate of 
positive SLN for di$erent breast cancer subtypes was determined. Logistic regression 
analysis was performed to determine correlated clinicopathological variables with 
positive SLN.
Results: In total 788 patients were included, of whom 25.0% (197/788) had positive 
SLN. cT1-3N0 ER+HER2+, cT1-3N0 ER-HER2+ , and cT1-2N0 triple-negative patients had 
the lowest rate of positive SLN: 7.2–11.5%, 0–6.3%, and 2.9–6.2%, respectively. cT1-3N0 
ER+HER2- and cT3N0 triple-negative patients had the highest rate of positive SLN: 23.8–
41.7% and 30.4%, respectively. Multivariable regression analysis showed that cT2 (odds 
ratio [OR] 1.93; 95% con!dence interval [CI] 1.01–3.96), cT3 (OR 2.56; 95% CI 1.30–5.38), 
grade 3 (OR 0.44; 95% CI 0.21–0.91), and ER+HER2- subtype (OR 3.94; 95% CI 1.77–8.74) 
were correlated with positive SLN.
Conclusions: In cT1-3N0 ER+HER2+, cT1-3N0 ER-HER2+, and cT1-2N0 triple-negative 
patients treated with NST, immediate reconstruction can be considered an acceptable 
option due to low risk of positive SLN. In cT1-3N0 ER+HER2- and cT3N0 triple-negative 
patients treated with NST, risks and bene!ts of immediate reconstruction should be 
discussed with patients due to the relatively high risk of positive SLN.
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INTRODUCTION
Neoadjuvant systemic therapy (NST) has become a more common approach for early-
stage breast cancer.1 NST targets both systemic and locoregional disease sites and can 
lead to pathologic down-staging. The increasing use of NST has a$ected the locoregional 
treatment decisions, including the surgical management of the breast and axillary 
lymph nodes, and the indications for postmastectomy radiation therapy (PMRT).1–3
Previous randomized, clinical trials have reported that PMRT is associated with a lower 
locoregional recurrence rate (LRR), and improved disease-free survival and overall 
survival.4–6 The indication for PMRT is not only dependent on the clinical disease stage 
and patient characteristics, but also on the !nal pathological disease stage after NST.7,8 
According to the current guidelines, residual axillary lymph node involvement after NST 
is the most determining factor for the indication of PMRT independent of other risk 
factors.9,10 However, axillary lymph node involvement after NST is di&cult to predict.
In parallel, breast reconstruction has become an important aspect of breast cancer 
treatment. Rates of reconstruction at the time of mastectomy (i.e., immediate breast 
reconstruction) have increased considerably over the past decades.11–13 This is important 
given that immediate breast reconstruction not only bene!ts the quality of life and 
reduces the adverse psychosocial consequences, but it is also preferred by most 
patients.14–18 If PMRT is indicated in women with immediate breast reconstruction, PMRT 
can adversely a$ect the aesthetic outcome of the reconstructed breast and increase 
the complication risks depending on the type of breast reconstruction.19–21 Preoperative 
identi!cation of patients who do need PMRT is essential to enable adequate shared 
decision-making when choosing the optimal timing of breast reconstruction.
Therefore, the purpose of this study was to determine the overall risk of a positive 
sentinel lymph node (SLN) after NST in cT1-3N0 breast cancer patients and for the 
di$erent breast cancer subtypes to support preoperative shared decision-making.
METHODS
This study was approved by the Privacy Review Board of the Netherlands Cancer 
Registry (NCR), managed by the Netherlands Comprehensive Cancer Organization 
(IKNL). All cT1-3N0 breast cancer patients who had undergone NST (chemotherapy with 
or without trastuzumab) with subsequent mastectomy and sentinel lymph node biopsy 
(SLNB), from January 2010 through December 2016, were identi!ed from the NCR.
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On-site trained registrars of NCR collect data from patients’ medical records from all 
hospitals in the Netherlands. Data were collected on age, tumor characteristics (clinical 
TNM stage and the pathological TNM stage after NST, tumor histology, tumor grade, and 
receptor status), and treatment regimens (systemic therapy, breast and axillary surgery, 
radiation therapy, and immediate breast reconstruction). The axillary nodal status 
was determined before NST administration by ultrasound. Patients were considered 
cN0 if ultrasound showed no suspicious lymph nodes or in the case of negative tissue 
sampling. The pathologic examination of the SLN was performed according to the 
national guidelines.22,23 The SLN was sliced on at least three levels with 250-,m spacing 
and stained with hematoxylin and eosin (H&E). In the case of H&E-negative SLN, 
immunohistochemistry was performed. The SLN outcome was considered positive in 
the case of micro- and/or macrometastases.24 In the case of isolated tumor cells, the SLN 
outcome was considered negative.24
The ER (Estrogen Receptor) and HER2 (Human Epidermal growth factor Receptor 2) 
status were determined by immunohistochemistry. Immunohistochemistry testing of 
ER and HER2 was in accordance with the Dutch national guidelines.22, 23 The method of 
scoring for ER status was based on the percentage of tumor cells with nuclear staining. 
ER was classi!ed as positive if the percentage was * 10%. The scoring of HER2 status 
was based on the membranous staining of invasive tumor cells. The scoring system 
is categorized according to coloration in 0 (<10% tumor cells stain), 1+ (> 10% tumor 
cells stain with weakly intensity), 2+ (>10% tumor cells stain with moderate intensity), 
or 3+ (>30% tumor cells stain with strong intensity). The coloration scores 0 and 1+ 
were classi!ed as negative, and the score 3+ was classi!ed as positive. In the case of 
a 2+ equivocal score, %uorescent in situ hybridization (FISH) was performed and the 
outcome of FISH overruled.
According to the Dutch national guidelines of 2008 and 2012, the indication for 
systemic therapy was based on age, tumor size, tumor grade, and receptor status.22,23 
Chemotherapy was recommended for: (1) N0 patients '35 years (except grade 1 tumors 
of '1.0 cm); (2) N0 patients *35 years with tumors 1.1–2.0 cm and grade 2, or tumors 
>2.0 cm; (3) N0 patients with HER2+ tumors *0.5 cm. These guidelines recommended 
the following chemotherapy regimens: 6 cycles of TAC (docetaxel, doxorubicin, and 
cyclophosphamide), or 3 cycles of FEC (%uorouracil, epirubicin, and cyclophosphamide), 
or 4 cycles of AC (doxorubicin and cyclophosphamide) followed by 12 cycles of paclitaxel 
or 4 cycles of docetaxel. In addition, HER2+ patients were also treated with trastuzumab 
for a total of 1 year. No additional HER2-targeted therapy was advised between 2010 
and 2016.
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Descriptive analyses were performed to evaluate the overall rate of a positive SLN and 
for the di$erent breast cancer subtypes for cT1-3N0 patients. Patients were strati!ed 
into four subtypes with ER-positive(+)HER2+, ER negative(-)HER2+, ER+HER2-, and 
triple-negative patients. The PR (Progesterone Receptor) was not included in the 
determination of the ER+HER2+, ER-HER2+, and ER+HER2- subtypes. Univariable logistic 
regression analysis was applied to determine the association of patient and/or tumor 
characteristics with a positive SLN. Multivariable logistic regression analysis was used 
to adjust for potential confounders. Odds ratios (ORs) with 95% con!dence interval (CI) 
were presented. A two-sided p value < 0.05 was considered statistically signi!cant. All 
statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS, version 25, IBM, Armonk, New York, NY).
RESULTS
A total of 1914 patients were diagnosed with cT1-3N0 breast cancer between January 
2010 and December 2016 in the Netherlands and treated with NST followed by 
mastectomy and SLNB. Patients were excluded if the SLNB had been performed before 
NST (n = 782). Other exclusion criteria were the unknown date of SLNB or NST (n = 259), 
unknown SLNB outcome (n = 33), neoadjuvant endocrine therapy (n = 30), unknown 
breast cancer subtype (n = 13), and distant metastases at primary breast cancer 
diagnosis or within 91 days after surgery (n = 9). A total of 788 patients (median age, 48 
[range, 18–78] years) were included for !nal analyses, of whom 106 (13.5%) ER+HER2+, 
54 (6.9%) ER-HER2+, 474 (60.1%) ER+HER2-, and 154 (19.5%) triple-negative patients. 
Immediate breast reconstruction was performed in 378 (48.0%) patients, and PMRT was 
applied to 288 (36.5%) patients. In patients with immediate breast reconstruction, 150 
(39.7%) received PMRT. PMRT was delivered in 156 (79.2%) patients with a positive SLN. 
A complete overview of all patient, tumor, and treatment characteristics is shown in 
Table 1.
Of the included patients, 591 (75.0%) had a negative SLN, 69 (8.8%) had micrometastases, 
and 128 (16.2%) had macrometastases. The overall rate of a positive SLN for cT1-3N0 
patients was 25.0% (197/788). The rate of a positive SLN per subtype was 10.4% (11/106) 
for the cT1-3N0 ER+HER2+, 3.7% (2/54) for the cT1-3N0 ER-HER2+, 35.9% (170/474) for 
the cT1-3N0 ER+HER-, and 9.1% (14/154) for the cT1-3N0 triple-negative patients. Table 
2 shows the SLN outcome for the di$erent breast cancer subtypes.
149873-samiei-layout.indd   189 11/03/2021   20:41
190
Chapter 8












Age (median; range) 48 [18-78] 47 [18-75] 49 [28-78] 49 [24-75] 47 [24-70]

































































288 (36.5) 27 (25.5) 13 (24.1) 214 (45.1) 34 (22.1)
Immediate breast 
reconstruction, No. (%)b
378 (48.0) 42 (39.6) 23 (42.6) 243 (51.3) 70 (45.5)
Abbreviations: ER, Estrogen Receptor; HER2, Human Epidermal growth factor Receptor 2; Triple negative, negative 
for ER, PR, and HER2
a Adenocarcinoma not further de#ned, metaplastic carcinoma, mucinous adenocarcinoma among others.
b Immediate breast reconstruction data were available from January 2011 until December 2016.
In the ER+HER2+ subgroup, 7.2% (2/28) of the cT1N0 patients had a positive SLN, 11.5% 
of the cT2N0 (6/52), and 11.5% (3/26) of the cT3N0 patients. Of these patients with a 
positive SLN, 27.3% (3/11) had micrometastases, and 72.7% (8/11) had macrometastases. 
In these ER+HER2+ patients, 86.8% (92/106) had received neoadjuvant trastuzumab.
In the ER-HER2+ subgroup, the cT1N0 and cT3N0 patients had no positive SLN, and 6.3% 
(2/32) of the cT2N0 patients had a positive SLN. Both cT2N0 patients with a positive SLN 
had micrometastases. Neoadjuvant trastuzumab was administered in 92.6% (50/54) of 
these ER-HER2+ patients.
In the ER+HER2- subgroup, 23.8% (20/84) of the cT1N0 patients had a positive SLN, 
36.6% (90/246) of the cT2N0, and 41.7% (60/144) of the cT3N0 patients. Of these 
patients with a positive SLN, 34.7% (59/170) had micrometastases and 65.3% (111/170) 
had macrometastases.
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TABLE 2. SLN outcome after NST for the di$erent breast cancer subtypes
SLN negative SLN positive






































































Abbreviations: ER, Estrogen Receptor; HER2, Human Epidermal growth factor Receptor 2; NST, Neoadjuvant 
systemic therapy; SLN, Sentinel lymph node; Triple negative, negative for ER, PR, and HER2
In the triple-negative subgroup, the rate of a positive SLN for cT1N0 and cT2N0 patients 
was respectively 2.9% (1/34) and 6.2% (6/97). This increased up to 30.4% (7/23) for the 
cT3N0 patients. Micrometastases were found in 35.7% (5/14) of the SLN positive patients 
and 64.3% (9/14) had macrometastases.
Clinical T1-3N0 ER+HER2+, cT1-3N0 ER-HER2+, and cT1-2N0 triple-negative patients 
had the lowest rate of a positive SLN: 7.2–11.5%, 0–6.3%, and 2.9–6.2%, respectively. 
Clinical T1-3N0 ER+HER2- and cT3N0 triple-negative patients had the highest rate of a 
positive SLN: 23.8–41.7% and 30.4%, respectively (Table 2).
The univariable analysis showed that age '40 years (OR 1.65, 95% CI 1.07–2.53, p = 
0.022), cT2 stage (OR 1.77, 95% CI 1.09–2.94, p = 0.021), cT3 stage (OR 2.78, 95% CI 1.64–
4.72, p<0.001), lobular histology (OR 1.77, 95% CI 1.20–2.62, p = 0.004), and ER+HER2- 
subtype (OR 4.83, 95% CI 2.52–9.27, p<0.001) were associated with higher odds of a 
positive SLN. Tumor grade 2 (OR 0.57, 95% CI 0.33–0.98, p = 0.043) and tumor grade 
3 (OR 0.21, 95% CI 0.11–0.40, p<0.001) were associated with lower odds of a positive 
SLN. After adjustment for confounders, the multivariable analysis showed that cT2 
stage (OR 1.93, 95% CI 1.01–3.69, p = 0.047), cT3 stage (OR 2.73, 95% CI 1.34–5.54, p = 
0.006), and ER+HER2- subtype (OR 3.82, 95% CI 1.72–8.84, p = 0.001) were correlated 
149873-samiei-layout.indd   191 11/03/2021   20:41
192
Chapter 8
with higher odds of a positive SLN. Grade 3 (OR 0.44, 95% CI 0.21–0.91, p = 0.026) 
remained correlated with lower odds of a positive SLN. Table 3 shows the univariable 
and multivariable logistic regression analysis for the outcome of positive SLN after NST.
TABLE 3. Logistic regression analysis for the outcome of positive SLN after NST
Univariable analysis Multivariable analysis
























































































Abbreviations: CI, Con#dence interval; ER, Estrogen Receptor; HER2, Human Epidermal growth factor Receptor 2; 
NST, Neoadjuvant systemic therapy; OR, Odds ratio; SLN, Sentinel lymph node; Triple negative, negative for ER, PR, 
and HER2
DISCUSSION
In this study, nationwide data were used to report on the risk of a positive SLN in cT1-
3N0 breast cancer patients, who had undergone NST followed by mastectomy and 
SLNB, regarding the need for PMRT and therefore the timing of breast reconstruction 
(immediate or delayed). We found that cT2 stage, cT3 stage, and ER+HER2- subtype 
were correlated with higher odds of a positive SLN after NST. Grade 3 was correlated 
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with lower odds of a positive SLN after NST. The lowest risk of a positive SLN was in 
the ER-HER2+ subtype (3.7%), whereas the highest risk of a positive SLN was in the 
ER+HER2- subtype (35.7%).
At present, there are no results of randomized trials addressing the role of PMRT following 
NST. The pooled analysis of National Surgical Breast and Bowel Project (NSABP) B-18 
and B-27, and several retrospective studies have addressed the advantages of PMRT 
after NST.2,3,7,8,25 Available studies showed that age ' 40 years, triple-negative subtype, 
grade 3 tumors, lymphovascular invasion, and advanced clinical and pathological stage 
are high-risk features associated with LRR and should require PMRT after NST. Residual 
axillary lymph node involvement after NST is, in particular, an important prognostic 
factor for LRR and the most determining factor for the indication of PMRT independent 
of the risk factors.9,26,27 In our study, independent clinicopathological variables have 
been assessed that are correlated with a positive SLN after NST. The correlation between 
cT2 stage, cT3 stage, and ER+HER2- subtype with higher odds of a positive SLN after 
NST is supported by previous research.27–29 Both clinical tumor size and tumor subtype 
are independent predictors of pathologic complete response (pCR). We also showed 
that patients with larger breast tumors and ER+HER2- subtype have the lowest axillary 
lymph node response to NST. On the other hand, we demonstrated that tumor grade 
3 is an independent predictor correlated with lower odds of a positive SLN after NST. 
This is in line with previous research given that high-grade tumors are associated with 
higher rates of axillary pCR.30–33
The increasing use of NST and the inability to predict the axillary lymph node status after 
NST have raised questions regarding the patients who do need PMRT and increased 
the complexity of immediate breast reconstruction planning. Immediate breast 
reconstruction reduces the number of surgical procedures and has a better aesthetic 
outcome due to decreased scarring and preservation of the breast skin envelope.34–37 
However, there can be potential reconstruction-related complications with performing 
an immediate breast reconstruction in patients that unexpectedly require additional 
PMRT after NST.38,39 The type of reconstruction (i.e., implant vs. autologous) can a$ect 
the complication risks in the setting of radiation therapy. PMRT in the setting of implants 
can adversely a$ect the aesthetic outcome and is associated with an increased risk 
of complications, such as capsular contraction and implant failure.19,40,41 Existing data 
on autologous reconstruction and PMRT found an increased odds of fat necrosis and 
volume loss, but acceptable results with regard to complications.21,41–45 In patients who 
elect to undergo immediate breast reconstruction, the potential need for PMRT should 
be determined before surgery to diminish the risks of unexpected indication for PMRT 
and preserve patient satisfaction.
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Clinical decision-making regarding the need for PMRT and immediate breast 
reconstruction requires a multidisciplinary approach and careful patient counseling. 
The results in this study indicate that cT1-3N0 ER+HER2- and cT3N0 triple-negative 
patients treated with NST have a high-risk of a positive SLN. For these patients, SLNB 
as a separate procedure preceding to reconstruction can be considered to provide 
information about the pathologic axillary lymph nodes prior to de!nitive surgery. If 
the SLN is positive, the breast reconstruction can then be delayed, or a tissue expander 
can be placed to preserve the breast skin envelope.46 Data about the axillary lymph 
nodes prior to a mastectomy can improve the surgical plan for breast reconstruction 
by incorporating the need for PMRT in surgical decision-making. If PMRT is required, 
these patients should be well informed throughout the entire decision-making process 
about the possibility of unfavorable outcomes due to irradiation and contribute to the 
sequence of breast reconstruction and PMRT.
It has not been fully elucidated whether micrometastases in the axillary lymph nodes 
after NST should be counted as an indicator for treatment with PMRT. Limited data are 
available on micrometastases and the LRR rate. In the Mamtani et al.47 study, 352 T1–T2 
breast cancer patients were included, who had undergone primary mastectomy with 
isolated tumor cells or micrometastases in the axillary lymph nodes. Of these patients, 
95% received adjuvant systemic therapy. The LRR rate without PMRT was 2.8% after 6 
years and no LRR occurred among the patients who had received PMRT. There was no 
signi!cant di$erence in LRR rate for patients treated with or without PMRT. A limitation is 
that these results only apply to patients treated with adjuvant rather than neoadjuvant 
systemic therapy so that the resistance or response to NST is not taken into account. In 
a study by van Nijnatten et al.,48 disease-free survival (DFS) and overall survival (OS) of 
clinically node-positive patients treated with NST and subsequent axillary lymph node 
dissection were compared between three groups: axillary pCR (ypN0), isolated tumor 
cells or micrometastases, and macrometastases. They showed that DFS and OS are not 
signi!cantly di$erent between patients with axillary pCR and isolated tumor cells or 
micrometastases, but is signi!cantly lower for patients with macrometastases. In our 
study, micrometastases were considered as node positive as according to the current 
guidelines.24 Micrometastases were detected in 35.0% (69/197) of the positive SLNs. 
If only macrometastases were considered as node positive, the positive SLN outcome 
for all subtypes would be considerably lower. For the cT1-3N0 ER+HER2+ patients, 
this would even mean that none of the patients had a positive SLN and therefore no 
indication for PMRT. Further data are needed on whether PMRT is indicated in cN0 
patients treated in the neoadjuvant setting with chemoresistant disease.
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A strength of this study is the nationwide character of the data including general, 
academic, and cancer centers, and thus all patients in the Netherlands. Also, the large 
patient population gave us the opportunity to divide patients into subgroups and 
therefore the ability to determine the risk of a positive SLN for the di$erent breast cancer 
subtypes. This study also has certain limitations, such as its retrospective design which 
made it impossible to retrieve missing data on tumor grade or subtype, date of SLNB or 
NST, and SLNB outcome. Furthermore, based on the available data it was not possible to 
determine whether a full course of chemotherapy regimen was completed. Lastly, the 
lymphovascular invasion was not available in the NCR database and could therefore not 
be included in the analyses.
CONCLUSIONS
In conclusion, these results showed that in cT1-3N0 ER+HER2+, cT1-3N0 ER-HER2+, and 
cT1-2N0 triple-negative patients treated with NST, immediate breast reconstruction can 
be considered an acceptable option due to the low risk of a positive SLN and therefore a 
decreased likelihood of PMRT. However, in cT1-3N0 ER+HER2- and cT3N0 triple-negative 
patients treated with NST, the risks and bene!ts of immediate breast reconstruction 
should be discussed with these patients due to the relatively high risk of a positive SLN 
and therefore an increased likelihood of PMRT. In these high-risk patients with a desire 
for immediate breast reconstruction, an SLNB after NST can be performed before breast 
surgery to determine the need for PMRT and discuss the potential complications of PMRT 
thoroughly with the patient in the case of a positive SLN prior to the reconstruction. For 
both situations, this study provides data for adequate shared decision-making.
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PAST
Immediate breast reconstruction and postmastectomy radiation therapy (PMRT) each 
play an integral part in multimodal breast cancer treatment. With the increasing use of 
neoadjuvant systemic therapy (NST) in early-stage breast cancer, the indications for PMRT 
are a$ected, and this contributes to the complexity of immediate breast reconstruction 
planning. The choice between immediate or delayed reconstruction is dependent 
on the preoperative need for PMRT. Residual axillary lymph node involvement after 
NST is the main determinant for PMRT since these patients have an increased risk of 
locoregional recurrence.1 However, the axillary lymph node status in patients treated 
with NST is unknown prior to mastectomy, and the decision to perform immediate 
breast reconstruction is made without knowledge of the pathologic axillary outcome. 
In the case of immediate breast reconstruction, PMRT can not only adversely a$ect the 
cosmetic outcome of the reconstructed breast but can also increase the complication 
risks depending on the type of reconstruction.2,3 Therefore, preoperative identi!cation 
of patients who do need PMRT after NST is advantageous to enable adequate shared 
decision-making regarding the timing and type of reconstruction.
PRESENT
This study reports on the risk of positive sentinel lymph node (SLN) after NST in 
clinically node-negative breast cancer patients and therefore the likelihood of PMRT.4 
The ER-HER2+ subtype had the lowest rate (3.7%) of a positive SLN, whereas the 
highest rate (35.7%) was in the ER+HER2- subtype. In low-risk SLN positive patients 
(cT1-3N0 ER+HER2+, cT1-3N0 ER-HER2+, cT1-2N0 triple negative), immediate breast 
reconstruction can be considered an acceptable option due to the decreased likelihood 
of PMRT. On the other hand, in high-risk SLN positive patients (cT1-3N0 ER+HER2-, 
cT3N0 triple negative), risks and bene!ts of immediate breast reconstruction should be 
discussed with the patient due to an increased likelihood of PMRT. For both situations, 
this study provides data for adequate shared decision-making regarding the need for 
PMRT and timing of breast reconstruction (immediate or delayed).




Both breast reconstruction and PMRT are increasingly used, and the integration of these 
two important treatments requires a multidisciplinary approach and careful patient 
counseling. Our study provides data about low and high-risk PMRT patients and can be 
included in the decision-making process. In high-risk SLN positive patients with a desire 
for immediate breast reconstruction, a sentinel lymph node biopsy can be performed 
after NST prior breast surgery in order to determine the pathologic axillary outcome 
and, consequently, the need for PMRT. If PMRT is required, the patient should be well-
informed on the pros and cons of the combination of immediate breast reconstruction 
and PMRT, as well as the possibility of a delayed reconstruction. Finally, the decision 
to perform immediate or delayed reconstruction in the setting of PMRT must be 
individualized and must take into account the experience of the (plastic) surgeon and 
the expectations of the patient.
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Doel: Het risico op axillaire lymfekliermetastasen na neoadjuvante systemische 
therapie (d.w.z. ypN+) bij borstkankerpatiënten onderzoeken. Hiermee kan de kans op 
postmastectomieradiotherapie (PMRT) preoperatief worden bepaald bij patiënten die 
een directe borstreconstructie willen ondergaan ter ondersteuning van preoperatieve 
gedeelde besluitvorming.
Methode: De gegevens van patiënten (klinisch tumorstadium T1-T3) met een 
klinisch kliernegatieve (cN0) of klierpositieve (cN1) borstkanker werden geanalyseerd, 
die neoadjuvante systemische therapie hebben ondergaan met daaropvolgend 
mastectomie en axillaire chirurgie, geregistreerd in de Nederlandse Kankerregistratie 
van 2010–2016. Het percentage ypN+# voor verschillende subtypen van borstkanker 
werd bepaald. Logistische regressieanalyse werd uitgevoerd om de correlatie van 
klinische en pathologische variabelen te bepalen met de uitkomstmaat ypN+.#
Resultaten: In totaal werden 1.868 patiënten geïncludeerd, van wie 56% ypN+#hadden. 
cT1-3N0 ER+HER2+, cT1-3N0 ER(HER2+#en cT1-2N0 triple-negatieve patiënten hadden 
het laagste percentage ypN+: respectievelijk 16%, 7% en 7%. cT1-2N1 ER+HER2+, cT1-
2N1 ER(HER2+, cT1-3N0 ER+HER2(, cT1-2N1 ER+HER2(, cT3N0 en cT1-2N1 triple-
negatieve patiënten hadden het hoogste percentage ypN+: respectievelijk 67%, 59%, 
39%, 93%, 31% en 65%. De multivariabele regressieanalyse liet zien dat cT2 (OR 1,72), cT3 
(OR 2,58), cN1 (OR 24,9) en ER+HER2(-subtype (OR 4,09) positief gecorreleerd zijn met 
ypN+. Graad 3 (OR 0,54) en ER(HER2+-subtype (OR 0,40) waren negatief gecorreleerd 
met ypN+.
Conclusie: Bij patiënten met laag risico (cT1-3N0 ER+/-HER2+# en cT1-2N0 triple-
negatief ) op ypN+#en daardoor lage kans op PMRT, kan een directe borstreconstructie 
als een aanvaardbare mogelijkheid worden beschouwd. Bij de andere patiënten geldt 
een hoog risico op ypN+#en daardoor hoge kans op PMRT.
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INLEIDING
Systemische therapie in neoadjuvante setting wordt steeds vaker gegeven bij patiënten 
met een vroeg stadium borstkanker.1#Neoadjuvante systemische therapie kan leiden tot 
een pathologisch complete respons van zowel de primaire borsttumor als de axillaire 
lymfekliermetastasen. Dit kan niet alleen leiden tot meer borstsparende chirurgie 
en de-escalatie van axillaire chirurgie, maar heeft ook invloed op de indicaties voor 
postmastectomieradiotherapie (PMRT) van de thoraxwand met eventueel meebestralen 
van de regionale lymfeklieren.2
Eerdere onderzoeken hebben aangetoond dat PMRT is geassocieerd met een lager 
locoregionaal recidiefrisico, verbeterde ziektevrije overleving en totale overleving.3,4#De 
indicatie voor PMRT is niet alleen afhankelijk van het klinische TNM-stadium en patiënt- 
en tumorkenmerken, maar is ook afhankelijk van het pathologische TNM-stadium 
na neoadjuvante systemische therapie.5# Volgens de huidige richtlijnen is residuele 
axillaire lymfekliermetastase na neoadjuvante systemische therapie (d.w.z. ypN+) 
de doorslaggevende factor voor de indicatie van PMRT, onafhankelijk van de andere 
risicofactoren die worden gebruikt voor de indicatie van PMRT, zoals tumorgraad 3, 
triple-negatief subtype, lymfangioinvasie en leeftijd '40 jaar.6#Het is echter voorafgaand 
aan de operatie lastig te voorspellen of sprake is van ypN+#en daardoor op dat moment 
onduidelijk of er een indicatie is voor PMRT.
Naast radiotherapie is borstreconstructie tegenwoordig een belangrijk aspect van 
de behandeling van borstkankerpatiënten. Het aantal reconstructies ten tijde van 
een mastectomie (d.w.z. een directe borstreconstructie) is het afgelopen decennium 
aanzienlijk toegenomen.7# Directe borstreconstructies kunnen de kwaliteit van 
leven positief beïnvloeden, de negatieve psychosociale gevolgen van borstkanker 
verminderen en heeft ook de voorkeur bij de meeste patiënten.8(10# Indien er een 
indicatie is voor PMRT bij patiënten die een directe reconstructie hebben ondergaan, 
dan kan radiotherapie het esthetisch resultaat van de gereconstrueerde borst nadelig 
beïnvloeden en het risico op complicaties vergroten die verschillend zijn per type 
borstreconstructie.11,12#Preoperatieve identi!catie van patiënten die een PMRT-indicatie 
hebben, is essentieel om gedeelde besluitvorming mogelijk te maken bij de keuze van 
de optimale timing van borstreconstructie.
Het doel van dit onderzoek was om het risico op ypN+#te bepalen voor de verschillende 
subtypen van borstkanker, zodat per patiënt preoperatief een adequate inschatting kan 
worden gemaakt van de kans op PMRT in geval van mastectomie en de wens tot directe 
borstreconstructie.




Alle patiënten (klinisch tumorstadium T1-T3) met klinisch kliernegatieve (cN0) of 
klierpositieve (cN1) borstkanker, die neoadjuvante systemische therapie (chemotherapie 
met wel of geen trastuzumab) hebben ondergaan met daaropvolgend mastectomie 
en axillaire chirurgie, werden geïdenti!ceerd uit de Nederlandse Kankerregistratie van 
2010–2016. Alle cT3N1-patiënten werden geëxcludeerd, gezien deze patiënten ondanks 
een eventuele respons van axillaire lymfekliermetastasen na neoadjuvante systemische 
therapie reeds een PMRT-indicatie hebben. De volgende gegevens waren beschikbaar 
in de Nederlandse Kankerregistratie-database: leeftijd, tumorkarakteristieken (klinisch 
TNM-stadium en pathologisch TNM-stadium na neoadjuvante systemische therapie, 
tumorhistologie, tumorgraad en receptorstatus) en behandeling (systemische therapie, 
borst- en axillaire chirurgie, PMRT en directe borstreconstructie).
De axillaire klierstatus werd vóór de start van neoadjuvante systemische therapie 
beoordeeld door middel van echogra!e. Patiënten werden beschouwd als cN0 
indien echogra!e geen verdachte axillaire lymfeklieren vertoonde of in geval van een 
negatieve cytologische punctie of histologisch biopt. Patiënten werden beschouwd 
als cN1 indien verdachte axillaire lymfeklieren met echogra!e werden bevestigd voor 
metastase door middel van een cytologische punctie of histologisch biopt. De axillaire 
chirurgie bestond uit de schildwachtklierprocedure en/of okselklierdissectie voor cN0-
patiënten en okselklierdissectie voor cN1-patiënten. Na axillaire chirurgie werd de oksel 
als ypN+# (positief voor lymfekliermetastasen na neoadjuvante systemische therapie) 
beschouwd in geval van micro- (>0,2 mm en '2,0 mm) en/of macrometastasen (>0,2 
mm).13# In geval van geen tumorcellen of geïsoleerde tumorcellen ('0,2 mm) werd 
de oksel als ypN0 (negatief voor lymfekliermetastasen na neoadjuvante systemische 
therapie) beschouwd.13
Volgens de nationale richtlijnen die tussen 2010–2016 van toepassing waren, was de 
indicatie voor systemische therapie gebaseerd op leeftijd, tumorgrootte, klierstatus, 
tumorgraad en receptorstatus.14,15# Chemotherapie werd aanbevolen voor: (1) N0-
patiënten <35 jaar (behalve graad 1-tumoren '1,0 cm), (2) N0-patiënten *35 jaar met 
tumoren 1,1–2,0 cm en graad 2 of hoger of tumoren >2,0 cm, (3) N0-patiënten met 
HER2+# (humane epidermale groeifactorreceptor 2-positieve) tumoren *0,5–1,0 cm, 
en (4) alle N+-patiënten (ook chemotherapie overwegen bij !tte patiënten >70 jaar 
met hormoonreceptor-negatieve tumoren). In deze richtlijnen werden de volgende 
chemotherapieschema’s aanbevolen: zes cycli van TAC (docetaxel, doxorubicine en 
cyclofosfamide) of drie cycli van FEC (%uorouracil, epirubicine en cyclofosfamide) of vier 
cycli van AC (doxorubicine en cyclofosfamide) gevolgd door 12 cycli van paclitaxel of 
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vier cycli docetaxel. Bovendien werden HER2+-patiënten in totaal 1 jaar behandeld met 
trastuzumab. Tussen 2010–2016 werd geen andere aanvullende anti-HER2-therapie 
geadviseerd.
Statistische analyse
Het totale percentage ypN+ werd bepaald voor alle borstkankerpatiënten en 
onderverdeeld in de vier subtypen: oestrogeenreceptor-positief (ER+)HER2+, 
ER(HER2+, ER+HER2( en triple-negatief. Univariabele en multivariabele 
logistische regressieanalyses werden uitgevoerd om de associatie van patiënt- en 
tumorkarakteristieken met de uitkomstmaat ypN+ te bepalen. Hiervoor werden 
oddsratio’s (OR) met 95%-betrouwbaarheidsintervallen (BI) berekend. Een tweezijdige 
p-waarde <0,05 werd als statistisch signi!cant beschouwd. Alle statistische analyses 
werden uitgevoerd met behulp van SPSS versie 25.
RESULTATEN
In totaal werden 4.460 patiënten van 2010–2016 in Nederland gediagnosticeerd 
met cT1-3N0-1-borstkanker en behandeld met neoadjuvante systemische therapie 
gevolgd door mastectomie en axillaire chirurgie. Patiënten werden geëxcludeerd als 
de schildwachtklierprocedure voor start van de neoadjuvante systemische therapie 
was uitgevoerd. Andere exclusiecriteria waren: onbekende axillaire chirurgie, 
geen okselklierdissectie in geval van cN1, neoadjuvante endocriene therapie, 
metastasen op afstand, onbekende axillaire chirurgieuitkomst, onbekend subtype en 
schildwachtklierproceduredatum niet geregistreerd. Figuur 1, toont het stroomschema 
van geëxcludeerde en geïncludeerde patiënten.
In totaal werden 1.868 patiënten geïncludeerd, van wie 1.050 (56%) een ypN+#hadden. 
Directe borstreconstructie werd uitgevoerd bij 577 (31%) patiënten en PMRT werd 
gegeven bij 1.067 (57%) patiënten. Van de patiënten met een directe borstreconstructie 
ondergingen 204 (35%) patiënten PMRT. PMRT werd gegeven bij 814 (78%) patiënten 
met ypN+. Een volledig overzicht van alle patiënt-, tumor- en behandelkenmerken is 
weergegeven in Tabel 1.
Van de ER+HER2+-subgroep had 16% (19/121) van de cT1-3N0-patiënten ypN+#en 67% 
(87/129) van de cT1-2N1-patiënten. Bij deze ER+HER2+-patiënten had 88% (221/250) 
neoadjuvant trastuzumab gekregen. Tabel 2 toont de axillaire lymfeklierstatus na 
neoadjuvante systemische therapie voor de verschillende subtypen van borstkanker.
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FIGUUR 1. Stroomschema van geëxcludeerde en geïncludeerde patiënten
Afkortingen: cN1, klinisch klierpositief; ER, oestrogeen receptor; HER2, humane epidermale groeifactorreceptor 
2; NST, neoadjuvante systemische therapie; OKD, okselklierdissectie; SWK, schildwachtklierprocedure
Van de ER-HER2+-subgroep had 7% (4/61) van de cT1-3N0-patiënten ypN+# en 59% 
(52/88) van de cT1-2N1-patiënten. Neoadjuvant trastuzumab werd gegeven bij 93% 
(139/149) van deze ER(HER2+-patiënten. Van de ER+HER2(-subgroep had 39% 
(218/557) van de cT1-3N0-patiënten ypN+#en 93% (523/563) van de cT1-2N1-patiënten. 
Van de triple-negatieve subgroep had 11% (19/170) van de cT1-3N0-patiënten ypN+#en 
65% (116/179) van de cT1-2N1-patiënten.
cT1-3N0 ER+HER2+, cT1-3N0 ER(HER2+#en cT1-2N0 triple-negatieve patiënten hadden 
het laagste percentage ypN+: respectievelijk gemiddeld 16% (variërend van 7 tot 21%), 
7% (variërend van 9 tot 12%) en 7% (variërend van 7 tot 8%) (zie#Tabel 2). cT1-2N1 
ER+HER2+, cT1-2N1 ER(HER2+, cT1-3N0 ER+HER2(, cT1-2N1 ER+HER2(, cT3N0 en cT1-
2N1 triple-negatieve patiënten hadden het hoogste percentage ypN+: respectievelijk 
gemiddeld 67% (variërend van 50 tot 71%), 59% (variërend van 50 tot 62%), 39% 
(variërend van 26 tot 46%), 93%, 31% en 65% (variërend van 32 tot 72%) (zie#Tabel 2).
149873-samiei-layout.indd   212 11/03/2021   20:41
213
 Axillaire lymfekliermetastasen na NST





































































































































Postmastectomieradiotherapie (%) 1067 (57,1) 116 (46,6) 66 (44,3) 707 (63,1) 178 (51,0)
Directe borstreconstructie (%)c 577 (30,9) 91 (36,4) 44 (29,5) 328 (29,3) 114 (32,7)
Afkortingen: cN0, klinisch kliernegatief; cN1, klinisch klierpositief; ER, oestrogeen receptor; HER2, humane 
epidermale groeifactor receptor 2
a  cT1, klinische tumorgrootte <2 cm; cT2, klinische tumorgrootte 2 - '5 cm; cT3, klinische tumorgrootte >5 cm
b Onder andere: adenocarcinoom niet nader gede#nieerd, metaplastisch carcinoom, mucineus adenocarcinoom
c Gegevens van directe borstreconstructie waren beschikbaar van 2011-2016
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Afkortingen: cN0, klinisch kliernegatief; cN1, klinisch klierpositief; cT1, klinische tumorgrootte <2 cm; cT2, klinische 
tumorgrootte 2 - '5 cm; cT3, klinische tumorgrootte >5 cm; ER, oestrogeen receptor; HER2, humane epidermale 
groeifactorreceptor 2; ypN0, geen axillaire lymfekliermetastasen na neoadjuvante systemische therapie; ypN+, 
axillaire lymfekliermetastasen na neoadjuvante systemische therapie
De multivariabele analyse toonde aan dat cT2 (OR 1,72; 95%-BI 1,11–2,67), cT3 (OR 2,58; 
95%-BI 1,47–4,53), cN1 (OR 24,9; 95%-BI 16,8–37,0) en ER+HER2(-subtype (OR 4,09; 
95%-BI 2,41–6,94) positief gecorreleerd waren met ypN+. Graad 3 (OR 0,54; 95%-BI 0,31-
0,95) en ER(HER2+-subtype (OR 0,40; 95%-BI 0,19-0,88) waren negatief gecorreleerd 
met ypN+.# Tabel 3# toont de univariabele en multivariabele regressieanalyse met de 
uitkomstmaat ypN+.
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TABEL 3. Univariabele en multivariabele regressieanalyse van klinische en pathologische variabelen met de 
uitkomstmaat ypN+
Variabele 
Univariabele analyse Multivariabele analyse














































































Afkortingen: BI, betrouwbaarheidsinterval; cN0, klinisch kliernegatief; cN1, klinisch klierpositief; ER, 
oestrogeenreceptor; HER2, humane epidermale groeifactorreceptor 2; OR, oddsratio; ypN+, axillaire 
lymfekliermetastase na neoadjuvante systemische therapie
a cT1, klinische tumorgrootte <2 cm; cT2, klinische tumorgrootte 2 - '5 cm; cT3, klinische tumorgrootte >5 cm
b Onder andere: adenocarcinoom niet nader gede#nieerd, metaplastisch carcinoom, mucineus adenocarcinoom
* De p-waarden van de uitkomsten met een sterretje zijn statisch signi#cant (p<0.05)
BESCHOUWING
In dit onderzoek werden landelijke gegevens gebruikt om het risico op residuele 
axillaire lymfeklierenmetastase na neoadjuvante systemische therapie (d.w.z. ypN+) en 
daarmee de kans op PMRT te bepalen bij borstkankerpatiënten die zijn behandeld met 
systemische therapie gevolgd door mastectomie en axillaire chirurgie. Hieruit bleek dat 
cT2-stadium, cT3-stadium, cN1-klierstatus en ER+HER2(-subtype gecorreleerd waren 
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met een hogere kans op ypN+. Graad 3 en ER(HER2+-subtype waren gecorreleerd 
met een lagere kans op ypN+. Het laagste risico op ypN+# was bij cT1-3N0 ER(
HER2+-patiënten (7%), terwijl het hoogste risico op ypN+# bij patiënten met cT1-2N1 
ER+HER2(#was (93%).
In dit onderzoek zijn onafhankelijke klinische en pathologische variabelen beoordeeld 
die gecorreleerd zijn met de uitkomstmaat#ypN+. De correlatie tussen tumorgrootte, 
klierstatus en ER+HER2(-subtype met hogere kans op ypN+#wordt ondersteund door 
eerder onderzoek.16,17#Zowel tumorgrootte, klierstatus als subtype zijn onafhankelijke 
voorspellers voor pathologisch complete respons. Aan de andere kant is aangetoond 
dat graad 3 en ER(HER2+-subtype onafhankelijke voorspellers zijn gecorreleerd 
met een lagere kans op ypN+. Dit is in lijn met eerder onderzoek gezien het feit dat 
hooggradige tumoren en ER(HER2+-subtype geassocieerd zijn met een hogere axillaire 
pathologisch complete responskans.18(20
Het toenemend gebruik van neoadjuvante systemische therapie en het onvermogen 
om de axillaire lymfeklierstatus na neoadjuvante systemische therapie te voorspellen, 
heeft vragen opgeroepen over welke patiënten, die een directe borstreconstructie 
zouden willen ondergaan, een PMRT-indicatie hebben. Een directe borstreconstructie 
vermindert het aantal chirurgische ingrepen en heeft een beter esthetische 
resultaat.21,22#Er kunnen echter ook complicaties optreden bij#het geven van PMRT na 
een directe borstreconstructie.23,24# Het type reconstructie (implantaat of autoloog) 
kan het risico op complicaties beïnvloeden in geval van radiotherapie. PMRT in 
de setting van implantaten kan een negatieve invloed hebben op het esthetische 
resultaat en wordt geassocieerd met een verhoogde kans op kapselcontractuur en 
implantaatfalen.25(27#Gegevens over autologe reconstructie en PMRT toonden aan dat 
er een verhoogde kans is op vetnecrose en volumeverlies, maar acceptabele resultaten 
met betrekking tot complicaties.25,28,29#Bij patiënten die ervoor kiezen om een directe 
borstreconstructie te ondergaan, moet de PMRT-indicatie vóór de operatie worden 
bepaald om de risico’s van onverwachte radiotherapie te voorkomen en daarmee de 
kwaliteit van leven te behouden.
Klinische besluitvorming over de PMRT-indicatie en directe borstreconstructie vereist 
een multidisciplinaire aanpak en zorgvuldige counseling van de patiënt. Voor patiënten 
met een hoog risico op ypN+#en een wens tot directe reconstructie kan de chirurgische 
axillaire stadiëring vóór de borstoperatie worden uitgevoerd om de eventuele PMRT-
indicatie preoperatief vast te stellen. Indien sprake is van ypN+# en daardoor een 
indicatie voor PMRT, dan kan de borstreconstructie worden uitgesteld of een ‘tissue 
expander’ worden geplaatst om de huidenvelop te behouden.30# Gegevens over de 
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axillaire lymfeklierstatus voorafgaand aan de borstoperatie kan het chirurgische plan 
voor een reconstructie verbeteren doordat de eventuele indicatie voor PMRT bij de 
chirurgische besluitvorming kan worden meegenomen. Als er een indicatie is voor 
PMRT, dan kunnen deze patiënten tijdens het gehele besluitvormingsproces goed 
worden geïnformeerd over de mogelijkheid van ongunstige resultaten als gevolg 
van radiotherapie en bijdragen aan de timing van borstreconstructie. In de toekomst 
zou het een alternatief kunnen zijn om patiënten bij wie de radiotherapie-indicatie al 
vaststaat voor de mastectomie, te bestralen voorafgaand aan de operatie. Momenteel 
worden voorbereidingen getro$en om een gerandomiseerde studie op te zetten waar 
preoperatieve radiotherapie wordt vergeleken met de standaard PMRT, om op deze 
manier toch een directe reconstructie mogelijk te maken (BRENAR-studie).
Dit onderzoek heeft ook beperkingen. Het excluderen van patiënten van wie niet 
alle gegevens beschikbaar waren, zoals soort axillaire chirurgie en uitkomst, subtype 
of datum van schildwachtklierprocedure, kan de resultaten hebben beïnvloed. De 
tumorgraad was onbekend bij ongeveer 44% van de patiënten, hetgeen mogelijk 
invloed heeft gehad op de negatieve correlatie tussen graad 3 en ypN+. Verder zijn er 
tot op heden veranderingen in systemische therapie en was op basis van de beschikbare 
gegevens niet duidelijk of het chemotherapieschema volledig was voltooid, waardoor 
de resultaten kunnen zijn beïnvloed. Ten slotte waren er geen gegevens over lymfangio-
invasie (één van de risicofactoren voor de besluitvorming tot PMRT) beschikbaar in de 
Nederlandse Kankerregistratie-database en daardoor kon dit gegeven niet worden 
meegenomen in de analyses.
CONCLUSIE
De resultaten van dit onderzoek toonden aan dat bij cT1-3N0 ER+/-HER2+#en cT1-2N0 
triple-negatieve patiënten behandeld met neoadjuvante systemische therapie, directe 
borstreconstructie als een aanvaardbare mogelijkheid kan worden beschouwd vanwege 
het lage risico op ypN+# en daardoor een lage kans op PMRT. Bij alle cN1-patiënten, 
ongeacht het subtype, cT1-3N0 ER+HER2(#en cT3N0 triple-negatieve patiënten die zijn 
behandeld met neoadjuvante systemische therapie, moeten de voor- en nadelen van 
een directe borstreconstructie worden besproken met de patiënt vanwege het relatief 
hoge risico op ypN+#en daardoor een hoge kans op PMRT. Bij deze hoogrisicopatiënten 
met een wens tot directe reconstructie kan de chirurgische axillaire stadiëring vóór de 
borstoperatie worden uitgevoerd om de eventuele PMRT-indicatie preoperatief vast te 
stellen. Voor beide situaties levert dit onderzoek gegevens voor een adequate gedeelde 
besluitvorming.
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This thesis demonstrated insights into di$erent aspects of the axillary management of 
breast cancer patients. In the !rst part, MRI and MRI-based radiomics were investigated 
for optimizing the axillary lymph node staging in the preoperative setting. In addition, 
currently applied imaging modalities were evaluated for the axillary lymph node staging 
after neoadjuvant systemic therapy. In the second part, axillary pathologic complete 
response (pCR) after neoadjuvant systemic therapy was predicted based on the breast 
tumor response and for di$erent breast cancer subtypes. In the third part, residual 
axillary lymph node disease was predicted in mastectomy patients for the indication 
of postmastectomy radiation therapy, and therefore determining the timing of breast 
reconstruction.
Primary noninvasive axillary lymph node staging
At the time of breast cancer diagnosis, the presence and extent of axillary lymph node 
metastasis can help in determining the surgical treatment plan, the need for (neo)
adjuvant systemic therapy, and the indication of postmastectomy radiation therapy.1 
Although preoperative imaging of the axillary lymph nodes with ultrasound is the 
primary method, breast MRI has been investigated for improved assessment of the axilla. 
The assessment of axillary lymph nodes on MRI could be of added value for patients 
detected with breast cancer via MRI screening or for patients undergoing a preoperative 
standard breast MRI, whereby in both cases, an axillary ultrasound can be super%uous. 
Since the axillary region is limited on breast MRI in about 40% of the patients, previous 
research with MRI focused on improving the visualization of axillary levels II and III with 
dedicated axilla coils.2-6 However, a dedicated axillary protocol complementary to the 
standard breast MRI protocol is an additional examination and requires more scanning 
time. In chapter 2, we compared both MRI protocols within a single cohort of breast 
cancer patients.7 The diagnostic performance of unenhanced T2-weighted (T2W) breast 
MRI with a complete !eld of view of the axillary region was comparable to unenhanced 
T2W dedicated axillary MRI for the assessment of node-negative and node-positive 
breast cancer. Both MRI examinations showed a high negative predictive value (NPV) 
between 88-92% for excluding node-negative patients. The comparable diagnostic 
performance implies that a dedicated axillary MRI examination is redundant if the 
standard breast MRI protocol includes the complete !eld of view of the axillary region.
In clinically node-positive patients, the pretreatment di$erentiation between 1-3 
(pN1) and *4 (pN2-3) axillary lymph node metastases is essential for guiding adjuvant 
locoregional radiation therapy in primary setting, especially important if a mastectomy 
patient desires an immediate breast reconstruction.8 In the neoadjuvant setting, the 
pretreatment di$erentiation between pN1 and pN2-3 can guide the extent of the axillary 
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surgery and adjuvant locoregional radiation therapy.8 A positive axillary ultrasound 
cannot accurately di$erentiate between pN1 and pN2-3.9 In chapter 3, we investigated 
the diagnostic performance of an additional breast MRI in 49 clinically node-positive 
patients based on ultrasound-guided biopsy.7 Two breast radiologists independently 
evaluated the breast MRI examinations. In the case of 1-3 suspicious axillary lymph 
nodes evaluated on breast MRI, 75-77% of the patients had correctly pN1 disease. In 
the case of *4 suspicious axillary lymph nodes evaluated on breast MRI, 58-61% of the 
patients had correctly pN2-3 disease. We found that the diagnostic performance of a 
standard breast MRI in clinically node-positive patients is limited for the di$erentiation 
between pN1 and pN2-3, and therefore not recommended in everyday clinical practice.
The assessment of axillary lymph node metastasis on MRI is based on prede!ned 
qualitative descriptors, such as irregular margin, cortical thickness, absence of fatty 
hilum, perifocal edema, and asymmetry of number and size of lymph nodes compared 
to the contralateral side.10 With these qualitative descriptors, the accurate assessment of 
axillary lymph node metastasis on MRI is still not optimal. The introduction of radiomics 
has made it possible to explore the full potential of medical images by extracting 
quantitative features, which can be used to improve the diagnostic performance of the 
imaging modality for diagnosis, prognosis, or prediction.11 Radiomics features extracted 
from the delineated breast tumor has shown potential for the preoperative prediction 
of axillary lymph node metastasis with AUC values between 0.77-0.82.12-14 In chapter 4, 
radiomics features were extracted from 511 (475 negative and 36 positive) delineated 
axillary lymph nodes on the T2W sequence of dedicated axillary MR images. Each 
cohort split resulted in a di$erent number of lymph nodes in the training cohorts and 
a di$erent set of selected features. The performance of the radiomics models showed 
a wide range of AUC values between 0.48-0.89 and 0.37-0.99 in the training cohorts 
and validation cohorts, respectively. With these results, it was not possible to obtain a 
!nal radiomics model for the prediction of axillary lymph node metastasis. The skewed 
distribution of node-negative and node-positive disease, and the unknown e$ect of MR 
image acquisition and reconstruction parameters on feature values, most likely played 
a role in the obtained results. It was concluded that larger datasets combined with MRI 
phantom data are necessary to determine if further radiomics research using dedicated 
axillary MR images is of added value.
Axillary pCR in node-negative and node-positive breast cancer
Over the years, the use of neoadjuvant systemic therapy has increased in breast cancer.15 
In patients treated with neoadjuvant systemic therapy, pCR of the primary breast tumor 
and/or metastatic axillary lymph nodes can be achieved.16 With the advancements 
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in systemic therapy and breast imaging, ongoing trials are currently evaluating the 
accuracy of percutaneous image-guided biopsy to determine breast pCR in order to 
omit breast surgery.17,18 Theoretically, if there is a strong correlation between breast 
pCR and axillary pCR, patients who achieve breast pCR could avoid axillary surgery. In 
chapter 6, we performed a nationwide cohort study with 1674 clinically node-negative 
and 2410 clinically node-positive patients to investigate the correlation between 
breast pCR and the absence of axillary lymph node metastases (ypN0).19 We reported a 
strong correlation for clinically node-negative patients, with 97.7% of the patients who 
achieved breast pCR had ypN0. This correlation was particularly strong in HER2-positive 
and triple-negative subtypes. These !ndings can guide the omission of axillary surgery 
in the case of breast pCR in selected clinically node-negative patients. In clinically node-
positive patients, this correlation was less strong, with 45% of the patients who achieved 
breast pCR had ypN0. Clinically node-positive patients remain at risk of having residual 
axillary lymph node disease after neoadjuvant systemic therapy, irrespective of breast 
pCR.
If the radiological response of the axilla to neoadjuvant systemic therapy could be 
accurately assessed in clinically node-positive patients, it can enable the omission 
of axillary lymph node dissection (ALND) in the case of axillary pCR. In chapter 5, 
we performed a systematic review and meta-analysis to determine the diagnostic 
performance of currently applied imaging modalities for assessing axillary pCR in 
clinically node-positive patients. Thirteen studies describing 2380 patients were 
included, of whom 1322 had undergone axillary ultrasound, 849 breast MRI, and 209 
whole body 18F-FDG PET-CT. For detecting axillary pCR, ultrasound showed an NPV of 
50% with a false-negative rate (FNR) of 35%; MRI showed an NPV of 58% with an FNR 
of 40%; and PET-CT showed an NPV of 49% with an FNR of 62%. These !ndings indicate 
that none of the current imaging modalities can contribute to the accurate assessment 
of axillary pCR, most likely caused by the limited spatial resolution of the di$erent 
modalities. Underestimation of residual disease can occur if the lymph nodes are too 
small for detection or if the anatomy of the lymph node has not been a$ected but 
contains viable tumor cells.20 Future imaging research should preclude isolated tumor 
cells from the axillary pCR de!nition and focus on how breast cancer subtype a$ects 
the diagnostic performance of post neoadjuvant systemic therapy imaging of the axilla.
For clinically node-positive patients, several less invasive axillary staging procedures 
have been explored over the past years for accurate identi!cation of axillary pCR to 
avoid overtreatment with ALND and consequently preventing the associated morbidity. 
Among these less invasive procedures are sentinel lymph node biopsy, the removal of 
the marked pre-treatment positive lymph node (for example, the MARI procedure), and 
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a combination procedure of removing the marked pre-treatment positive lymph node 
and sentinel lymph node(s) (for example, targeted axillary dissection).21-25 However, 
these procedures are associated with FNRs of up to 17%, and it is unknown whether 
the accuracy is dependent on the breast cancer subtype.26 Identifying patients in whom 
axillary pCR after neoadjuvant systemic therapy is most likely can help select patients 
for less invasive axillary staging procedures. In chapter 7, we performed a systematic 
review and meta-analysis to provide pooled axillary pCR rates among di$erent breast 
cancer subtypes in initially clinically node-positive patients. A total of 33 studies with 
57.531 patients were included. Seven subtypes were identi!ed as reported in the 
included articles, with the HR-negative/HER2-positive subtype associated with the 
highest (60%) axillary pCR rate and luminal A with the lowest (13%). The remaining 
subtypes were associated with the following axillary pCR rates in decreasing order: 59% 
for HER2-positive, 48% for triple-negative, 45% for HR-positive/HER2-positive, 35% for 
luminal B, and 18% for HR-positive/HER2-negative breast cancer. With the introduction 
of minimally invasive staging approaches, the results of this meta-analysis may also 
guide adjuvant treatment to select patients who are more likely to have residual axillary 
lymph node disease after neoadjuvant systemic therapy. Two recent trials reported 
on improved disease-free and overall survival in HER2-positive patients with residual 
disease treated with adjuvant T-DM1 and HER2-negative patients with residual disease 
treated with adjuvant capecitabine.27,28 These results demonstrated that accurate 
staging is essential as missed residual disease could prevent patients from receiving 
optimal adjuvant treatment.
Implications of residual axillary disease after neoadjuvant systemic 
therapy
In the neoadjuvant setting, residual axillary lymph node disease is the decisive factor 
for the indication of postmastectomy radiation therapy.29 In the case of immediate 
breast reconstruction, postmastectomy radiation therapy can adversely a$ect the 
aesthetic outcome of the reconstructed breast and increase the complication risks, 
varying per reconstruction type (i.e., implant versus autologous).30,31 The decision to 
perform immediate breast reconstruction is often made without the knowledge of the 
indication for postmastectomy radiation therapy since residual axillary lymph node 
disease is di&cult to predict. Several intraoperative examinations of the sentinel lymph 
nodes have been investigated, such as frozen section, imprint cytology, and molecular 
techniques.32 Unfortunately, these techniques yield high false-negative results, especially 
for the detection of micrometastasis.32 In chapters 8 and 9, we performed a population-
based cohort study to determine the risk of residual axillary lymph node disease 
after neoadjuvant systemic therapy and thereby the likelihood of postmastectomy 
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radiation therapy preoperatively in patients who wish to undergo immediate breast 
reconstruction.33 High (cT1-3N0 HR-positive/HER2-negative, cT3N0 triple-negative, 
cN1) and low (cT1-3N0 HER2-positive, cT1-2N0 triple-negative) risk postmastectomy 
radiation therapy patients were identi!ed. In high risk patients, the axillary surgery can 
be performed prior to the de!nitive breast surgery or the breast reconstruction can be 
delayed. If the patient desires one surgical treatment and the radiation therapy risk is 
acceptable, a tissue expander can be placed to preserve the breast skin envelope, or 
a !nal implant if there is an adequate skin envelope to cover the implant, preserving 
the autologous reconstruction as a salvage procedure. Our results can be taken into 
account during the multidisciplinary meeting when the need for mastectomy and the 
desire for immediate breast reconstruction is known. In the end, decisions about the 
timing and type of breast reconstruction in the setting of postmastectomy radiation 
therapy must be individualized according to the experience of the (plastic) surgeon and 
the expectations of the patient.
MAIN CONCLUSIONS
• A dedicated axillary MRI is redundant for the assessment of node-negative and 
node-positive breast cancer if the standard breast MRI includes the complete !eld 
of view of the axillary region.
• An additional breast MRI cannot accurately di$erentiate between pN1 and pN2-3 in 
clinically node-positive patients.
• Dedicated axillary MRI-based radiomics with node-by-node analysis did not 
contribute to the prediction of axillary lymph node metastasis.
• In clinically node-negative patients, particularly HER2-positive and triple-negative, 
breast pCR is strongly correlated with ypN0. This !nding can guide the omission of 
axillary surgery in the case of breast pCR identi!ed by image-guided biopsy.
• In clinically node-positive patients, axillary ultrasound, breast MRI, and PET-CT after 
neoadjuvant systemic therapy are inaccurate for the assessment of axillary pCR.
• The HR-negative/HER2-positive subtype is associated with the highest axillary pCR 
rate and the luminal A subtype with the lowest axillary pCR rate. The prediction 
of axillary pCR can help identify patients who may bene!t from de-escalation or 
escalation of treatment.
149873-samiei-layout.indd   227 11/03/2021   20:41
228
Chapter 10
• All clinically node-positive patients (regardless of subtype), cT1-3N0 HR-positive/
HER2-negative, and cT3N0 triple-negative patients treated with neoadjuvant 
systemic therapy have a relatively high risk for postmastectomy radiation therapy. 
In these high risk patients with a desire for immediate breast reconstruction, the 
axillary surgery can be performed prior to breast surgery or the breast reconstruction 
can be delayed.
FUTURE PERSPECTIVES
Noninvasive imaging modalities in neoadjuvant setting
A shown in chapter 5, currently applied imaging modalities in clinics are inaccurate for 
the axillary lymph node staging after neoadjuvant systemic therapy, given the high 
FNR between 35-62%. In our systematic review and meta-analysis, breast MRI had the 
highest combination of positive predictive value (PPV) and NPV compared to axillary 
ultrasound and whole-body PET-CT. Recent research has focused on combining the 
diagnostic advantages of MRI (high-resolution anatomical images) and PET (metabolic 
data) with the hybrid PET-MRI scanner. In a previous feasibility study, the use of PET-MRI 
in the primary setting resulted in a clinical nodal status change of 22-75% compared to 
ultrasound, MRI, and PET-CT in clinically node-positive patients.34 These results indicated 
that PET-MRI could improve the diagnostic workup in breast cancer patients. However, 
this study was based on a small number of patients, and further research of PET/MRI 
in the neoadjuvant setting is warranted. Our research team is currently analyzing PET-
MRI examinations after neoadjuvant systemic therapy in initially clinically node-positive 
patients. Future research should also focus on combining the most accurate imaging 
modalities with less invasive axillary staging procedures to explore the complementary 
value.
Eliminating breast and axillary surgery
In the 70s to 90s, several studies investigated radiation therapy only of the breast in 
complete clinical responders, assessed by physical examination and imaging, after 
neoadjuvant systemic therapy.35 These studies resulted in high locoregional recurrence 
rates.35 With the improvement of systemic therapy yielding high pCR rates in breast and 
axillary lymph nodes, our understanding of breast cancer subtypes, and better imaging 
modalities, the safe elimination of breast surgery is currently under investigation. In the 
NOSTRA feasibility trial, a total of 150 ER-negative/HER2-positive invasive breast cancer 
patients treated with neoadjuvant systemic therapy will be included to determine 
whether residual cancer can be identi!ed with up to 8 ultrasound-guided biopsies of 
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the tumor bed.18 The primary outcome is the FNR that will be obtained after standard 
surgery. On the other hand, at the MD Anderson Cancer Center, the !rst no breast 
surgery trial is currently enrolling patients with HER2-positive or triple-negative invasive 
breast cancer (<5cm, '4 suspicious axillary lymph nodes).17 Fifty patients, treated with 
neoadjuvant systemic therapy, will be included. Patients who have no residual disease 
documented by a minimum of 12 image-guided biopsies of the tumor bed will move on 
to receive whole breast radiation therapy and a boost without surgery. After completion 
of treatment, patients are followed up with imaging every 6 months until 5-years. The 
primary outcome is the 5-year locoregional recurrence rate among patients without 
breast surgery. Identifying breast pCR may guide the omission of axillary surgery, given 
the strong correlation between breast pCR and ypN0 in selected clinically node-negative 
patients. Future clinical trials should investigate if the omission of axillary surgery in 
these selected patients is safe when image-guided biopsy identi!es breast pCR.
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Summary / Samenvatting
This thesis has addressed three di$erent aspects of the axillary management of breast 
cancer patients: optimizing the diagnostic axillary lymph node staging, prediction of 
axillary pathologic complete response (pCR) after neoadjuvant systemic therapy for 
de-escalation or escalation of treatment, and improving the treatment sequence and 
outcome of breast reconstruction in the case of postmastectomy radiation therapy 
based on the axillary response after neoadjuvant systemic therapy.
Part I Non-invasive axillary lymph node staging
Chapter 2 compared the diagnostic performance of breast MRI to dedicated axillary 
MRI for assessing node-negative and node-positive axillary disease in 47 breast cancer 
patients who had undergone both MRI examinations. The T2-weighted and di$usion-
weighted (DW) images of both MRI examinations were independently assessed by two 
breast radiologists. There was no di$erence between the diagnostic performance of 
T2-weighted breast MRI with a complete !eld of view of the axillary region compared 
to dedicated axillary MRI. Optimization of the standard breast MRI protocol with a 
complete !eld of view of the axillary region can be recommended in clinical practice 
for assessing axillary lymph nodes. For both MRI examinations, additional DW images 
(including apparent di$usion coe&cient measurements) were found to have no added 
value for the assessment of axillary lymph nodes.
In chapter 3, the diagnostic performance of preoperative axillary ultrasound and breast 
MRI was investigated for the di$erentiation between limited (pN1) and advanced (pN2-
3) axillary lymph node disease in 49 clinically node-positive breast cancer patients. The 
total number of suspicious axillary lymph nodes on ultrasound was retrospectively 
collected. The T2-weighted MR images were independently assessed by two breast 
radiologists. The results showed that the diagnostic performance of axillary ultrasound 
and breast MRI was comparable and limited for the preoperative di$erentiation between 
pN1 and pN2-3. In the case of 1-3 suspicious axillary lymph nodes on ultrasound, an 
additional breast MRI correctly diagnosed pN2-3 in only 50-54.5% patients. Based on 
these !ndings, there is no added value in clinics for a breast MRI in patients with a 
positive axillary ultrasound for di$erentiating between pN1 and pN2-3.
Chapter 4 investigated whether radiomics features based on T2-weighted dedicated 
axillary MRI can contribute to an increased diagnostic performance of MRI for the 
prediction of axillary lymph node metastases. Seventy-!ve patients were included, of 
whom 511 axillary lymph nodes were manually delineated and matched with pathology. 
A total of 105 original radiomics features were extracted from the MR images. Each 
cohort split resulted in a di$erent number of lymph nodes in the training cohorts and a 
di$erent set of selected features. The performance of the clinical and radiomics models 
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showed a wide range of AUC values between 0.41-0.74 and 0.48-0.89 in the training 
cohorts, respectively, and between 0.30-0.98 and 0.37-0.99 in the validation cohorts, 
respectively. With these results, it was not possible to obtain a !nal prediction model. 
In conclusion, dedicated axillary MRI-based radiomics analysis did not contribute to the 
prediction of axillary lymph node metastasis in breast cancer.
In chapter 5, a systematic review and meta-analysis was conducted to determine the 
diagnostic performance of current noninvasive imaging modalities for the assessment 
of axillary lymph node response after neoadjuvant systemic therapy in initially clinically 
node-positive breast cancer patients. A total of 13 articles were included in which 1322 
patients had undergone an axillary ultrasound, 849 patients a breast MRI, and 209 
patients a whole-body PET-CT scan. The pooled sensitivity and speci!city for ultrasound 
were 65% and 69%, for MRI 60% and 76%, and for PET-CT 38% and 86%, respectively. 
The pooled positive predictive value and negative predictive value for ultrasound 
were 77% and 50%, for MRI 78% and 58%, and for PET-CT 78% and 49%, respectively. 
These results showed that the diagnostic performance of these imaging modalities 
after neoadjuvant systemic therapy is limited to accurately assess axillary lymph node 
response, and therefore cannot contribute to or replace the axillary surgical procedures.
Part II Prediction of axillary pathologic complete response after 
neoadjuvant systemic therapy
Chapter 6 described whether there is a correlation between pCR of the breast and the 
absence of axillary lymph node metastases (ypN0) in 4084 patients from the Netherlands 
Cancer Registry treated with neoadjuvant systemic therapy. In clinically node-negative 
patients (particularly HER2-positive and triple-negative), this correlation was strong, as 
97.7% of the patients with breast pCR had ypN0. In clinically node-positive patients, 
this correlation was less strong, as only 45% of the patients with breast pCR had ypN0. 
Future studies with image-guided biopsy demonstrating breast pCR should indicate if 
axillary surgery can be safely omitted in selected clinically node-negative patients.
In chapter 7, a systematic review and meta-analysis was performed to obtain an overview 
of pooled axillary pCR rates for di$erent breast cancer subtypes, divided into patients 
with and without pathologically proven clinically node-positive disease. A total of 33 
articles were included, consisting of 57.531 patients for the meta-analysis. The pooled 
axillary pCR rates for each of the 7 identi!ed subtypes were in decreasing order: 60% for 
HR-negative/HER2-positive, 59% for HER2-positive, 48% for triple-negative, 45% for HR-
positive/HER2-positive, 35% for luminal B, 18% for HR-positive/HER2-negative, and 13% 
for luminal A breast cancer. No major di$erences were found in the axillary pCR rates per 
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subtype for patients with and without pathologically proven clinically node-positive 
disease. These results can help predict axillary treatment response in the neoadjuvant 
setting and thus select patients for more or less invasive axillary procedures.
Part III Implications of residual axillary lymph node disease after 
neoadjuvant systemic therapy
In chapter 8, the risk of axillary lymph node metastasis after neoadjuvant systemic 
therapy was investigated in clinically node-negative patients and expanded with 
clinically node-positive patients in chapter 9 using the Netherlands Cancer Registry 
to determine the likelihood of postmastectomy radiation therapy preoperatively in 
patients who wish to undergo immediate breast reconstruction. The results of these 
chapters showed that in cT1-3N0 HER2-positive and cT1-2N0 triple-negative patients 
treated with neoadjuvant systemic therapy, immediate breast reconstruction can be 
considered an acceptable option as there is a relatively low risk of axillary lymph node 
metastasis, and therefore a decreased likelihood of postmastectomy radiation therapy. 
All clinically node-positive patients regardless of subtype, cT1-3N0 HR-positive/HER2-
negative, and cT3N0 triple-negative patients treated with neoadjuvant systemic therapy 
had a relatively high risk of axillary lymph node metastasis, and therefore an increased 
likelihood of postmastectomy radiation therapy. In chapter 8, a brief commentary 
described that these results on low and high risk postmastectomy radiation therapy 
can contribute to a multidisciplinary and individualized decision-making process when 
immediate breast reconstruction is desired.
149873-samiei-layout.indd   239 11/03/2021   20:41




Dit proefschrift heeft drie verschillende aspecten behandeld met betrekking tot de 
axillaire lymfeklieren in borstkankerpatiënten: optimalisatie van de diagnostische axillaire 
lymfeklierstadiëring, predictie van axillaire pathologisch complete respons (pCR) na 
neoadjuvante systemische therapie voor de-escalatie of escalatie van de behandeling, 
en verbetering van de behandelvolgorde en uitkomst van borstreconstructie indien er 
een indicatie is voor postmastectomie radiotherapie gebaseerd op de axillaire respons 
na neoadjuvante systemische therapie.
Deel I Niet-invasive axillaire lymfeklierstadiëring
Hoofdstuk 2 vergeleek de diagnostische accuratesse van de MRI mammae met de 
axillaire MRI voor het beoordelen van kliernegatieve en klierpositieve axillaire ziekte in 47 
borstkankerpatiënten die beide MRI onderzoeken hadden ondergaan. De T2-gewogen 
en di$usie gewogen opnames van beide MRI onderzoeken werden onafhankelijk 
beoordeeld door twee mammaradiologen. Er werd geen verschil gezien tussen de 
diagnostische accuratesse van de T2-gewogen opname van de MRI mammae waarbij 
de axilla volledig in beeld was gebracht vergeleken met de axillaire MRI. Optimalisatie 
van het MRI mammae protocol waarbij de axilla volledig in beeld wordt gebracht, 
kan worden aanbevolen in de klinische praktijk voor het beoordelen van axillaire 
lymfeklieren. Voor beide MRI onderzoeken bleken aanvullende di$usie gewogen 
opnames (inclusief de apparent di$usion coë&ciënt metingen) geen toegevoegde 
waarde te hebben voor de beoordeling van axillaire lymfeklieren.
In hoofdstuk 3 werd de diagnostische accuratesse van preoperatieve axillaire 
echogra!e en MRI mammae onderzocht voor de di$erentiatie tussen beperkte (pN1) 
en gevorderde (pN2-3) axillaire lymfeklieruitzaaiingen in 49 klinisch klierpositieve 
borstkankerpatiënten. Het totale aantal verdachte axillaire lymfeklieren op echogra!e 
werd retrospectief verzameld. De T2-gewogen MRI opnames werden onafhankelijk 
beoordeeld door twee mammaradiologen. De diagnostische accuratesse van axillaire 
echogra!e en MRI mammae waren vergelijkbaar en beperkt voor de preoperatieve 
di$erentiatie tussen pN1 en pN2-3. In geval van 1-3 verdachte axillaire lymfeklieren op 
echogra!e, toonde een aanvullende MRI mammae bij slechts 50-54,5% van de patiënten 
pN2-3 aan. Op basis van deze bevindingen is er geen klinische meerwaarde voor een 
preoperatieve MRI mammae in patiënten met een positieve axillaire echogra!e voor 
het di$erentiëren tussen pN1 en pN2-3.
Hoofdstuk 4 onderzocht of radiomics-beeldeigenschappen gebaseerd op T2-gewogen 
opnames van axillare MRI kunnen bijdragen aan een betere diagnostische accuratesse 
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van MRI voor de predictie van axillaire lymfekliermetastasen. Van de 75 geïncludeerde 
patiënten werden 511 axillaire lymfeklieren handmatig gesegmenteerd en gematcht 
met pathologie. In totaal werden 105 originele radiomics-beeldeigenschappen 
uit de MRI beelden gehaald. Elke cohort-splitsing resulteerde in een ander aantal 
lymfeklieren in de trainingscohorten en een andere reeks geselecteerde kwantitatieve 
beeldeigenschappen. De klinische en radiomics modellen resulteerden in brede 
AUC waarden van respectievelijk 0,41-0,74 en 0,48-0,89 in de trainingschorten en 
respectievelijk 0,30-0,98 en 0,37-0,99 in de validatiecohorten. Met deze resultaten was 
het niet mogelijk om een  de!nitief predictiemodel te verkrijgen. Concluderend heeft 
axillaire MRI-gebaseerde radiomics analyse niet bijgedragen aan de predictie van 
axillaire lymfekliermetastasen bij borstkanker.
In hoofdstuk 5 werd een systematische review en meta-analyse uitgevoerd om de 
diagnostische accuratesse van de huidige niet-invasieve beeldvormingsmodaliteiten 
te bepalen voor de beoordeling van axillaire lymfeklierrespons na neoadjuvante 
systemische therapie in klinisch klierpositieve borstkankerpatiënten. In totaal werden 
13 artikelen geïncludeerd waarin 1322 patiënten een axillaire echogra!e hadden 
ondergaan, 849 patiënten een MRI mammae en 209 patiënten een PET-CT scan. De 
gepoolde sensitiviteit en speci!citeit voor echogra!e waren respectievelijk 65% en 69%, 
voor MRI 60% en 76%, en voor PET-CT 38% en 86%. De gepoolde positief voorspellende 
waarde en negatief voorspellende waarde voor echogra!e waren respectievelijk 77% en 
50%, voor MRI 78% en 58%, en voor PET-CT 78% en 49%. Deze resultaten toonden aan dat 
de diagnostische accuratesse van deze beeldvormingsmodaliteiten na neoadjuvante 
systemische therapie beperkt is om de axillaire respons nauwkeurig te beoordelen, en 
daardoor niet kan bijdragen aan of de axillaire chirurgische behandeling vervangen.
Deel II Predictie van axillaire pathologisch complete respons na 
neoadjuvante systemische therapie
In hoofdstuk 6 werd onderzocht of er een correlatie is tussen pCR van de borst en de 
afwezigheid van axillaire lymfekliermetastasen (ypN0) bij 4084 patiënten behandeld 
met neoadjuvante systemische therapie verkregen uit de Integraal Kankercentrum 
Nederland (IKNL) database. In klinisch kliernegatieve patiënten (vooral bij HER2-positief 
en triple-negatief ) was deze correlatie sterk, aangezien er bij 97,7% van de patiënten 
met een pCR van de borst er sprake was van ypN0. In klinisch klierpositieve patiënten 
was deze correlatie minder sterk, aangezien er bij 45% van de patiënten met een pCR 
van de borst er sprake was van ypN0. Toekomstige onderzoeken met beeldgeleide 
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biopsie om een pCR van de borst aan te tonen, moeten uitwijzen of in geselecteerde 
klinisch kliernegatieve patiënten de axillaire operatie veilig achterwege gelaten kan 
worden.
In hoofdstuk 7 werd een systematische review en meta-analyse uitgevoerd om een 
overzicht te verkrijgen van gepoolde axillaire pCR percentages voor verschillende 
subtypes van borstkanker, onderverdeeld in patiënten met en zonder pathologisch 
bewezen klinisch klierpositieve ziekte. In totaal werden 33 artikelen geïncludeerd, 
bestaande uit 57.531 patiënten voor de meta-analyse. De gepoolde axillaire pCR 
percentages voor elk van de 7 geïdenti!ceerde subtypes waren in afnemende volgorde: 
60% voor HR-negatief/HER2-positief, 59% voor HER2-positief, 48% voor triple-negatief, 
45% voor HR-positief/HER2-positief, 35% voor luminaal B, 18% voor HR-positief/
HER2-negatief en 13% voor luminaal A borstkanker. Er werden geen grote verschillen 
gevonden in de axillaire pCR percentages per subtype voor patiënten met en zonder 
pathologisch bewezen klinisch klierpositieve ziekte. Deze resultaten kunnen helpen 
bij het voorspellen van de axillaire respons in de neoadjuvante setting en zodoende 
patiënten selecteren voor meer of minder invasieve axillaire chirurgie.
Deel III Gevolgen van residuele axillaire lymfekliermetastase na 
neoadjuvante systemische therapie
In hoofdstuk 8 werd het risico op axillaire lymfekliermetastase na neoadjuvante 
systemische therapie onderzocht in klinisch kliernegatieve patiënten en uitgebreid 
met klinisch klierpositieve patiënten in hoofdstuk 9 verkregen uit de IKNL database 
om de kans op postmastectomie radiotherapie preoperatief te bepalen in patiënten die 
een directe borstreconstructie willen ondergaan. De resultaten van deze hoofdstukken 
toonden aan dat in cT1-3N0 HER2-positief en cT1-2N0 triple-negatieve patiënten 
behandeld met neoadjuvante systemische therapie, directe borstreconstructie als 
een aanvaardbare optie kan worden beschouwd aangezien er een relatief lage risico 
is op axillaire lymfekliermetastase en daardoor een lage kans op postmastectomie 
radiotherapie. Alle klinisch klierpositieve patiënten ongeacht het subtype, cT1-3N0 
HR-positief/HER2-negatief en cT3N0 triple-negatieve patiënten die behandeld zijn 
met neoadjuvante systemische therapie hebben een relatief hoge risico op axillaire 
lymfekliermetastase en daardoor een hoge kans op postmastectomie radiotherapie. 
In hoofdstuk 8 werd in het kort toegelicht dat deze resultaten over laag en hoog 
risico postmastectomie radiotherapie kunnen bijdragen aan een multidisciplinaire 
en geïndividualiseerde besluitvormingsproces indien een patiënt een directe 
borstreconstructie wenst.
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Breast cancer is the most common cancer amongst women worldwide and a major 
public health issue. Each year approximately 15.000 patients are diagnosed with invasive 
breast cancer in the Netherlands, accounting for 14.8% of the cancer health care costs. 
Over the past decades, the survival rates of breast cancer patients have increased 
substantially due to widespread screening, improved diagnosis, and treatment. The 
breast cancer treatment consists of breast and axillary surgery, complemented by 
radiation therapy and/or systemic therapy (chemotherapy, immunotherapy, hormone 
therapy) if indicated. Due to the improvement of survival rates, the treatment outcome 
has increasingly focused on optimizing the quality of life as well as the aesthetic 
outcome while preserving oncological safety.
At the time of breast cancer diagnosis, accurate assessment of the presence and extent 
of axillary lymph node metastasis plays a central role in disease prognosis, breast cancer 
staging, and treatment decision-making. Imaging techniques play an important role in 
the axillary lymph node staging to provide extensive preoperative information. Over 
the years, axillary staging for clinically node-negative patients (i.e, negative !ndings 
based on physical examination and axillary ultrasound) has evolved from axillary 
lymph node dissection (ALND; the surgical removal of all axillary lymph nodes) with 
its associated morbidity to the less invasive sentinel lymph node biopsy (SLNB; the 
surgical removal of the !rst lymph node(s) to which the breast tumor is likely to spread) 
procedure. For clinically node-positive patients (i.e., biopsy-proven axillary lymph node 
metastasis before any treatment), ALND or less invasive axillary staging procedures can 
be performed.
Relevance of the scienti"c results in this thesis
The !rst part of this thesis focused on optimizing the axillary lymph node staging with 
noninvasive imaging modalities. In the preoperative diagnostic workup, breast MRI is 
performed in around 30% of the breast cancer patients and enables the simultaneous 
assessment of the breast tumor and axillary lymph nodes in the same !eld of view. 
However, approximately 40% of the breast MRI examinations have an incomplete !eld 
of view of the axillary region. Therefore, dedicated axillary MRI (i.e., MRI of the complete 
axillary region) has been explored to improve axillary lymph node imaging. Within a 
single group of breast cancer patients, we compared breast MRI with a complete !eld 
of view of the axillary region to dedicated axillary MRI to investigate the axillary lymph 
node staging. Both MRI examinations showed no di$erence in diagnostic performance. 
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In clinical practice, a dedicated axillary MRI is therefore unnecessary if the standard 
breast MRI protocol is optimized with a complete !eld of view of the axillary region for 
the assessment of axillary lymph nodes.
Approximately 30% of breast cancer patients are treated with neoadjuvant systemic 
therapy (i.e., systemic therapy prior to de!nitive surgical treatment). Clinically node-
positive patients treated with systemic therapy in the neoadjuvant setting can achieve a 
pathologic complete response (pCR; eradication of cancer cells) of the metastatic axillary 
lymph node(s), varying per breast cancer subtype. Currently, there is no noninvasive 
imaging modality that can accurately assess axillary pCR after neoadjuvant systemic 
therapy. Therefore, there is a trend towards less invasive axillary staging procedures 
to replace ALND. The second part of this thesis focused on the prediction of axillary 
pCR after neoadjuvant systemic therapy. We performed a systematic review and meta-
analysis to provide an overview of axillary pCR rates for all breast cancer subtypes 
to implement these results in clinical practice. These data can help predict axillary 
treatment response in the neoadjuvant setting and thus select patients for more or less 
invasive axillary procedures.
After neoadjuvant systemic therapy, mastectomy (i.e., surgical removal of one or both 
breasts) is performed in about 30% of breast cancer patients. In patients receiving a 
mastectomy, breast reconstruction is increasingly chosen by women. The timing of 
breast reconstruction is one of the main considerations if reconstruction is considered: 
immediate reconstruction (i.e., at the time of mastectomy) or delayed reconstruction 
(i.e., at a later time). Immediate breast reconstruction is associated with a better 
aesthetic outcome, a major patient advantage for the psychological outcome, and lower 
overall costs. However, if postmastectomy radiation therapy (i.e., radiation therapy to 
the chest wall with or without the regional lymph nodes) is required after immediate 
breast reconstruction, this can lead to a higher risk of reconstruction complications. 
Residual axillary lymph node disease following neoadjuvant systemic therapy is one of 
the most important factors for the indication of postmastectomy radiation therapy, but 
the axillary lymph node status after neoadjuvant systemic therapy is unknown before 
the de!nitive surgery. In the third part of this thesis, we identi!ed patient characteristics 
with a low and high risk of postmastectomy radiation therapy based on the axillary 
lymph node outcome after neoadjuvant systemic therapy to enable adequate shared 
decision-making regarding the timing of reconstruction.
Target population
The results of this thesis apply to newly diagnosed breast cancer patients who will 
undergo primary surgery or neoadjuvant systemic therapy. This thesis provides clinicians 
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in the multidisciplinary breast cancer team information about improving the imaging 
of the axillary lymph nodes. In addition, these results provide preoperative information 
about the axillary response to neoadjuvant systemic therapy to improve the selection 
of axillary surgery, and the sequence and outcome of breast reconstruction in the case 
of postmastectomy radiation therapy.
Implementation
In the !rst place, the results of this thesis were brought to attention by publications 
in renowned (inter)national journals with the breast cancer specialist as one of the 
target populations. In addition, these results were presented during both national and 
international meetings, creating a broad awareness among all clinicians involved in 
breast cancer care. By bringing these scienti!c results under the attention of clinicians, 
patients can be informed accordingly and contribute to adequate shared decision-
making. Eventually, the ultimate goal is the implementation of these results in clinical 
guidelines to optimize breast cancer management. The third part of this thesis was 
brought to the attention of breast cancer clinicians by presenting the results multiple 
times during OncoZON, an oncology network meeting of nine hospitals and one radiation 
therapy institute of the Southeast Netherlands region. During these network meetings, 
based on the experience of the plastic surgeons, it was decided to perform the axillary 
surgery before the breast surgery in order to include the information of the axillary 
lymph node status after neoadjuvant systemic therapy in the decision-making process 
about the timing of breast reconstruction. However, in other hospitals, the decision 
to perform immediate or delayed reconstruction in the setting of postmastectomy 
radiation therapy can be individualized and take into account the experience of the 
(plastic) surgeon and the expectations of the patient.
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